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ABSTRACT 
Introduction 
Chronic Kidney Disease (CKD) is common and is associated with cardiovascular morbidity and 
mortality. Few previous studies have assessed the ‘true’ prevalence of CKD in the general 
population and the predictors of morbidity and mortality in patients with stages 3-5 CKD 
Methods  
Using data from the Health Improvement Network, a large United Kingdom general practice 
database, the prevalence of stages 1-5 CKD was ascertained using both single and duplicate 
blood tests between 2005 and 2009. The prevalence of stages 3-5 ascertained from two 
blood results was compared to the CKD prevalence on the practice register determined by 
Quality Outcome Frameworks Read codes in 2009. The management of patients on the 
register, and those with CKD not on the register was compared. Cox proportional hazard 
models using routinely collected primary care data as co-variables were used identify 
potential predictors of i) all-cause mortality and ii) the composite of cardiovascular disease 
and all-cause mortality. Multiple imputations were used to allow for uncertainty in missing 
values such as blood pressure and body mass index in the general practice data sets. 
Results  
The prevalence of ‘true’ stages 1-5 CKD, i.e. where the chronicity of CKD is taken into 
account, was 5.01% and much less than estimates from previous studies. Using two 
laboratory eGFRs reported at least seven days apart, the prevalence of stages 3-5 CKD was 
4.7% in 2009. Over two percent of the population who had stages 3-5 CKD were not on their 
primary care practice register and 2.9% of the population were apparently misdiagnosed 
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with CKD. Patients with undiagnosed CKD tended to be younger and have less co-morbidity. 
Patients with CKD not on the practice register were associated with worse management than 
those on the practice register.  
The Cox proportional hazards models demonstrated that increasing age and co-morbidity 
were associated with worse outcomes, however continuous variables such as blood 
pressure, body mass index, haemoglobin and cholesterol were associated with an inverse J 
shaped relationship with log relative hazard ratio. Treatment with angiotensin blockade, 
beta-blockade, lipid lowering agents, and other antihypertensives was associated with 
improved outcomes, however blood thinning agents and diuretics were associated with 
worse outcomes. African Caribbean and Indian Sub-Continental ethnicity, though largely 
unreported, was also associated with better outcomes. 
Conclusions 
Stages 3-5 chronic kidney disease are common in UK primary care but not as common as 
previously reported. Many practices under record or mis-label CKD which impacts upon 
management. Redirection of resources to identify patients better could ensure better 
outcomes with a similar workload as more people would be removed than join disease 
registers. In these analyses some predictors of mortality and the composite of all cause 
mortality and cardiovascular disease are inconsistent with previous reports and this requires 
further investigation especially when considering blood pressure management. 
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CHAPTER 1. INTRODUCTION TO THE THESIS 
1.1.What Is Chronic Kidney Disease? 
Chronic Kidney Disease (CKD) is an umbrella term for kidney damage defined as a reduced 
glomerular filtration rate (GFR), a measure of renal function, and/or having evidence of 
structural damage.[1] CKD is typically subdivided into a series of stages defined by GFR 
and/or such structural damage. (Table 1-1) 
Table 1-1. Stages of Chronic Kidney defined by the National Kidney Foundation/ Kidney Outcomes Quality 
Initiative (N/KDOQI) guidelines  
Stage Glomerular 
Filtration Rate in 
ml/min/1.73 m
2
 
Description 
1 
90+ 
Normal renal function but has evidence of i.e. urinary 
abnormalities of proteinuria and or haematuria ii. Structural 
abnormalities iii. Genetic Renal trait  
2 
60-89 
Mildly reduced kidney function but evidence of the 
abnormalities in stage 1 
3a or 3a P* 
3b or 3b P* 
45-59 
30-44 
Moderately reduced kidney function 
4 or 4P* 15-29 Severely reduced kidney function 
5 or 5P* 
<15 or on dialysis 
Very severe, or End-stage Renal Disease 
May require dialysis 
* Denotes additional staging where P is added if the patient has proteinuria  
As will be discussed further in this chapter CKD is highly prevalent in the general population 
(though the exact proportion remains unclear) and the mortality and the morbidity is very 
high. This chapter will describe how renal function is measured and in greater detail how 
chronic kidney disease is staged. This chapter will then summarise the prevalence of CKD, 
the impact of CKD on the population and then summarise risk factors for mortality and 
morbidity in patients with CKD. This chapter will finally discuss why primary care is suited to 
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for research in patients with moderate kidney dysfunction and the aims and objectives of 
this thesis. 
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1.2.Markers of Renal Damage: How is Kidney Function Measured? 
The following section details differing methods for determining glomerular filtration rate 
and/or urine protein excretion (a key marker of structural renal damage). It is split into two 
sections. 
1. Measurement of glomerular filtration rate  
2. Measurement of urine protein section 
 
Figure 1-1. A summary of kidney dysfunction 
 
 
 
 
 
 
 
 
 
1.2.1. Glomerular filtration rates and surrogate markers 
Glomerular filtration rate (GFR) is defined as the volume of fluid filtered from the glomerular 
capillaries in a specified period of time. The GFR, expressed in ml/min (for an assumed body 
surface area of 1.73m2), is higher in men than women who are age matched and declines 
with age.[2] Stages 3-5 CKD are defined by a reduction in GFR. This is intuitive as kidney 
damage will cause a reduction in the number of nephrons and as a consequence the GFR will 
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decrease. However in patients with kidney damage there are often compensatory 
mechanisms whereby the individual nephron filtration rate increases and hence there is little 
change in the GFR. In fact this compensatory mechanism, known as ‘hyperfiltration,’ can 
lead to elevated GFRs such as in patients with diabetic nephropathy.[3] 
Because so much of this thesis depends on understanding the effects and influences of the 
measurement of GFR and of renal damage, the next sections consider these issues in detail. 
1.2.2.Measuring GFR 
GFR can be measured by the clearance of a continually infused exogenously administered 
substance such as inulin, which is freely filtered but not absorbed at the glomerulus.[4] 
However this measurement is invasive for the patient. The current gold standard for 
measured GFR is from clearance of single injection of 125I – labelled iothalamate or another 
radio labelled substances such as Ethylenediaminetetraacetic acid (EDTA), which 
corresponds closely with inulin clearance. However, though not as invasive as inulin 
clearance, these tests are expensive and time consuming and may not have any additional 
advantage when compared to estimated GFR (eGFR).[5] 
1.2.3.Creatinine based estimation 
In practice the measurement of the clearance of an endogenous substance called creatinine 
has been utilised for GFR estimation.[6] Creatinine is a breakdown product of creatinine 
phosphate in muscle. This substance is not protein bound, not metabolised by the kidney, is 
freely filtered through the glomerulus and is easy to measure.[7] Until the advent of directly 
reported eGFRs, serum or plasma creatinine was the most widespread method of 
determining kidney dysfunction and clinicians would use absolute values or trends to 
determine decline or improvement in renal function. However serum creatinine is affected 
by varying muscle mass and is hence affected by age, gender and race. Therefore the same 
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serum creatinine value in different individuals may reflect very different glomerular filtration 
rates.[8] A young black male with a serum creatinine of 150 µmol/l may not have renal 
dysfunction but an elderly white woman with the same result may have stage 3 CKD. 
Furthermore, creatinine is secreted by the tubule and hence serum levels are affected by 
medications that may interfere with this and diet, i.e. intake of meat will also affect levels.[7]  
1.2.4.Creatinine measurement 
Creatinine measurement originated in 1886 using the Jaffe reaction.[7] Current laboratory 
methods still use the basis of this reaction but other substances such as glucose and bilirubin 
molecules can be mistaken for creatinine. These are so called ‘non creatinine 
chromagens’.[9] An American initiative to improve the accuracy of creatinine measure 
suggested that laboratories implement creatinine analysis that is traceable to Isotopic 
Dilution Mass Spectroscopy (IDMS).[9] IDMS is the gold standard of measuring creatinine 
(non creatinine chromagens are not measured) but is prohibitively expensive. However 
assays exist that are aligned or traceable to IDMS and these are more accurate at measuring 
the serum creatinine as they are less likely to mistake non creatinine chromagens. These are 
advantageous compared to analyses performed using non IDMS methods which are less 
specific and will therefore report higher levels of creatinine. This difference can be as high as 
20%.[9] Additionally, there is considerable variability between non IDMS methods making 
comparability between laboratories difficult. Finally, serum creatinine measurement can be 
inaccurate when levels are low especially when under 88.4 µmol/litre.[9] 
Another method of assessing kidney function is through the measurement of creatinine 
clearance. As creatinine is freely filtered at the level of the glomerulus, creatinine clearance 
can be calculated using serum creatinine and the creatinine concentration of a timed urine 
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collection over 24 hours.[7] The formula is given in Box 1-1. However creatinine clearance is 
cumbersome and requires accurate urine collections which patients find difficult.[10;11] 
 Box 1-1. Creatinine clearance measurement 
For creatinine in mmol/l 
Creatinine clearance in ml/min 
	

		×	
	  
The urine flow rate is calculated from the volume of urine produced in the time period 
collected 
Investigators have therefore sought to estimate GFR from simpler methods that are less 
patient intensive. Cockcroft and Gault found a linear correlation between mean serum 
creatinine and age and developed a formula (CG) which estimates creatinine clearance from 
the serum creatinine and uses surrogate markers such age, body weight and sex to adjust for 
differences in endogenous creatinine production (Box 1-2).[12] The study was carried out 
using only 249 men and applied an arbitrary adjustment factor of 0.85 to the creatinine 
clearance for women to account for reduced body mass without verifying this formula in this 
group. Creatinine clearance is overestimated as 15% of creatinine is secreted in the distal 
tubule.  
Box 1-2. Cockcroft Gault estimation of creatinine clearance 
Cockcroft Gault formula – This calculates the creatinine clearance which is estimation of 
glomerular filtration rate 
For creatinine in mmol/l 
Creatinine clearance in ml/min = 
×	×..
	  
 
1.2.5.MDRD equation 
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The investigators of the Modification of Diet in Renal Disease (MDRD) study of CKD patients 
developed a new formula to estimate GFR.[13] In their study, 1628 patients had their GFR 
assessed by measuring the clearance of 125I – labelled iothalamate serum. Additionally they 
measured the serum creatinine and a 24 urine collection for urinary creatinine. They then 
calculated the measured creatinine clearance and Cockcroft Gault clearance. Using other 
demographic and biochemical variables collected they developed mathematical models and 
created a 6 variable formula that demonstrated better precision and accuracy at estimating 
GFR in comparison with the CG formula (Figure 1-2).[13;14]  
Figure 1-2. Relation of estimated GFR to measured GFR in the participants of the MDRD study.  
 
Each point represents the baseline measurement. The solid line represents the line of identity. The bold 
dashed line represents the fitted line with smoothing splines function plotted for the the 2. and 97.5 
percentile of estimated EGFR. The thin dashed lines repesent the difference of ± 30 percent between 
estimated and measured GFR 
The same investigators then further validated a simplified equation (4 variable MDRD 
equation in Box 1-3) that only required the serum creatinine, age, gender and black or non-
black ethnicity.[15] 
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Box 1-3. The MDRD Equation to calculate eGFR  
Modification of Diet in Renal Disease formulae.  
This estimated the glomerular filtration rate (eGFR) for creatinine in mmol/l 
For serum creatinines not analyzed by the standardized creatinine assay traceable to IDMS 
methods  
Estimated Glomerular filtration in mls/min/173m2  
= 186 ∗× $Creatininemmol/litre88.4 1
.2
× Age. × 0.742iffemale
× 1.21ifblack 
*175 when IDMS method used 
 
However several factors must be considered when interpreting eGFR using the MDRD 
equation. This equation has not been validated in certain ethnic groups. Adjustments to the 
formula have to be made for patients in Japan, China and Korea as these patients may have 
been under-represented in the MDRD cohort.[16-18] Though there were sufficient numbers 
of African Americans in this cohort, they are unlikely to represent all black patients. In South 
African blacks, the MDRD eGFR, with correction for ethnicity, overestimated GFR and the 
equation for white people corresponded more closely with actual renal function.[19] 
Additionally it is likely that the MDRD eGFR underestimates eGFR when the eGFR is above 60 
ml/min/1.73m2.[20] Only patients with CKD were included in the MDRD cohort and studies 
in living kidney donors show the MDRD equation underestimates GFR.[21] Additionally both 
the Cockcroft Gault and the MDRD equation perform less well in obese individuals. It is 
difficult to comment how applicable this formula is to the UK population as estimated eGFR 
has not been compared to measured GFR in the UK. This may be particulary relevent to the 
large minority population of Indian-subcontinentals who were mostly absent in the MDRD 
study.[19] 
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1.2.6.The Mayo Quadratic formula 
In order to more accurately describe renal function in healthy individuals as well as those 
with CKD, investigators modelled and developed the Mayo Quadratic Formula(Box 1-4).[22] 
Using 900 individuals (of whom a third had CKD and the rest were healthy), who had their 
renal function tested formally using isotopic methods, the investigators found better 
agreement with this formula in their cohort then the MDRD equation. In another study 
performed in secondary care patients classified with CKD using the Mayo equation were 
more likely to develop cardiovascular disease then when classified by the MDRD equation 
suggesting better risk prognostication if the Mayo formula is used.[23] However as will be 
discussed later in this section, this formula was developed using a different creatinine assay 
to the MDRD and the MDRD equation may not have been accurately used. In subsequent 
studies the MDRD equation has performed better in general populations and healthy 
individuals.[24;25] 
Box 1-4. The Mayo Quadratic formula 
For creatinine in mg/dl 
Estimated Glomerular filtration in mls/min/1.73m2 = exp1.911 + 2.@	 −
 .	B − 0.00686 × CDE − 0.205GHHEIJKE 
If Serum creatinine < 0.8mg/dl then assume creatinine is 0.8 
 
1.2.7.The Chronic Kidney Disease Epidemiology Collaboration (CKD EPI) formula 
The same group that developed the MDRD equation have subsequently developed another 
set of equations (Box 1-5) aiming to improve accuracy in the black ethnicity and at higher 
GFRs >60mls/min/m2.[26] The investigators developed their equations from ten 
multinational studies which included patients with measured GFR and then validated this 
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against patients with measured GFRs from a further 16 studies. This cohort was much more 
diverse and included patients who were healthy and had a higher proportion of black 
patients (31-33% versus 12% in the MDRD study). The new equation (CKD-EPI) had better 
performance in the elderly, patients with eGFRs above 60 ml/min/1.73m2, obese individuals 
and transplant patients.[27;28] However the eGFR was more likely to be accurate with the 
MDRD equation at lower eGFRS.[29] 
Box 1-5. The CKD EPI formulae 
If Female: 
eGFR= 144$ × MNOPQRSRSOT.@
P × 0.993VWO 
If serum creatinine (Scr) <= 61.9 mmol/l than a = −0.329  
If Scr > 61.9 mmol/l than a= -1.209 
 $If black race multiply by 166 instead of 144 
If male 
eGFR= 141£ ×MNOPQRSRSOY@.T
P × 0.993VWO 
If serum creatinine (Scr) <=79.6 mmol/l than a=-0.411  
If serum creatinine (Scr) > 79.6 mmol/l than a=--1.209 
£ Multiply by 163 instead of 141 if Black race  
Estimated Glomerular filtration in mls/min/1.73m2 
1.2.8.The impact of creatinine measurement on eGFR 
As mentioned above, creatinine values vary due to laboratory methods and these 
differences can have a big impact upon eGFR measurement. Prior to the advocacy of IDMS 
standardisation as discussed above, considerable variation existed between non IDMS 
methods. The original MDRD equation was derived using creatinines analysed using the 
Beckman Analysis (Non IDMS method). However if the creatinine is measured by a different 
assay and was not ‘calibrated’ to the Beckman method then at a GFR of 60 ml/min/1.73m2 
there could be up to a 10% difference in the eGFR.[30] As the GFR increases beyond 
60ml/min/1.73m2 this percentage error increases and consequently some laboratories 
report the eGFR simply as above 60 ml/min/1.73m2 rather than an actual figure.[30] This can 
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lead to difficulty in classifying stages 1-2 CKD. In the UK, laboratories report this ‘un-
calibrated’ serum creatinine, then apply an adjustment factor to the creatinine to make it 
equivalent to Beckman method and then calculate the eGFR using the MDRD equation.[31]  
In order to counter the variability in serum creatinine assay, a laboratory working group was 
devised by National Kidney Disease Education Program (NKDEP).[9] The NKDEP 
recommended in 2006 that creatinine is measured by methods traceable to IDMS and that 
laboratories should aim to reduce the error to less than 10% between separate 
measurements of eGFR.[9] Laboratory methods aligned to IDMS allow calibration and 
standardisation of serum creatinine measurement, however serum creatinines appear lower 
and the MDRD equation had to be altered to reflect this (Box 1-3).[32] 
In the United Kingdom although the Department of Health recommends IDMS aligned 
methods the uptake across laboratories has been not been universal: even by 2009 only 50-
60% of laboratories were using IDMS aligned methods.[31] The CKD EPI equation has been 
validated using only IDMS aligned laboratory methods. The variation in laboratory methods 
may be why the MAYO equation was not applicable to other populations. The variation in 
formula to estimate eGFR may lead to differing estimates in the prevalence of CKD and this 
is discussed and explored in section 1.4 and Chapter 2. 
1.2.9.What is proteinuria and how is it measured? 
Proteinuria, is excess protein excretion into urine and is a marker for renal progression and 
cardiovascular disease.[33] In a normal kidney, only small amounts of albumin (the main 
protein in the body) are excreted in the urine. In diseased kidneys, (e.g. those found in 
patients with diabetes), the glomerular barrier is damaged and greater amounts of albumin 
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are filtered into the glomerulus, which the nephron is unable to absorb downstream and 
therefore albumin passes into the urine resulting in albuminuria.[34] 
Even moderate levels of urine albumin excretion i.e. ‘high’ albuminuria (albumin excretion of 
30-300mg per day or urine albumin to creatinine ratio of 3-30mg/mmol) are a sensitive 
marker for glomerular pathology prior to reduction of glomerular filtration rate. Therefore 
the Kidney Disease Improving Global Outcomes (KDIGO) guidelines use this threshold to 
diagnose proteinuria and classify those with stages 1-2 CKD patients (if they have normal 
range GFRs). These guidelines should not to be confused with N/KDOQI guidelines above. 
The differentiation between different levels of albuminuria/proteinuria are show in Table 
1-2.[33] The different methods of measuring albuminuria are discussed later.  
Table 1-2. Quantification of proteinuria: comparison of different methods 
 
 Microalbuminuria Macroalbuminuria/Sign
ificant proteinuria 
Overt Proteinuria 
24 hour Urine 
Collection of Protein 
(mg/24 hours) 
N/A 500-999 1000+ 
Protein Creatinine 
Ratio in mg/mmol 
N/A 50-99+ 100+ 
24 Urine Collection 
of Albumin(mg/24 
hours) 
30 - 299 mg >300mg NA 
Albumin Creatinine 
Ratio in mg/mmol 
3.5 in women 
2.5 in men 
30-69 70 
Urine Dip test Trace/1+ >1+ NA 
Definition in 
contemporary 
literature[35] 
High Very High 
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1.2.9.1.Methods for measuring urine protein excretion 
1.2.9.2.Laboratory Methods 
The gold standard for quantifying proteinuria is 24 hour collection of urine for protein or 
albumin levels.[33] However this method is expensive, patients find this cumbersome and 
difficult to comply with and subsequently many samples are inadequate.[10;11] Spot urine 
protein creatinine ratio (urine PCR) is effective at ruling out proteinuria, correlates highly 
with 24 hour collections but is not as sensitive.[36-38] Additionally exercise and fever can 
affect levels of urine PCR but these are the trade-offs for an easier test.[39] In practice spot 
urine albumin:creatinine ratio (Urine ACR) is used: high albuminuria is a marker of kidney 
damage and predictive of morbidity and mortality and cannot be detected by Urine PCR.[33]  
1.2.9.3.Urine dipsticks: Advantages and Disadvantages 
Urine dipsticks are cheap, easy to use and give an immediate result for multiple analytes 
including protein, blood, nitrates and leucocytes. They semi-quantitatively analyse amounts 
of albumin in urine and give results of negative, trace, 1+, 2+ and 3+ for the presence of 
protein (Table 1-2). However their use in clinical practice is problematic and has several 
major criticisms. Firstly the results of dipstick tests are user dependent as the colour on the 
dipstick is compared to a colour chart. Secondly, urine albumin excretion is dependent upon 
urine volume and dipsticks do not account for this and erroneous results are possible. 
Consequently studies report that they have variable sensitivities and specificities.[40;41] 
More recently, automated urine dip testing has become common place and consequently 
dipstick results may be more accurate.[33]  
 In a screening study of 10944 Australians aged over 25, where individuals had concomitant 
urine dipstick using Bayer Multistick (automated result) and Urine ACRs, a dipstick threshold 
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of 1+ detected an ACR above 3.4mg/mmol with a sensitivity of 58% and the specificity of 
95%. To detect an ACR of 33.9 mg/mmol the sensitivity was 99% and the specificity was only 
93%. This indicates that urine dip has poor sensitivity at detecting albuminuria but if a 
dipstick is positive then the patient is likely to have albuminuria.[42] 
The equivalent results from urine PCR, ACR, 24 urine protein excretion and urine dipstick are 
shown in Table 1-2 and are adapted from the KDIGO report.[33]  
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1.3.The Current Classification of CKD: Evidence Base 
The current classification of CKD in the United Kingdom according to NICE (National Institute 
for Clinical Excellence) is based on the N/KDOQI guidelines (Table 1-1).[1] The N/KDOQI 
guidelines have been updated and adopted internationally with the guidelines being 
produced by the Kidney Disease Improving Global Outcomes (KDIGO) in 2012.[43] These 
original N/KDOQI guidelines were developed after a systematic review was undertaken, and 
although eGFR below 15 ml/min/1.73m2 was strongly associated with poor outcomes such as 
requiring dialysis or cardiovascular events, there were few studies on the relationship 
between stages 1-4 CKD and clinical outcomes.[1]  
To classify patients with stages 3-5 CKD requires two eGFRS under 60 mls/min/1.73m2 
measured on two occasions sufficiently apart to rule out a temporary reduction in GFR (eg 
from acute kidney injury); the impact of this on the prevalence will be discussed 
later.(Chapter 2.1) This definition has been operationalised by KDIGO as at least three 
months apart and adopted by the UK National Institute of Clinical Excellence (NICE) 
guidelines for CKD.[1;44] However, the UK payment for performance system called Quality 
Outcomes Framework (QOF) defined stages 3-5 CKD by using two eGFRs under 60 
mls/min/1.73m2 within 3 months(for QOF 2008/2009).[44;45]  
The definition of proteinuria is interesting; the original guidelines state a definition of 
proteinuria with a PCR of 23mg/mmol, the UK and Scottish guidelines (SIGN) define 
proteinuria as a PCR of 70mg/mmol and 100mg/mmol respectively.[44;46] The recent KDIGO 
guidelines suggest even lower thresholds of ACR of 3.4mg/mmol as proteinuria but note that 
as low levels of albuminuria can be transient, it should be confirmed over a period of 3 
months (the original NKDOQI guidelines stated that this be above 2 weeks).[47] For CKD 
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stages 3-5, The UK and Scottish guidelines suggest that if patients have proteinuria, a ‘p’ 
suffix should be used e.g. CKD stage 3aP if the patient has proteinuria.[44;46]  
The relationship between eGFR and increasing albuminuria and clinical outcomes is 
independent and this is not accounted for in the current classification. In the CKD Prognosis 
Consortium, patients with an eGFR 45-60 (CKD stage 3a) but no albuminuria had a HR for 
death 1.3 times to that of the reference group, but a patient with an eGFR of 60-75 
ml/min/1.72m2 and an ACR above 30 mg/mmol (CKD Stage 2) had a HR of 2.7.[43] Based on 
these observations Tonelli et al proposed a classification system based on actual risk of 
developing renal sequelae (Table 1-3),[35] this system resulted in some patients being 
reclassified to lower risk category.[35] 
Table 1-3. Current NKF KDOQI CKD staging system and alternate system of CKD risk categories 
Current NKF KDOQI System 
GFR ml/min/1.73m2 Albuminuria 
Normal High High 
90 Stage 0 
(no CKD) 
Stage 1 
60-89.9 Stage 2 
45-59.9 
Stage 3 
30-44.9 
15-29.9 Stage 4 
Alternate System 
 Albuminuria 
GFR ml/min/1.73m2 Normal High Heavy 
90 Risk category 0 
(no CKD) 
Risk category 
1 
Risk category 
3 60-89.9 
45-59.9 Risk category 
1 
Risk category 
2 Risk category 
4 30-44.9 Risk category 
2 
Risk category 
3 
15-29.9 Risk category 
3 
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KDIGO using the CKD Prognosis Consortium data, has suggested in their 2012 guidelines that 
patients should be graded according to their level of albuminuria as well as eGFR and have 
introduced the use of a heat map to allow the clinician to predict risk(Figure 1-3).[43;47] 
Figure 1-3. Composite Ranking for Relative Risks by glomerular filtration rate (GFR) and Albuminuria 
  
(Kidney Disease: Improving Global Outcomes (KDIGO) 2009). The risk for morbidity is from lowest to 
highest by colour is Green, Yellow, Amber, Red and Red with hashes. 
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1.4.The Prevalence of Stages 1-5 CKD 
The prevalence of stages CKD 1-5 will be discussed in length in chapter 2.1 but is introduced 
here. There is considerable variation in how creatinine is measured (hence variation in eGFR 
result) and the methods of estimating eGFR i.e. MDRD and CKD EPI as demonstrated in 
Chapter 1.2. This inconsistency in eGFR leads to changeable estimations of stages 3-5 CKD 
prevalence of between 1%-13.6%. Over half these patients have stages 3, discussed and 
developed further in chapter 2.1.[48] To counter this unpredictability in eGFR, all CKD 
guidelines state that stages CKD 3-5 should be confirmed using two eGFRs below 60 
ml/min/1.73m2. However only one prevalence study has attempted to correct for chronicity 
of stages 3-5 CKD i.e. estimate the prevalence of CKD using two blood results and this was 
6.76%.[49] This study used two blood tests where available and a single blood test where 
two blood tests were not available to define stages 3-5 CKD.[49] This leads to the important 
question of what is the prevalence of stages 3-5 CKD as the mortality and morbidity is very 
high and this disease state requires considerable resources.(Chapter 1.5) 
The prevalence of stages 1-2 CKD have generally been ascertained on excess urine protein 
secretion and this, like eGFR estimates, depends upon testing in the first place and also what 
methodology is used to define proteinuria.  
Table 1-4. Prevalence variation of Stages CKD 1-5 adapted from Chapter 2.1 [8;49-91] 
Method Prevalence 
Stages 3-5 CKD using MDRD formula 
Single blood result 
1.0 - 13.6% 
 
Stages 3-5 CKD using MDRD formula 
Two blood results 
6.8% 
(Adapted from the QICKD paper)[49] 
Stages 3-5 CKD using CKD EPI formula 
Single blood result 
4.4 – 6.0 % 
Stages 1-2 CKD 1.6- 12.1% 
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1.5.CKD: What Are The Mortality And Morbidity Implications? 
1.5.1.Cardiovascular disease and mortality 
The commonest CKD stage is Stage 3 (30-50% of all patients with CKD).[48] However renal 
sequelae such as reaching stage 5 CKD and or requiring dialysis are uncommon in this group. 
In a cohort of nearly 28 000 patients in the US, only 1% of patients with stage 3 CKD 
developed ESRD after 5 years follow up.[92] However in the same study, despite the 
relatively low risk of ESRD, the mortality rate was extremely high at 24.5% for stage 3 CKD 
compared to 10.2% mortality in those without CKD.[92] .  
Subsequently the CKD Prognosis Consortium conducted several meta-analyses to examine 
the impact of CKD in general, high risk and kidney disease populations.[34;43;93-95] The 
largest study consisted of 1 234 182 individuals included in 23 studies of the general 
population.[93] In a multivariable analysis, the hazard ratio for all-cause mortality was 1.18 
(95% CI 1.05-1.32) for patients with stage 3a CKD (a cubic spline knot at an eGFR of 60 
ml/min/1/73m2) in comparison to patients with normal renal function (a cubic spline knot at 
95 ml/min/1/73m2).[93] The risk increased as the GFR fell (Figure 1-4). This risk could be 
further stratified by the level of proteinuria with increased levels of proteinuria being 
associated with a stepwise increase in mortality and cardiovascular disease (Figure 1-4). 
Even small amounts of albumininuria were associated with increased morbidity and 
mortality. A large proportions of deaths in the study were attributable to cardiovascular 
disease (20%, 9637/45 584) [93].  
1.5.2.Renal Outcomes 
In two further meta-analyses, a stepwise increase in albuminuria and decreased eGFR was 
associated with increased likelihood of requiring renal replacement therapy, developing 
Page 36 of 375 
 
progressive renal disease and acute kidney injury in the general population, high risk and 
kidney disease cohorts.[95] In the general population, patients with CKD stage 3a (HR 9.6 
95% CI 7.0-13.2) were 10 times less likely to develop ESRD compared to Stage 3b (HR 98.1, 
61-8-156), in comparison with the reference group (those with an average eGFR of 
95ml/min/1.73m2). The risk of developing ESRD rose exponentially to 573 times more likely 
for patients with Stage 4 compared to patients with the reference group.[95] 
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1.5.3.Economic Impact of CKD 
The healthcare cost of CKD will discussed in this subsection but it is worth highlighting that 
CKD is not only associated with these costs. A review by Perico et al, suggests that 
renal/urinary tract diseases were associated with 830,000 deaths per year world wide and 1 
886 700 disability adjusted life years in 2001.[96] 
Although the risk of ESRD is not high, where it occurs, these patients require renal 
replacement therapy (RRT, either dialysis or transplantation) and this is expensive.[97] Renal 
replacement programmes costs from developed countries varied from 2% (Australian 
Healthcare expenditure on RRT in 2004) to 6.7% (United States Medicare Budget in 
2006).[98;99] In the UK in 2009 there were 49 808 patients on RRT and of these 25 790 
patients were on dialysis.[100] The annual cost of dialysis alone was over £780 million 
comprising 1.6% of the annual National Health Service (NHS) budget of £48 billion in 
2009.[97;100] Such costs are highly disproportionate since patients with ESRD only comprise 
of small proportion of the population.  
The true economic impact of all stages of CKD is likely to be much higher. In United States, in 
the Medicare health care systems (patents aged over 65 and or long term conditions), care 
for CKD patients accounts for nearly 27% of the costs.[101] In a UK model, investigators 
modelled the cost of CKD stages 3-5 based on RRT costs, primary care costs, outpatient 
attendances and inpatient costs between 2009-2010 and found the cost to be £1.45 billion 
pounds, approximately 3% of NHS budget.[97]  
In summary these studies highlight the large public health burden of CKD and as will be 
discussed further in this chapter, this disease is not uncommon and therefore the risk factors 
for cardiovascular disease and mortality require further discussion and exploration. 
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1.6.Risk Factors for Cardiovascular Disease and Mortality 
As described earlier in this chapter, incident cardiovascular disease and mortality is 
abundant in patients with chronic kidney disease. However as will be described in further 
detail in chapter 4, cardiovascular risk factors such as diabetes, hypertension, 
hypercholesterolaemia, obesity, and atrial fibrillation are associated with the development 
of CKD.[102-108] This is a paradox when considering risk factors for cardiovascular disease in 
patients with CKD.[109] For example smoking is associated with increased cardiovascular 
disease, diabetes and cancers. However smoking is implicated in the development of 
CKD.[103]  
As shown in Table 1.5, there is a complex relationship between risk factors and subsequent 
mortality and morbidity. Many of the continuous risk factors have a non linear relationship 
such as BP, BMI and cholesterol. This may be a result of reverse causation as the CKD disease 
state modifies the relationship between the risk factor and the outcome.  
Additionally most of these studies are not CKD specific and are either post hoc or sub group 
analyses.[110;111]  
Additionally there are CKD specific risk factors such as low haemoglobin, bone mineral 
disorders and proteinuria.[112;113] The complexity of these risk factors and the lack of 
available evidence make it difficult to prognosticate risk in cohorts associated with high rates 
of death and cardiovascular disease.  
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Table 1-5. Traditional and Non traditional risk factors for CVD and Mortality in CKD: a comparison with the 
general population. 
Traditional CVD Risk 
factors 
Effect in general population Effect in CKD population 
Blood pressure (BP) & 
Antihypertensive drugs 
Increasing BP associated with 
increased mortality and treatment 
with all classes beneficial[114;115] 
U shaped relationship with 
mortality. Angiotensin blockers 
demonstrate greatest efficacy with 
questionable benefits from other 
agents.[116-118] 
Anti platelet agents Secondary prevention of CVD[119] As general population but with 
increased bleeding[120] 
Cholesterol reduction & 
Statins 
Raised cholesterol and reduction 
with statins beneficial[121;122] 
Raised cholesterol has U shaped 
relationship with CVD risk but 
statins beneficial[121;123;124] 
Smoking  Increased risk[113] Same as general population[113] 
Atrial Fibrillation Increased risk[125] Same as general population[126] 
Body Mass Index Increased risk[125] U shaped relationship[127;128] 
Ethnic Group Increased risk with black and Asian 
population[125] 
Unknown. Asian and black 
population with ESRD have 
increased survival[129] 
Deprivation index – 
Townsend Quintiles 
Increased risk with lower 
deprivation[130] 
Same as general population[130] 
CKD SPECIFIC RISK 
FACTORS 
  
Proteinuria NA Increased risk with high and very 
high albuminuria[93] 
Haemoglobin NA Increased risk with low Hb but also 
treatment with 
erythropoietin[131;132] 
Bone Mineral Disorder NA Increased risk with Bone mineral 
disorders[112;113] 
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1.7.Why is Primary Care the Ideal Forum for CKD Research? 
As will be discussed in the introduction in chapter 3, NICE guidelines suggest that stage 3 
CKD should be managed in primary care unless patients are hypertensive or have 
progressive renal dysfunction.[44] This is the largest group of CKD patients and may 
constitute up to 5% of the population.[133] Primary care is suited to epidemiological 
research in CKD because primary care physicians are the point of access for all patient in the 
UK.[134] The majority of the population (98%) are registered with a General Practice and 
most primary care providers have complete electronic records.[134;135]  
Electronic patient record (EPR) systems have existed for many years.[136] These contain 
demographic information, clinical information about consultations, and prescriptions and 
locally recorded medical information such as weight or blood pressure. Additionally they are 
linked to local pathology data such as blood and radiology test results. 
Pharmaco-epidemiological information within the EPR is generally accurate and the 
diagnoses recorded, such as cardiovascular disease, have been shown correspond with 
diagnoses made in secondary care.[137;138] Table 1-6 shows examples of research 
conducted using primary care databases and their utility in research. 
  
42 of 375 
Table 1-6. Example of routinely collected database studies in the United Kingdom with emphasis on kidney 
disease and cardiovascular disease 
Title Database Description 
Q Risk 
Cardiovascular risk 
Calculator 2007[138;139] 
Q Research/ 
THIN 
A cohort study in which patients were free of 
cardiovascular disease and diabetes. The investigators 
modelled risk factors in 1.28 million patients aged 35-74 to 
determine cardiovascular disease. This model was 
externally validated by analysing the THIN cohort [140]  
Q Risk 2  
Cardiovascular risk calculator 
2008[124] 
Q Research/ 
THIN 
A similar cohort study as above where they CVD outcomes 
were analysed in 2.3 million patients in primary care. A 
better calibrated cardiovascular risk prediction tool was 
developed then the Framingham equation.[141] 
Q Kidney 2010[142] Q Research/ 
THIN 
CKD disease predicting model derived from over 1.5 
million patients aged 35-79. External validation from 
analysis of the THIN database. Had missing creatinine 
data[143] 
Patients with Hypertension: A 
Population-Based Case-Control 
Study [144] 
 
THIN Case control study in hypertensive patients with new 
incident Gout (n= 24 768) compared with matched 
controls (n=50 000). Found that calcium channel blockers 
and losartan were independently associated with Gout 
Suicide related Events in 
patients treated with anti-
epileptic drugs[145] 
THIN Case control study where patients with epilepsy, 
depression and bipolar disorder were studied to determine 
whether anti-epileptics were associated with increased 
suicide related events 
Use of Antihypertensive 
Medications and Mortality of 
Patients With Autosomal 
Dominant Polycystic Kidney 
Disease: A Population-Based 
Study[146] 
CPRD 2085 patients with polycystic kidney disease. They found 
that the number of patients with anti-hypertensives 
increased by 2008 and there was a decrease in mortality 
Risk of cardiovascular disease 
and all cause mortality among 
patients with type 2 diabetes 
prescribed oral anti-diabetes 
drugs: retrospective cohort 
study using UK general practice 
research database.[147] 
CPRD 915 21 patients with diabetes. Patients on sulphonyuria 
monotherapy compared to metformin were found to have 
increased mortality. Pioglitazone was found to be 
associated with less risk compared to rosiglitazone 
Exposure to oral 
bisphosphinates and risk of 
oesophageal cancer[148] 
CPRD Case control study examining bisphosphonate use and 
association with oesophageal cancer. The study found no 
association with bisphosphinates 
  
43 of 375 
However despite primary care being a sensible setting for CKD research, there are a lack of 
specific CKD prognostic studies in primary care. QRESEARCH incorporates CKD as a variable 
into their risk prediction model but do not delineate risk by CKD stage.[125] Another primary 
care CKD study models the development of stage 5 CKD in patients with CKD.[139]. However 
as discussed before stage 5 CKD is relatively uncommon sequelae of CKD in comparison 
cardiovascular disease.[95] Therefore there is gap in cardiovascular research in CKD patients 
in primary care despite this being suitable setting for such research 
1.7.1. Quality Outcomes Framework 
Management of CKD in primary care is incentivised by the Quality Outcomes 
Framework.[140] This specifies that primary care physicians should produce a CKD register. 
However the proportion of patients on this register is less than national estimates.[140] This 
suggests that patients may not be recognised with CKD. This may affect subsequent 
management of patients with CKD as in other diseases, those not QOF disease register had 
worse management.[141] In a secondary care setting patients not identified with CKD were 
less likely to have monitoring for CKD complications.[142] Therefore primary care should be 
evaluated for CKD recognition and management of patients identified. 
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1.8.Large Primary Care Databases and their Utility in Research 
The primary care resource chosen for use in this thesis was the ‘Health Improvement 
Network’ (THIN) and its use in epidemiological research is described in the next section.  
Medical research databases in the United Kingdom began in 1987 when Value Added 
Medical Practice system Ltd (VAMP) was conceived.[136] This was initially an electronic 
practice system set up by Dr Alan Dean in the UK, to manage his practice and then 
subsequently was taken up by other practices. VAMP consisted of two components, the 
practice data computer system and practice research database. Funding to support the 
system was obtained by selling data to pharmaceutical companies. In 1993 the VAMP 
research database was no longer profitable and VAMP was split into the clinical system and 
research database. The clinical system was sold to Reuters [becoming what is now known as 
“Vision”] and the research system sold to the UK Government and labelled as the General 
Practice Research Database (GPRD) for use in non-profit research.[143] This system was 
eventually managed by the Medicines Healthcare Regulatory Authority (MHRA) and has 
recently been relabelled as Clinical Practice Research Datalink. (CPRD) CPRD now receives 
information from other sources other than VAMP and Vision.[143]  
At the time of the development of CPRD, a separate licence for the research data was 
maintained by Epidemiology and Pharmacology Information Core (EPIC UK). In 2002, 
following the expiry of the original licence, EPIC (UK) set up the Health Improvement 
Network (THIN) in collaboration with In Practice Systems ltd. (INPS).[136] This practice 
research database received information from participating practices using Vision software 
(owned by INPS). Due to the common origin of data source for CPRD and THIN half of the 
practices that contribute data to CPRD also contribute data to THIN. CPRD is the largest 
primary care research database followed by QRESEARCH and then THIN.[136;143] 
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THIN consists of anonymised primary care records from general practices in the United 
Kingdom: in November 2009 there were just over six million patients in the database from 
426 practices comprising approximately 6% of the United Kingdom population.[136] Data 
include historical records from 1980 when VAMP began and has been collected 
prospectively by VISION practices since 2002. Routinely collected data is entered into the 
patient’s record forming the general practice clinical record and is automatically anonymised 
and sent to THIN. The data has pre-approved ethics for research with a scientific committee 
overseeing new applications for use of the data. The data consists of five components which 
are described in Table 5. All data files have common elements of a unique practice identifier 
and unique patient identifier in the practice.[136] 
1.8.1.The strength and limitations of THIN 
1.8.1.1.Strengths 
The THIN database has been used in a number of research studies (Table 2). THIN covers 6% 
of the population and is broadly representative in age and sex of the UK general 
population(Figure 1-5).[144] As THIN is an unselected patient population it is more likely to 
represent a ‘real-world’ cohort where the impact of different treatments and guidelines can 
be evaluated.[136] 
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Figure 1-5. Comparison of the structure of The Health Improvement Network (THIN) population on 1 July 
2008 with the Office for National Statistics (ONS) mid-2008 UK population estimate. 
 
The consultation patterns and prescription rates documented in THIN are similar to national 
estimates from the general household survey (an annual survey of private households by the 
Office of National Statistics) and Department of Health.[145] Research using the THIN 
database shows that known cardiovascular risk factors are associated with cardiovascular 
disease and these results were similar to those from GPRD.[146] The THIN database 
demonstrates the association of HMG Co-A reductase inhibitors (statins) with the reduction 
in vascular outcomes similar to reductions observed in the Heart Protection Study clinical 
trial.[147] THIN prevalence and incidence of smoking and coronary heart disease mirror 
national estimates and estimates from other trials.[144;148;149] 
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1.8.1.2.Limitations 
THIN has a number of limitations. The mortality rate is 5 % less than national averages 
probably reflecting reduced deprivation in practice areas contributing patient records to 
THIN such as the south of England.[144;150] In THIN, 22.7% of people are within the most 
affluent quintile according to the national Townsend score and 12.2% are in the least 
affluent quintile suggesting deprived areas are under-represented.[150] THIN is not useful at 
examining personal patient’s characteristics such as non-compliance and over the counter 
medication because this information is not recorded. Like any of the research databases 
there is poor linkage to secondary care.[144;151]  
1.8.1.3.Using THIN database for research – key considerations and data components: 
After a patient registers with a practice, their medical records may take another 6 months to 
arrive and be entered electronically. Therefore only data after this 6 month period is likely to 
be accurate; especially for older data captured before GP to GP data transfer was 
available.[138;144;146;148;152;153] Additionally data is only likely to be accurate in 
patient’s records after the acceptable mortality reporting (AMR) date. The AMR date is a 
date when the practice’s reported mortality rate was analogous to the standardised 
mortality rate of the practice since this is likely to represent when the practice information 
was accurately computerised. This date not only represents from when death reporting was 
likely to be accurate, therefore reducing immortal time bias, but from when the practice was 
likely to report all events.[150] The data components of THIN are shown in Table 1-7.[136] 
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Table 1-7. Description of THIN data components. 
Data Component Description 
Patient File This includes the practice identifier and patient identifier, 
the date of registration at the practice, year of birth, date 
of deregistration and the date of death if applicable. 
ADDITIONAL HEALTH DATA(AHD) 
 
Includes all vaccinations, laboratory results, patient 
measurements and information about smoking, and 
death. 
THERAPY DATA This includes all issued prescriptions which include the 
date, the mode of administration, the dosage, quantity 
and how frequently the prescription is taken.  
POST CODE VARIABLE INDICTORS  
DATA 
This includes the patient’s post code linked socio-
economic data which is represented in a national quintile 
for the Townsend Index of Deprivation (this is based on 
unemployment, car ownership, type of housing and 
overcrowding), ethnicity and environmental indices.[154] 
MEDICAL DATA 
 
This includes the medical diagnoses and other 
consultation data, which are entered in the form of Read 
codes.  
These are a system of hierarchal codes that specify types 
of diseases, symptoms, diagnoses or other medical 
information from consultations or letters. These codes 
allow some standardisation of diagnosis across medical 
practices and allow ease of extraction for medical 
diagnosis for research and audit purposes. However they 
are not truly hierarchal and have had gaps in coding that 
have been remedied with annual updates. Read codes 
(Version 2) are accompanied by the date of the diagnosis 
and location of diagnosis. [155] 
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1.9.Thesis Aims and Objectives  
Having introduced the thesis and discussed some of the gaps in our knowledge of CKD 
patient outcomes, this final section of my first chapter states the overall aims and objectives. 
Subsequent chapters (2-5) include a specific introduction, methods, results and conclusion: 
1.9.1. Thesis Aims 
The overall aim of the thesis was to evaluate the prevalence and management of CKD in UK 
general practice and identify potentially modifiable risk factors that can be used to inform 
individual patient care and UK health policy.  
1.9.2.Thesis Objectives and Organisation 
The thesis had a number of specific objectives: 
1) What is the prevalence of CKD in primary care in the UK?  
This is described in Chapter 2. 
2) How accurately is CKD recorded in the Quality Outcomes Framework and how does 
this affect management of care? This is described in Chapter 3. 
3) What routinely collected primary care data predicts all-cause mortality in stages 3-5 
CKD patients? This is described in Chapter 4. 
4) What routinely collected primary care data predicts the composite outcome of 
cardiovascular disease or all-cause mortality in stages 3-5 CKD patients? This is 
described in Chapter 5. 
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1.10.Executive Summary 
• CKD is defined by NKF/KDOQI guidelines 
• It is based upon GFR and urine protein excretion 
• CKD is associated with high rates of morbidity and mortality 
• Estimates of CKD prevalence are variable and will be discussed further in Chapter 2 
• Primary care is ideal setting to conduct research  
• The THIN database is a useful tool for pharmaco-epidemiological research in primary 
care. 
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CHAPTER 2. THE PREVALENCE OF CKD IN PRIMARY CARE 
The purpose of chapter 2 is to address the first objective of the thesis: To provide a robust 
estimate of the prevalence of CKD in UK primary care. The introduction to this chapter 
reviews existing prevalence data and considers the strengths and limitations of these 
estimates as applied to the UK population. The methods for estimating prevalence using the 
THIN database are described and findings presented. These findings are then discussed in 
the context of previous prevalence estimates.  
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2.1.The Prevalence of CKD: A review of the existing literature 
This section summarises prevalence estimates for CKD in the literature. A systematic review 
published in 2008 described the prevalence of stages 3-5 CKD from populations greater than 
1000 patients.[77] Zhang et al included studies that defined CKD Stages 3-5 CKD were the 
creatinine clearance (using Cockcroft Gault eGFR) or eGFR (using the non IDMS MDRD 
equation) was less than 60 ml/min. They found 26 studies meeting inclusion criteria from 
around the world. Note this study didn’t examine the prevalence of CKD stages 1-2 or the 
prevalence using CKD-EPI formula. 
Table 2-1 - Table 2-3 shows prevalence of stages 1-5 CKD by continent and were adapted 
from this systematic review to include more contemporary studies till 2012, studies 
including stages 1-2 CKD and studies defining CKD using the CKD-EPI formula. The prevalence 
according to Cockcroft Gault is not reported as the MDRD equation has superseded 
Cockcroft Gault in accuracy.[13] 
In all studies the prevalence of CKD was higher in women (Table 2-1 - Table 2-3). The studies 
that only included populations over the age of 40 are underlined. The prevalence was 
variable between studies and continents. There were no studies from Africa and this may 
have been due to the exclusion of studies with less than 1000. The majority of patients had 
stage 3a CKD (data not shown). 
In most of the North American studies, patients had been prospectively screened (Table 
2-1). The prevalence of CKD stages 1-2 varied from 4.4% to 4.9% [50;52] and CKD stages 3-5 
varied from 1.0% to 8.6%.[50;51] CKD prevalence was higher in patients aged over 45 
varying from 23.4% - 43.5%.[54;55] However the high prevalence in this age group was due 
to inclusion of the REGARDS study.[54] This may reflect the inclusion of a relatively high 
proportion of participants from ethnic minorities. 
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All the European studies (Table 2-2) were screening studies apart from those in UK which will 
be discussed later (2.1.1). In contrast to the North American studies, stages 1-2 CKD 
prevalence varied considerably from 1.6% to 13.2%. Studies at the lower estimation of 
prevalence were likely due to the use of dipsticks to define proteinuria which as discussed 
earlier is an insensitive method (Chapter 1.2).[59] Studies with higher estimates were likely 
due to using an ACR corresponding high albuminuria to define stages CKD 1-2.[65] The 
prevalence of CKD stages 3-5 varied from 4.7 to 8.1% [61;62] and as described previously in 
North American studies prevalence was higher in older populations 19.9% to 35.8%.[68;70] 
In Australian and Asian studies (Table 2-3) stages 1-2 CKD prevalence varied from 2.4 to 
12.1% [71;77] and stages 3-5 CKD prevalence varied from 1.7 to 13.6%.[89] Older 
populations had higher prevalence of CKD and there was marked variation in CKD prevalence 
in countries such as China, Thailand and Taiwan. 
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2.1.1.The prevalence of CKD in the UK 
In the United Kingdom and Ireland (in italics in Table 2-2), with the exception of Health 
Survey for England study (HSE), included studies using retrospective 
databases.[49;63;66;67;69;133] Only the HSE used screening to establish the 
prevalence of stages 1-2 CKD (7.5%). Stage 3-5 CKD prevalence varied from 4.9 to 
8.5%[66;133], and was more common in older individuals.[69] Only one study from the 
UK (shaded in grey in Table 2-2), partially attempted to correct for chronicity of CKD 
and this estimated the prevalence of stages 3-5 as 6.8% (using the MDRD 
equation).[49] This study used laboratory blood results extracted from primary care 
databases from various centres from the UK. Individuals were identified as having 
stages 3-5 CKD if they two blood results 3 months apart and had eGFR (calculated or 
laboratory) persistently below 60ml/min/1.73m2 as per the KDOQI guideline. However 
individuals would also be labelled as having stages 3-5 CKD if they had lab eGFR or 
calculated eGFR, on the basis of a single blood result, below 60ml/min/1.73m2. 
In studies reporting prevalence of stages 3-5 CKD using both the MDRD and CKD EPI 
formula, the prevalence was lower using the CKD EPI formula.[49;66;67;80;87] This 
was likely due to that equation resulting in the eGFR being higher.  
2.1.2.The variation in prevalence 
The prevalence between studies and countries is highly variable. For stages 1-2 CKD 
this is likely due to whether urine dipstick or ACR was used to determine proteinuria. 
Urine dip associated estimates where likely to be lower as this method is insensitive at 
determining proteinuria. Prevalence will obviously be higher in groups where patients 
are older due to aging being related to reduced eGFR. This is illustrated by the Dallas 
57 of 375 
study where the patients were under 65 and the prevalence was only 1%.[50] CKD 
prevalence could also vary between countries especially for the MDRD equation which 
hasn’t been validated outside the United States.[13] Additionally variability in the 
United States could be due to sampling groups with more ethnic minorities.[54]
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2.2.Research Questions: What is the prevalence of CKD in primary care? 
In section 2.1 the prevalence of CKD varied from 1%-14% for stages 3-5 and 2-12% for 
stages 1-2 CKD. Stages 1-2 CKD are defined generally using urine protein excretion and 
defining stages CKD 1-2 is difficult in primary care as very few patients are likely to 
have a urine ACR measured but many patients have urine dipsticks for proteinuria. 
There was very limited evidence on the prevalence ‘true’ of stages CKD 3-5 based on 
two tests of renal function. Additionally the new CKD-EPI formula may be more 
accurate in determining eGFR but the prevalence changes from when the GFR is 
estimated by the MDRD equation.(Chapter 1.2) 
As CKD is major risk factor for cardiovascular disease and mortality in the population 
and associated with high economic burden (Chapter 1.5),it is important to determine 
the accurate prevalence of CKD using two blood results (to account for variation in GFR 
measurement) to allow these high risks groups to be targeted for intervention and 
predict resource requirement for this population. The latter has implications for whole 
NHS budget. Estimates from a large scale cohort such as THIN could allow the burden 
of CKD to be truly ascertained. 
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This chapter will address the first objective of the thesis to assess the prevalence of 
CKD stages 1-5 in UK general practice using the THIN database. 
Specifically the chapter will address the following research questions: 
1. What is the prevalence of stages 3-5 CKD from two blood results seven days 
apart? Stages 3-5 CKD will be defined by either two lab eGFRs or two calculated 
(using the non IDMS formula) eGFRs (using the non IDMS formula) below 60 
ml/min/1.73m
2
. 
2. Does the prevalence of CKD vary using different equations for eGFR calculated 
by the serum creatinine and laboratory reported eGFR? This is the secondary 
analysis. 
3. What is the prevalence of stages 3-5 CKD using a single blood result? This will 
be the sensitivity analysis. 
4.  Can urine dip data and albumin creatinine ratio be used to define the 
prevalence of CKD stages 1 and 2? 
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2.3.Methods 
This section highlights the methods used to: 1) prepare the database for analysis and 
examine the raw data; 2) compare laboratory eGFR and calculated eGFR; 3) ascertain 
the prevalence of CKD stages 3-5 using a single or two blood results; 4) compare urine 
ACR to urine dipstick and to determine the prevalence of stages 1-2 CKD. 
2.3.1.Preparing the database: first dataset 
All analyses were undertaken in SAS statistical software (SAS v9.2, SAS Institute, Cary, 
NC, USA) and R 2.15.1 software version (http://www.r-project.org/). The following 
data were received in a THIN data file containing data until November 2009:  
1. Clinical Data 
a. Serum creatinine data (numerical variable) 
b. Laboratory reported estimated glomerular filtration rates  
(numerical variable) 
c. Urine albumin creatinine ratios (ACR) (numerical variable) 
d. Urine micro albumin data (numerical variable) 
e. Urine dip for protein data (categorical variable) 
2. Patient File – This contained the patient demographics such as year of birth and 
gender and registration status 
3. AMR File – This contained the date the practice attained Acceptable mortality 
reporting indicating that data entry was accurate.[150] 
4. Midyear Counts. These consisted of the total number of patients split by age and 
for all the years since the creation of THIN. 
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2.3.1.1.Preparing and examining the dataset 
A summary of the steps taken to prepare the database for analysis is shown in Table 
2-4. Histograms were constructed for numerical variables using the SAS procedure  
(Proc Univariate). These included plots of creatinine; laboratory reported eGFR, urine 
dip data, ACR, weight, height and urine microalbumin data.  
Table 2-4. Preparation of database to determine CKD prevalence  
Database preparation Method and Rationale 
Removal of entries with missing event date  
Any additional Health Data with null values 
removed 
Data with null values coded as 0, 0000000, and 
0.000000 were removed. 0 values are removed as 
cannot be distinguished from nonsense values 
Dataset merged with patient file and then AMR 
file 
 
Any patients with AHD values occurring before 
the age of 18, 6 months prior to registration and 
prior to AMR date removed 
Data, 6 months pre registration is removed as 
when a patient is newly registered there is a lag 
between the arrival of their notes from their last 
primary care provider.[148] 
Data removed pre AMR date is discussed before. 
[150] 
Only patients with permanent or temporary 
registration retained 
 
Data split into constituent variables files  
 
  
67 of 375 
 
2.3.2.Examining renal function 
2.3.2.1.Calculating eGFR: Does laboratory eGFR correspond with calculated eGFR? 
The MDRD (both Non IDMS and IDMS formula), the CKD EPI and Mayo quadratic 
formula were used to calculate the eGFR as detailed in Box 1-3-Box 1-5. Lab eGFR was 
compared to the non IDMS calculated eGFR using Bland-Altman plots. (This will be 
relevant in Chapter 4 to 5 where only calculated eGFRs were used to determine CKD) 
There was considerable variability in the method by which creatinine was measured 
across the study period; scatter plots and Bland Altman plots were used to compare 
the consistency of calculated and lab eGFRs in patients with creatinine and lab based 
eGFR data recorded on the same day.[109] These comparisons were made only when 
the eGFR was below 60 as lab eGFRs are only likely to be reported directly below this 
threshold and many eGFRs would have been reported as ‘above 60’.[31] Additionally 
plots of CKD EPI versus the non MDRD equation were drawn.  
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2.3.3.The prevalence of stages 3-5 Chronic Kidney Disease 
2.3.3.1. The principal analysis 
The primary question is what the is prevalence of stages 3-5 CKD? There is 
considerable variability in eGFR (Chapter 1.2) and therefore all the guidelines state 
that patients should have a persistent reduction in eGFR over 3 months. In the QICKD 
study the prevalence was derived from patients with one or two blood test results and 
the prevalence may not reflect the actual prevalence and therefore the true 
prevalence of CKD needs to be ascertained. The principal analysis was to identify 
prevalence using two consecutive blood results. 
In the UK, the Quality and Outcomes Framework defines stages 3-5 CKD as two eGFRs 
below 60mls/min/m2 within 3 months and two blood results seven days apart were 
taken as a pragmatic definition to capture all those with two blood results as it was 
likely that much less of the population would have two blood tests 3 months apart and 
there is good agreement between two blood results.[49;157]  
The prevalence of CKD was ascertained for the years 2005-2009. For the year in 
question, the population included for this analysis had to have the following: be alive 
and registered prior to July; two consecutive laboratory eGFRs seven days apart or if 
these were not available two consecutive calculated eGFRs (using the non IDMS 
equation in Box 1-3) from serum creatinine. The proportion of patients with stages 3a, 
3b, 4 and 5, in the year in question, were determined using the higher eGFR from the 
two blood results.  
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2.3.3.2.Secondary analysis 
In the secondary analysis the prevalence was ascertained using two calculated eGFRs 
seven days apart where the eGFR was calculated using the non IDMS MDRD equation, 
IDMS MDRD equation, CKD-EPI equation and the Mayo Quadratic equation (Box 1-3-
Box 1-5). This prevalence was also extracted from those with two consecutive 
laboratory reported eGFRS. 
A separate sensitivity analysis was carried out using the single blood test results to 
determine prevalence using either calculated eGFR or laboratory eGFR from the latest 
blood result before July in each year in question and in addition the observed time 
difference between blood results was calculated.  
As the THIN population is older than the general population, it was necessary to age 
and gender standardise the prevalence.[144] To calculate this, for all CKD stages for 
each formula, the patients were split by gender and age and these groups were 
weighted using United Kingdom Office for National statistics population estimates for 
each year in question (Box 2-1).[135] This is known as direct standardisation.[158] 
Following this, 95% confidence intervals for proportions were constructed (Box 
2-1).[158] 
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Box 2-1. Crude Prevalence, Age and Gender Standardisation, 95% Confidence Intervals 
 Calculating crude prevalence  
Z[\]E^[E_JKE`aE = bcbJK`\IdE[cHaJeEeJbJDG_E`bGIEG. E^JbGE`befGbℎZhibcbJK^c^\KJbGc`JbbℎJbbGIE  
Age and gender standardisation 
j = kl^l  
Where j is age and gender standardised prevalence, N is the population (in this case the 
Office of National Statistics yearly age and gender estimates) for the age group i p is the 
prevalence of the condition in the cohort in question in age group i. 
Calculating 95% Confidence intervals for proportions e.g. prevalence rates 
Lower Confidence interval = ^ − 1.96 × mnno  
Upper Confidence interval = ^ + 1.96 × mnno  
Where p is the proportion and N is the population. 
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2.3.4.Defining Proteinuria 
2.3.4.1.Urine dip distribution and comparison with ACR in detecting microalbuminuria 
High albuminuria was used as a definition point over very high albuminuria, as even 
small amounts of albuminuria are predictive of cardiovascular risk and progression of 
renal disease (Chapter 1.5).[93] In primary care, patients are more likely to have urine 
dip data to estimate urine protein.[33] This is a semi-quantitative method that has 
poor negative predictive value but reasonable positive predictive value to detect 
microalbuminuria.[42] For the purpose of using urine dip data in the cardiovascular 
disease or all cause mortality model (Chapter 4 & 5), how adequately the urine dip 
result predicted microalbuminuria was determined. Urine dip data were transformed 
to the universal scale of nil, trace, 1+, 2+, 3+ and 4+ and frequency distribution of this 
was plotted in a bar graph. The ACR file was merged with the urine dip file where both 
ACR and urine dip occurred on the same event date. A box and whisker plot was 
constructed to examine a trend between urine dip data and ACR spread as well as 
Receiver Operating Characteristic curve.[109] 
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2.3.5.Prevalence of CKD stages 1-2 
Stages 1-2 CKD are defined by evidence of kidney damage (Chapter 1.3). This can 
either be the presence of persistent albuminuria and or persistent haematuria, or 
presence of structural kidney disease such as Adult Polycystic Kidney Disease 
(APKD).[1] As haematuria and evidence of APKD were not available, CKD 1-2 was 
staged using only urine protein excretion. The KDIGO definition of stages 1-2 CKD was 
used i.e. persistent “high” albuminuria (A urine ACR of 3 or above). This definition was 
used as even small amounts are associated with mortality.[93] By combining urine dip 
values that corresponded to high albuminuria (Table 1-2) and the standard definitions 
for high albuminuria from ACR, patients were coded as having high albuminuria or not. 
As with eGFR, albuminuria had to be persistent as it can be transient or due to 
measurement error and therefore needs confirmation on second measurement.[33] 
Patients with “high” albuminuria on two occasions at least one week apart, who were 
still registered by the 1st of July in the years 2005-2009 were included in the 
prevalence calculations. The crude prevalence was calculated for each year as detailed 
above (Box 2-1). Prevalence of stages 1-2 CKD were then age and gender standardised 
as above. Following this 95% confidence intervals for proportions were 
constructed.[158] 
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2.4.Results 
The results for prevalence of CKD in UK general practice are split into two sections:1) 
The prevalence of CKD stages 3-5 and 2) the prevalence of CKD stages 1-2. 
In the first section, the raw data used to identify stages CKD 3-5 are presented. Initially 
this comprises laboratory reported eGFR (lab eGFR). The section then further explores 
whether investigator calculated eGFR, using reported serum creatinine and the non 
IDMS MDRD equation, was comparable to laboratory reported eGFR. Furthermore, 
how the different methods of calculating eGFR such as the Mayo Quadratic or CKD EPI 
formula compared to the MDRD eGFR. This section then describes the prevalence of 
CKD 3-5 using the principal analysis, the secondary analysis and the sensitivity analysis. 
The 2nd section details the distribution of ACR and how accurate Urine Dip determines 
albuminuria. The prevalence of CKD stages 1-2 is then reported. 
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2.4.1. Stages 3-5 CKD: Identifying CKD in the cohort and Raw data distribution 
Patients with CKD 3- 5 were identified using either creatinine data or laboratory eGFRs. 
The baseline cohort consisted of 6 581 419 patients.  
• In total 1 982 568 patients (54.7% female) had a reported serum creatinine 
with a mean age of 62.9 (± 16.4) years.  
• 1 296 783 patients had a reported laboratory eGFR. The mean age was 62.9 (± 
16.9) years and 55.0% were female. 
• There were 688 518 patients who had a serum creatinine but no lab eGFR. 
The bar histograms for creatinine and laboratory eGFR are shown in Figure 2-1 to 
Figure 2-4. The medium serum creatinine was 87 (range 40 to 1000) mmol/litre and 
serum creatinine was slightly positively skewed. The histogram for calculated eGFR 
using the non IDMS MDRD equation showed a slight positive skew approaching a 
normal distribution (Figure 2-2) and the median calculated eGFR was 71.0 (range 3.4 to 
254.0) mmol/litre/1.73m2. The mean lab eGFR was 70.5 (Standard deviation ± 93.8) 
mmol/litre/1.73m2 and lab eGFR appeared normally distributed but there were large 
peaks where eGFR was equal to 60 and 90 ml/litre/1.73m2. These two peaks 
accounted for 30% of the data with the larger peak at 60 ml/litre/1.73m2. Laboratories 
reported eGFRs at either the 60 or 90 ml/litre/1.73m2 thresholds rather than actual 
values above these thresholds (Figure 2-3)  
  
Page 75 of 375 
 
Figure 2-1. Distribution of Serum creatinine 
 
 
 
Figure 2-2. Distribution of calculated eGFR 
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Figure 2-3. Histogram distribution of laboratory reported MDRD eGFR 
 
Figure 2-4. Histogram distribution of eGFR calculated by MDRD equation 
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2.4.1.1.Stages 3-5 CKD: Comparing different equations 
2.4.1.1.1.Comparing eGFRS: Laboratory eGFR versus non IDMS MDRD calculated eGFR 
In patients with both a serum creatinine and lab eGFR reported on the same blood 
results, scatter plots of lab eGFR showed a correlation between lab eGFR and calc 
eGFR (using the non IDMS equation) but there were vertical lines at where the lab 
eGFR equaled 15, 60, 90, 120, 150 and 180 ml/litre/1.73m2 (Figure 2-5). This was due 
to laboratories reporting the eGFR thresholds as an absolute value; for example if 
eGFR was above 60 ml/litre/1.73m2 it was reported as 60 ml/litre/1.73m2. In a plot 
where lab eGFR and calc eGFR were less than 60 ml/litre/1.73m2 the relationship again 
appeared linear (Figure 2-6). In a Bland-Altman plot (Figure 2-7), comparing calc eGFR 
versus lab eGFR, where both values were under 60 ml/min/1.73m2, the majority of 
data points lay within two standard deviations of the difference. There was a diagonal 
line emerging where the mean was 15 ml/litre/1.73m2and this was likely to represent 
where an eGFR of 15 ml/litre/1.73m2or below was reported at 15 ml/litre/1.73m2 by 
laboratories.  
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Figure 2-5. Laboratory MDRD eGFR versus Calculated EGFR using non IDMS MDRD equation 
 
 
Figure 2-6. Laboratory MDRD eGFR versus Calculated EGFR using non IDMS MDRD equation where 
both below 60 ml/min/1.73m
2 
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Figure 2-7. Bland Altman Plot for laboratory eGFR and MDRD calculated eGFR (Non IDMS) 
 
 
2.4.1.1.2.Comparing eGFRS: Non IDMS MDRD versus CKD EPI and Mayo Quadratic eGFRS 
When comparing the different equations for calculating eGFR (Box 3-6 in Methods), 
the MDRD eGFR (non IDMS equation) was compared to Mayo Quadratic eGFR and CKD 
EPI eGFR ( CKD EPI eGFR and the MDRD eGFR. (Figure 2-8 to Figure 2-9) in scatter plots 
split by gender. The Mayo plots initially showed a positive linear relationship between 
Mayo eGFR and MDRD eGFR. However the Mayo eGFR was higher at the same MDRD 
eGFR. For example when the MDRD eGFR was 70 ml/min/1.73m2 the Mayo eGFR was 
100 ml/min/1.73m2 in men. Above a MDRD eGFR of 75 ml/min/1.73m2 in men and 60 
ml/min/1.73m2 in women, the Mayo eGFR increased less sharply. There was a similar 
relationship between the CKD EPI eGFR and the MDRD eGFR.  
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Figure 2-8. Calculated MDRD (non IDMS) eGFR versus Mayo Quadratic and CKD EPI derived eGFRs in 
Men 
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Figure 2-9. Calculated MDRD (non IDMS) eGFR versus Mayo Quadratic and CKD EPI derived eGFRs in 
Women 
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2.4.2.Prevalence of stages 3-5 CKD using different equations and definitions 
The following section details how the prevalence varies when Stages 3-5 CKD are 
staged using: 
• Principal analysis – Prevalence ascertained from two blood results - either lab 
or calculated eGFR (if no eGFR reported) using the Non IDMS MDRD equation 
• Secondary analysis – Prevalence ascertained from two blood results 
o Two consecutive calculated eGFRs using Non IDMS MDRD, IDMS MDRD 
equation, CKD EPI equation and Mayo Quadratic equation 
o Two consecutive laboratory eGFRS 
2.4.2.1.1.: Principal analysis: CKD staged using two blood results either lab eGFR or 
calculated eGFR 
How the cohort was derived from the original THIN cohort for the principal analysis is 
shown in Figure 2-10. The proportion of patients with two serum creatinines seven 
days apart during the study period rose from 20.9% in 2005 to 34.5% in 2009. The 
median time apart from each laboratory report was 288 days (Interquartile range 126 
to 457 days) and by 2009 this was 339 days (153 to 579 days). The following 
proportions in text will be reported as age and gender standardised unless otherwise 
stated. The age and gender standardised prevalence of Stages 3-5 CKD derived from 
two lab eGFRs or two calculated eGFRs(where lab eGFR not available), using the non 
IDMS MDRD equation, was 4.27% (95% CI 4.25 to 4.29) in 2005, rose to 5.19% (5.16 to 
5.20) by 2007, then fell in 2008 to 5.13% (5.10 to 5.14) and continued to fall by 2009 to 
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4.78% (4.76 to 4.79) (Table 2-5). Regardless of year the commonest CKD stage was CKD 
3a, with prevalence of 3.56 % (3.54 – 3.57) in 2009 (Table 2-5).  
CKD prevalence by age and gender 
When deriving prevalence by age group and gender, two things were apparent, 
patients over 60 and women were more likely to have CKD. In women aged over 75 
over 30% of the population had stages 3-5 CKD (defined using eGFR calculated using 
two serum creatinines and the Non IDMS MDRD equation) (Figure 2-11) and in men 
this was over 20%. 
Figure 2-10. How the cohorts were defined for the principal analysis.  
^ indicated the patients who were alive and still registered at the practice by July of the year in question. 
* Patients aged over 18, alive and registered at the practice in July of the year in question 
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2.4.2.1.2.Secondary Analysis: CKD staged using two blood results 
The prevalence of CKD using two calculated eGFR using the non IDMS equation was 
higher than the principal analysis. (4.78 vs 4.67%). The prevalence of CKD was even 
higher using the CKD EPI equation and the IDMS MDRD equation (Figure 2-12). The 
prevalence of stages 3-5 CKD using these two equations in 2009 was 5.59% (5.56-5.60) 
and 6.53% (6.50-6.54)(Figure 2-12). CKD stage 3a was the commonest CKD stage 
regardless of equation. 
The proportion of patients identified with CKD stages 3-5 based on the Mayo quadratic 
equation was considerably less and varied from 1.67% to 2.03% depending on the year 
CKD stage 3a was the commonest CKD stage regardless of equation, followed by CKD 
stage 3a, 4 and 5. (Figure 2-12) 
The proportion of patients with two laboratory eGFRs rose from 2.4% to 21.43% 
between 2005 and 2009 (crude proportions) and the prevalence of Stages 3-5 CKD 
rose from 0.37% to 4.03%.(Figure 2-12) 
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2.4.2.1.3.Sensitivity analysis :Prevalence based on a single blood results 
The proportion of patients with two serum creatinines rose from 36.9% in 2005 to 
50.8% in 2009 (crude proportions). The prevalence results followed similar trends to 
those observed estimated using two blood test; CKD 3-5 prevalence rose between 
2005 to 2007 and then fell in 2009, using eGFR calculated by serum creatinine. In 
comparison with patients staged with CKD using two blood test result the prevalence 
was much higher. The 2009 prevalence estimates according to the different formulae 
are shown in Figure 2-13. In summary the 2009 prevalence was estimated at 6.94% 
(95% CI 6.91 to 6.96) using the Non IDMS MDRD eGFR; and 9.73% (9.70 to 9.75) using 
the IDMS MDRD eGFR and 7.71% (7.68 to 7.73) using the CKD EPI MDRD equation.  
Figure 2-13. The prevalence of stages 3-5 CKD using a single blood result according to equation or two 
lab eGFRs 
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Similar to prevalence results using two blood tests, the majority of patients had CKD 
stage 3a, followed by CKD stage 3b, 4 and 5. (data not shown). The CKD prevalence 
using the Mayo formula was approximately 3% (Figure 2-13). CKD 3-5 prevalence 
defined by lab eGFR was 7.71% (7.69% to 7.73%) in 2009 (Figure 2-13). In patients with 
either 2 eGFRs or 2 calculated eGFRs using the non IDMS MDRD equation, CKD 
prevalence was 6.77% (Figure 2-13). 
2.4.3.Prevalence of stages 1-2 CKD: ACR and Urine Dip Data 
In whole THIN cohort, 173 107 patients had a urine ACR and 752 993 patients had a 
urine dip. (Figure 2-14). In patients with an ACR, 94 542 patients had two ACRs 7 days 
apart and 22 000 patients had persistent microalbuminuria. In 378 665 patients with 
two urine dips 7 days apart 17 162 had a urine dip of trace or above.  
Urine ACR was positively skewed and the median ACR was 1.5 mmol/mmol (range 0 to 
5000). (Figure 2-15) In patients with urine dips, the majority of results were no 
proteinuria (85.7%), followed by trace proteinuria (6.0%) and then 1+ proteinuria 
(4.0%). 
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Figure 2-14. Schematic of urine ACR/Prot Data and Derivation of CKD 1-2 
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Figure 2-15. Histogram of Albumin Creatinine Ratio 
 
 
2.4.3.1.The accuracy of urine dip  
There were 58 216 instances where patients had a urine dip and reported urine ACR on 
the same day. There was a trend for increasing albuminuria with increasing 
quantification on urine dip (Figure 2-16). 
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Figure 2-16. Box and Whisker plot of ACR versus urine dip 
  
If the urine dip was defined as trace proteinuria or above compared to ACR then the 
sensitivity of detecting albuminuria was 27.1%, the specificity was 91.6%, the positive 
predictive value was 41.7% and the negative predictive value was 85.0%. If defining 
albuminuria 1+ or above then sensitivity fell to 17.1%, the specificity rose to 96.3%, the 
positive predictive value rose to 50.4% and the negative predictive value fell to 84%. 
The ROC curves demonstrate this (detailed in Figure 2-17) and therefore trace 
proteinuria was used to define proteinuria.  
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Figure 2-17. ROC curve for urine dip to diagnose albuminuria 
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2.4.3.2. Prevalence of stages 1-2 CKD 
The proportion of patients with two consecutive ACRs rose from 5.51% to 8.26% 
(crude proportions) between 2005 and 2009. The proportion of patients with two 
urine dips greater than 14 days apart rose from 5.59% to 8.34% between 2005 to 2009. 
The age – standardised prevalence of CKD stages 1-2 rose from 0.04% (95% CI 0.041 to 
0.046) defined by albuminuria on ACR to 0.32% (0.312 to 0.325) between 2005 and 
2009 (Table 5). The age – standardised prevalence of CKD stages 1-2 rose from 0.21 % 
(95% CI 0.20 to 0.21) defined by urine dip of trace or above 0.34% (0.33 to 0.35) 
between 2005 and 2009 (Table 2-6).  
Table 2-6. Prevalence of CKD stages 1-2 using either ACR or Protein dipstick  
 Prevalence % (95% CI in brackets) 
Year 
(Denominator population) 
Using Urine ACR Using Urine Protein dipstick 
2005 
(2648075) 
0.04(0.04-0.05) 0.21(0.20-0.21) 
2006 
(2672312) 
0.08(0.08-0.09) 0.23(0.23-0.23) 
2007 
(2711880) 
0.13(0.13-0.14) 0.27(0.26-0.27) 
2008 
(2717171) 
0.24(0.23-0.24) 0.30(0.29-0.31) 
2009 
(2707130) 
 
0.32(0.31-0.33) 0.34(0.33-0.35) 
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2.5.Discussion. 
This section will discuss the results for prevalence of CKD using different combinations 
of reported results and different methods of estimating eGFR. Overall combining CKD 
3-5 with stages 1 and 2, the combined prevalence was 5.01%. Because of the different 
methodologies employed in defining CKD 3-5 and CKD 1-2, they will considered 
separately.  
2.5.1.Summary of key findings for stages 3-5 CKD 
2.5.1.1.The Prevalence of stages 3-5 chronic kidney disease 
In the principal analysis the prevalence of stages 3-5 was 4.67%. In the secondary and 
sensitivity analysis, prevalence varied according to available data (for lab eGFR), the 
equation used to derive eGFR (and therefore staging) and whether two blood results 
were available. The table below summarises the prevalence of stages 3-5 CKD using a 
single blood result or two consecutive blood results by equation used to derive eGFR 
and lab eGFR in 2009. The numbers are age and gender standardised. 
Table 2-7. Summary of prevalence of Stages 3-5 CKD in 2009 from the thesis 
Formula or Lab eGFR Two blood results A single blood result – 
sensitivity analysis 
Lab eGFR/non IDMS MDRD 4.67% 6.77% 
Non IDMS MDRD 4.78% 6.94% 
IDMS MDRD  6.53% 9.73% 
CKD EPI 5.59% 7.71% 
Mayo Quadratic 1.93% 2.63% 
Lab eGFR 4.03% 6.02% 
 
The commonest CKD stage was stage 3a CKD regardless of how eGFR was calculated. 
For example in 2009 using two consecutive lab eGFRS the prevalence of CKD stage 3a 
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was 3.56%. This accounted for 76% of people with stages 3-5 CKD. Stages 3-5 CKD 
were more common in patients aged over 60 and women.  
2.5.2.Interpretation of results and comparison to existing literature  
 
2.5.2.1.Prevalence of stages 3-5 CKD 
When comparing the lab eGFR and the eGFR calculated by the non IDMS MDRD 
formula, even though the lab and the method analysed was unknown the two tests 
showed reasonable agreement when the eGFR was below 60 ml/min/1.73m2. This 
suggests that, despite the method of measuring creatinine varied between 
laboratories, diagnosing stages CKD 3-5 with a calculated eGFR using the Non IDMS 
MDRD equation was reasonably accurate.  
This was supported by fact that the difference between the proportion of patients with 
CKD 3-5 using both lab eGFRS/calculated eGFR and only Non IDMS MDRD calculated 
eGFRS was similar. To further illustrate this point, by 2009, 931 262 patients had two 
serum creatinines and of these 645 852 had had a reported eGFR. If prevalence was 
defined by a calculated eGFR (Non IDMS MDRD) then the prevalence would be 4.78%. 
However the prevalence fell slightly to 4.67% when using both lab eGFR and calculated 
eGFR. This suggests a marginal understimation of calculated eGFR over lab eGFR. 
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CKD prevalence varied over time using the non IDMS MDRD equation. It is likely the 
observed increase and subsequent decrease in prevalence over the study period is due 
to changes in the creatinine analysis method used in laboratories providing blood 
results to practices in THIN.[31] Post 2006, to enable greater accuracy and 
generalisability of creatinine results, more laboratories switched to IDMS traceable 
methods of creatinine analysis.(1.2.8)[9] A creatinine generated by non IDMS methods 
was likely to be higher if the same blood test was analysed by IDMS methods (hence 
the change in coefficient in MDRD equation). So, as more laboratories switched to 
IDMS methods, serum creatinines would be lower (the lower the creatinine the higher 
the GFR) and hence the prevalence fell.[31] 
Table 2-8. Methods of creatinine analysis using UK National External Quality Assessment Service 
based laboratories[31] 
 Proportion of laboratories using this method 
 
Method of Measuring Creatinine April  
2006 
April 
2009 
December 
2010 
Dry slide 10.2 9.6 8.1 
Endpoint Jaffe 3.5 2.4 1.3 
Enzymatic* 0.8 3.9 9.4 
Compensated Kinetic Jaffe* 20.4 38.6 57.6 
Traditional Kinetic Jaffe 52.9 37.1 20.7 
O'Leary 10.6 7.5 2.9 
*Traceable to IDMS 
This is also the reason why the prevalence in general was higher when Stages 3-5 CKD 
are derived from IDMS calculated eGFR. The prevalence of CKD was likely to be more 
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accurate where CKD was staged by Non IDMS eGFR between 2005-2008; whereas the 
IDMS eGFR staged CKD would be more accurate in the later years i.e. 2009 onwards 
because the method of creatinine analysis was likely traceable to IMDS.   
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2.5.2.2.MDRD Equation single blood result 
Using a single blood test, the prevalence derived by the non IDMS MDRD formula 
6.94%. This was higher than results estimated from previous screening studies 
(NHANES -5.6 %, HUNT – 4.7%, HSE 6.0 %) but lower than single studies using primary 
care estimates such as NEOERICA (8.5%).[32;52;62] The reason that this was lower 
than the NEOERICA is because the NEOERICA study examined period prevalence rather 
than point prevalence, i.e. patients were diagnosed with CKD 3-5 if they had an eGFR 
below 60 between 1998 and 2003 and did not account for fluctuation in eGFR between 
years. The reason for these differences may be that the characteristics differ of 
patients who have been screened. People who participated in voluntary screening 
programmes or studies are likely to be co-operative and healthier patients. 
Interestingly the proportion of CKD 3-5 defined using a single lab eGFR and/or 
calculated eGFR in this study (6.77%) was similar to the prevalence observed in the UK 
based QICKD study (6.7%).[49] QICKD defined prevalence of CKD 3-5 using two 
consecutive lab eGFRs, two consecutive calculated eGFRS, a single lab eGFR and single 
calculated eGFR combined. They preferentially used lab reported eGFR and two results 
where available.  
 
2.5.2.3.Prevalence based on two blood results and MDRD equation 
Perhaps unsurprisingly, prevalence estimates based on two blood results were much 
lower than those based on a single blood test. Creatinine shows inherent fluctuation 
and may increase temporarily if the patient suffers acute kidney injury or has started 
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on angiotensin blockade. This will temporarily lower the eGFR. Serum creatinines show 
better calibration on more than one occasion.[32] This is why the N/KDOQI guidelines 
recommend confirmation of CKD in two blood tests three months apart. In the analysis 
in this thesis, a minimum difference of 7 days was specified but the majority of 
patients had serum creatinines taken more than 90 days apart (in 2009 this was 339 
days (IQR 153-579 days). As mentioned previously using two blood results is the best 
method to define CKD but with closer time points. (Chapter 2) 
The results showed that Stage 3 CKD was the most commonest stage and that the 
prevalence was higher in women and older patients. These findings are consistent with 
the literature.[48] 
 
2.5.2.4.Prevalence: other equations 
Prevalence of CKD 3-5 was also defined using a variety of other equations. The CKD EPI 
based CKD prevalence is higher than Non IDMS prevalence but lower than IMDS based 
prevalence. The CKD EPI formula was designed for serum creatinines analysed using 
IDMS methods and therefore non IDMS serum creatinines would be higher and inflate 
the prevalence of CKD. However CKD EPI formula tries to correct for under estimation 
of eGFR when using the (IDMS) MDRD equation and prevalence is therefore lower than 
the IDMS derived estimates.[27;49;66;67;80] Currently all laboratories use IDMS 
methods and therefore CKD EPI derived prevalence will not be confounded by 
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laboratory method. The risk of death and ESRD may be better predicted in those 
diagnosed with CKD by CKD EPI formula.[159] 
The prevalence derived using Mayo quadratic based equation was much lower. The 
Mayo quadratic formula was derived using serum creatinine analysed by a different 
assay from the MDRD and CPD EPI studies. It therefore requires a correction to make 
the creatinine comparable to serum creatinines analysed in the MDRD study.(Chapter 
1.2) 
 
2.5.3.Limitations and Strengths  
The biggest limitation in calculating the eGFR is that the method of creatinine analysis 
used in the lab contributing the result was unknown and furthermore that the 
ethnicity of many affected patients was unknown. The method of creatinine analysis 
may lead to inaccuracy when calculating eGFR: for example if the creatinine was 
analysed by IDMS methods and then the eGFR was calculated by Non IDMS MDRD 
equations, the prevalence of CKD will appear lower as the eGFR will be lower than 
expected.[9] The converse is true the other way round and this is why the prevalence 
dips after 2007. However the calculated eGFR using non IDMS formula and the lab 
eGFR were broadly comparable and this method of defining CKD will have a high 
specificity but still at least 80% sensitivity and is the optimal way to define CKD from a 
cohort such as this.[157] The combined two result prevalence of CKD derived from the 
lab eGFR and non IDMS MDRD equation is likely to be closest to the population 
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prevalence of Stages 3-5 CKD. This is provided that adults without 2 results do not have 
CKD. 
It is difficult to interpret the findings of prevalence using the non MDRD equations. The 
prevalence defined using CKD EPI is likely to inflate prevalence especially early in the 
study period years when the implementation of IDMS aligned creatinine analysis was 
low.  
A further limitation is that the proportion of patients with black ethnicity was 
unknown. In such patients the eGFR would have been under-estimated (black patients 
have higher muscle mass, therefore they have higher creatinines in comparison to 
white population). This population would have been misdiagnosed with CKD. However 
the proportion of those with black ethnicity in the UK at the time was only 3% and 
therefore this would have limited impact on the whole population prevalence.[135] 
The QICKD study found little difference in prevalence when eventually accounting for 
ethnicity.[49] 
Other drawbacks to this work include the usual limitations of retrospective studies. 
Though THIN data were collected prospectively, the data were analysed 
retrospectively. Patients who have had blood tests are not a randomly selected, which 
means they are less representative of the whole population: those likely to have serum 
creatinines are older and have more co-morbidity in comparison the general 
population.[66] Despite these caveats, this cohort is more likely to represent a ‘real 
world’ population than other secondary care based estimates and patients with higher 
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co-morbidity are more likely to have CKD.[133] Furthermore NICE advises that health 
care practitioners target high risk populations for CKD testing and screening.[44] Even 
if a large screening study were undertaken, it is likely that patients included in this 
study would not necessarily have participated and therefore this represents one of the 
largest samples from which the prevalence of stages 3-5 has been defined. Apart from 
the QICKD study this is the only study to examine the chronicity of CKD in primary 
care.[49] 
 
2.5.4.Summary of Results for Stages 1-2 CKD  
To derive the prevalence of stages 1-2 CKD, the accuracy of urine dip to detect high 
albuminuria was examined. When using the threshold of trace proteinuria or above on 
dipstick, the sensitivity was 27.1% and specificity was 91.6%. When using the threshold 
of 1+ proteinuria or above on dipstick there was a marginal increase in specificity 
(96.3%) at a cost of sensitivity (17.1%). Therefore high albuminuria was defined as 
trace proteinuria or above. The proportion with two urine dips, 7 days apart was 8.26% 
and two urine ACRS 7 days apart was 5.51%. Stages 1-2 CKD were rare and the age and 
gender standardised prevalence were 0.34% and 0.32% using urine dip and urine ACR 
respectively in 2009.  
2.5.5.Interpretation of Results and Comparison to existing literature 
Urine dip is insensitive but specific in detecting high albuminuria.[42] Therefore if a 
patient consistently has trace proteinuria they are likely to have high albuminuria 
levels. This study confirms the findings from the AUSDIAB study that urine dip was 
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insensitive but highly specific at detecting high albuminuria.[42] In this study 
population very few patients had two consecutive urine dip results and this may reflect 
under ascertainment of CKD as in the screening studies a significant larger proportion 
of patients had stages 1-2 CKD.[62]  
2.5.6.Strengths and Limitations 
The major limitation to this part of the thesis is that very few people had the gold 
standard of urine ACR and although many patients had urine dips, this is a relatively 
insensitive method to detect albuminuria.[42] Additionally stages 1-2 CKD was defined 
using high albuminuria as opposed very high albuminuria which is required by the 
NKDOQI, NICE, and SIGN guidelines. However the international KDIGO guidelines state 
that the high albuminuria threshold that should be used defined stages 1-2 CKD and 
patients with high albuminuria are at high risk of cardiovascular morbidity and 
mortality and therefore the KDIGO definition was adopted to define stages 1-2 CKD. 
Areas of future research will be discussed in chapter 6.[93] 
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2.5.7.Executive Summary 
• CKD is defined by reduced GFR or kidney damage i.e. proteinuria 
• eGFR can be estimated from creatinine based equations such as the MDRD or 
CKD-EPI formula 
• There can be considerable variation in creatinine measurement and this 
coupled with the different formulae can lead to a variation in eGFR and CKD  
• CKD prevalence is very variable between countries and study groups. 
• Overall this study found a combined prevalence of stages 1-5 CKD of 5.01% 
• In the primary analysis the prevalence of stages 3-5 CKD was 4.67% using two 
blood tests  
• CKD 3-5 prevalence varied according to the equation used to derive CKD. 
• CKD 3-5 was more common in women and the elderly. 
• Urine dip was insensitive but specific at determining microalbuminuria. 
• CKD 1-2 prevalence was relatively low was about 0.32-0.33% in 2009. 
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CHAPTER 3. DO PRIMARY CARE PRACTICES CORRECTLY DIAGNOSE 
STAGES 3-5 CKD COMPARED TO OBJECTIVE MEASURES AND HOW DOES 
THIS IMPACT ON PATIENT CARE? 
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3.1.Introduction 
This chapter describes current guidance for the management of CKD in primary care 
from an international and UK perspective. Specifically it describes the UK Quality 
Outcomes Framework for CKD which has driven primary care management in the UK. 
The chapter explores the accuracy of diagnosis based on QOF reporting compared to 
eGFR results. The management of CKD Stages 3-5, including those recognised, 
unrecognised and mislabelled, is reported and the implications for UK general practice 
discussed. 
In response to the public health problem of CKD, a variety of international and national 
guidelines for diagnosis and management of CKD have been produced.[1;43;160;161] 
Guidelines for CKD originate from work by the National Kidney Foundation Kidney 
Disease Outcomes Quality Initiative (N/KDOQI) [1] The guidelines call for early 
recognition of CKD so that earlier intervention can be implemented i.e. treatment of 
cardiovascular risk factors. They specify management guidelines, including 
interventions for blood pressure, cholesterol and anaemia.[1] 
The KDIGO guidelines were developed after an international conference in order to 
compare (and unify) different international guidelines in 2003 to improve the care and 
outcomes of CKD patients.[43] The guidelines have recently been updated for blood 
pressure, CKD classification and management. Interestingly they define proteinuria as 
“high albuminuria” (Table 1-2) when diagnosing CKD stages 1-2, this differs from 
current UK NICE guidance but may be adopted in the future.[43;44] 
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In the UK as a response to the high prevalence and poor outcomes of CKD, the 
Department of Health set up a specific National Service Framework (NSF) for dialysis 
and transplantation in 2004. CKD, acute renal failure and end of life care were added 
subsequently to the framework.[160] The NICE guidelines for the diagnosis and 
management of CKD were published with consultation with various stakeholders such 
as the Royal Colleges of Physicians, GPs and Pathologists plus charities including 
Diabetes UK and Kidney Research UK in 2008.[44] 
In brief, NICE specify guidelines for diagnosing and classifying CKD with emphasis on 
using IDMS aligned methods to report eGFR and ACR to define proteinuria.[44] They 
specify pathways for the diagnosis and monitoring of renal function in patients with 
and without diabetes and regard patients with an ACR above 30 mg/mmol as having 
proteinuria in non diabetics. They also specify management pathways for patients with 
or without diabetes. In patients with diabetic CKD, high albuminuria and hypertension, 
Angiotensin blockers are recommended whilst in patients with non-diabetic CKD, 
Angiotensin blockers are recommended in patients with hypertension and an ACR 
above 30 mg/mmol. Patients with non-diabetic CKD and an ACR below 30 should be 
offered standard antihypertensive regimes. The guidance also specifies referral to 
specialist (secondary care) if patients have stage 4 or 5 CKD, non Diabetic CKD and ACR 
above 70, declining eGFR, poorly controlled hypertension and rare diseases.[44] 
How these guidelines have impacted upon the management of CKD is difficult to 
estimate. In UK, health care is free at the point of access and primary care is the first 
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point where patients consult before being referred to additional services. Since 2006, 
as primary care physicians started to receive direct measures of renal function from 
laboratories for their patients, the diagnosis of CKD increased as did referrals to 
secondary care.[162] Stable CKD 3 patients without high levels of proteinuria and 
recalcitrant hypertension can be managed in primary care.[44] However, this is a huge 
undertaking as the majority of CKD patients newly diagnosed are in this category and 
specialist care has further discharged patients back to primary care.[163] 
3.1.1.The UK Quality Outcomes Framework 
The QOF is a payment for performance (P4P) scheme first introduced in the General 
Medical Services Contract for primary care physicians in the UK in 2004.[164] In a 
review of QOF and the selection of indicators it difficult to determine whether QOF 
aims to improve quality of care or implement basic standards.[164] The QOF consists 
of four domains which are clinical management, organisation of clinical services, 
patient experience and additional services. In the clinical domain, in 2009/2010 there 
were 20 diseases or health management areas covered and in total 86 management 
targets or indicators.[140] This accounted for up to 25% of the revenue that primary 
care physicians received from the NHS if they achieved targets in 70% of relevant 
patients.[45] Practices are remunerated in a scaled payment dependant on whether 
they achieve a certain proportion of the targets in their denominator population. This 
system was almost universally adopted by general practitioners by 2006.[165] 
QOF targets are specific to common conditions, have impact on morbidity and 
mortality, are identifiable and applicable to primary care.[164] Therefore it is not 
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surprising that there are clinical indicators for chronic disease management such as 
diabetes, asthma, hypertension and CKD. When managing these patients according to 
QOF, the primary care practice is asked to first identify patients with such a disease on 
the chronic disease register and then meet management targets. These QOF points are 
identified through coding in the primary care electronic patient records i.e. Read codes 
which are described further in the methods section.  
Chronic Disease registers not unique to the UK. European countries such as Sweden 
and Denmark have an extensive number of disease registers, for example Sweden had 
over 90 such registries (Table 3-1).[166] These have been shown to improve health and 
outcomes in both countries.[166] In the United States and Canada such national 
registers have only been developed in the last few years. For example in 2006 only 
52% of health care providers instituted P4P related disease registers.[167-169](Table 
25) 
Table 3-1. Countries with disease registers and involvement in payment for performance 
Country  Disease register Related to Payment for 
Performance 
Australia Diabetes 
Hypertension 
Chronic Kidney Disease 
Cancer  
Cardiovascular Disease 
COPD 
Yes[40] 
United States America Asthma 
Diabetes 
Hypertension 
Chronic Kidney Disease 
Arthritis 
Yes part of Medicare / 
Medicade called the Physician 
Quality Reporting System  
Also adopted by other Health 
care organisations[170] 
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Canada Cardiovascular Heart Disease 
Diabetes 
Hypertension  
 
Not at a national level[171] 
Finland Cardiovascular Disease Yes[172] 
Sweden Multiple Registers 
Heart Failure 
Diabetes 
Cancer 
Stroke 
COPD 
and another 70 conditions 
Yes multiple initiatives which 
incorporate use of 
registers[173] 
 
The UK QOF targets for CKD for the years 2008-2009 are described  
Table 3-2, but there are additional indicators that pertain to CKD such as diabetes 
(Table 3-3) and hypertension both of which are highly prevalent in CKD patients.[140] 
 
Table 3-2. QOF indicators for CKD in 2008/2009[140] 
Indictor Points 
Records  
CKD 1: The practice can produce a register of patients aged 18 years and over 
with CKD (US National Kidney Foundation: Stage 3 to 5 CKD) 
6 
Initial management  
CKD 2: The percentage of patients on the CKD register whose notes have a 
record of blood pressure in the previous 15 months 
6 
Ongoing management  
CKD 3: The percentage of patients on the CKD register in whom the last blood 
pressure reading, measured in the previous 15 months, is 140/85 or less 
11 
CKD 5: The percentage of patients on the CKD register with hypertension and 
proteinuria who are treated with an angiotensin converting enzyme inhibitor 
(ACE-I) or angiotensin receptor blocker (ARB) (unless a contraindication or side 
effects are recorded) 
4 
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 Table 3-3. QOF indicators for diabetes mellitus specific to CKD patients in 2008/2009 
Indicators Points 
Ongoing management  
DM 2. The percentage of patients with diabetes whose notes record BMI in the 
previous 15 months 
3 
DM 5. The percentage of patients with diabetes who have a record of HbA1c or 
equivalent in the previous 15 months 
3 
DM 20. The percentage of patients with diabetes in whom the last HbA1c is 7.5 
or less (or equivalent test/reference range depending on local laboratory) in 
the previous 15 months  
17 
DM 7. The percentage of patients with diabetes in whom the last HbA1c is 10 
or less (or equivalent test/reference range depending on local laboratory) in 
the previous 15 months  
11 
DM 11. The percentage of patients with diabetes who have a record of the 
blood pressure in the previous 15 months 
3 
DM 12. The percentage of patients with diabetes in whom the last blood 
pressure is 145/85 or less 
18 
DM 13. The percentage of patients with diabetes who have a record of micro-
albuminuria testing in the previous 15 months (exception reporting for patients 
with proteinuria) 
3 
DM 15. The percentage of patients with diabetes with a diagnosis of 
proteinuria or micro-albuminuria who are treated with ACE inhibitors (or A2 
antagonists) 
3 
DM 16. The percentage of patients with diabetes who 40-90% 
have a record of total cholesterol in the previous 15 months 
3 
DM 17. The percentage of patients with diabetes whose 40-70% 
last measured total cholesterol within the previous 15 months is 5mmol/l or 
less 
3 
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The advent of QOF has had advantages and disadvantages. QOF allows management of 
patients to universal standards, regardless of gender, ethnicity or socioecomnic 
background and evidence suggests that there is a reduction in health inequalities in 
some but not all of these areas.[174;175] There is also evidence to suggest 
improvement in indicators, such as the management of blood pressure in patients with 
hypertension, cardiovascular disease and diabetes [165] and glycaemic control and 
cholesterol in patients with diabetes.[141;176-178] The evidence for translation of 
achievement of short term goals to long term benefit is limited to two economic 
analyses, however both studies suggest a reduction in hospital admissions related to 
stroke and diabetes.[179;180] Potential arguments against the QOF are that universal 
care moves away from patient led care, evidenced based care should be standard and 
not incentivised, and care may not improve in non-incentivised areas.[165;181] 
For patients with CKD, limited evidence suggests that blood pressure management 
improved after the introduction of QOF but there have been no large published 
studies. Additionally recognition of CKD may not be accurate as in 2009 the crude 
prevalence of CKD was 4.2% according to QOF which substantially differs from 
previous UK prevalence estimates. This suggests that practices do not identify all 
patients with CKD. Given the evidence above that patients in other diseases are not 
appropriately managed if not recognised by the practice QOF disease registers, it is 
important to analyse QOF performance in patients with CKD.[45;63].  
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3.2.Research Questions 
This chapter will address the following research questions: 
1.  Do primary care practices correctly identify those people with stages 3-5 CKD 
on the QOF primary care register? 
This is ascertained by what proportion of patients with a QOF Read code for 
CKD had biochemical evidence of CKD.(Chapter 3.4.1) 
2. What is the burden of co-morbidity of those with CKD based on an e-GFR 
diagnosis and those on the primary care register and did they differ in a 
univariate analysis?(Chapter 3.4.1.1) 
3. What factors lead to exclusion from the primary care CKD register in a 
multivariate analysis? (Chapter 3.4.1.2) 
4. Does achievement of QOF indicators differ between CKD patients excluded from 
the practice register to those on the register? (Chapter 3.4.2) 
5. Does achievement of Diabetes QOF indicators differ between CKD patients with 
diabetes excluded from the practice register to those on the register? (Chapter 
3.4.2.1) 
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3.3. Methods 
3.3.1.Study Population  
3.3.2.Estimating prevalence of CKD 3-5 on primary care practice register between 
2005 to 2009 
The prevalence of stages 3-5 CKD identified on practice registers was calculated by 
extracting the proportion of patients with a QOF business code for CKD for the QOF 
year ( on the 1st April ) in question between 2005 and 2009. This period corresponds to 
the time when the QOF would be analysed nationally in each practice. QOF business 
codes are specific read codes that indicate diagnosis of a disease.[45] Crude 
prevalences were then age and gender standardised and 95% confidence intervals 
were calculated. (Box 1-1) 
3.3.3.Estimating the proportion of patients with CKD (stages 3-5) Read codes had 
biochemical evidence of CKD in the QOF analysis period of 2008-2009  
CKD was defined using laboratory eGFR. Patients had to demonstrate two eGFRs below 
60 ml/min/1.73m2, at least seven days apart, to be diagnosed with CKD stage 3-5 
before April 2009. Patients had to be aged 18 or above at the time of CKD diagnosis. 
The following groups were defined and the proportions in each calculated: 
• Confirmed CKD: sustained biochemical evidence of stages 3-5 CKD, i.e. laboratory 
eGFR under 60 mls/min/1.73m2 on the last two consecutive eGFRs before 1st April 
2009 that were at least seven days apart. 
• Labelled CKD: patients recorded by the practice as having stages 3-5 CKD by a Read 
code defined according to the UK QOF Business Rules.[140]  
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• Appropriately coded: patients with both a relevant Read Code for CKD and 
biochemical evidence of an eGFR under 60 mls/min/1.73m2 In the last two 
consecutive eGFRs before 1st April 2009 that were at least seven days apart. 
• Uncoded CKD: patients with confirmed CKD (i.e. biochemical evidence as per 
definition above) but no relevant CKD Read code entered into their records.  
• Miscoded CKD: patients with a relevant Read code for stages 3-5 CKD but no 
biochemical evidence of stages 3-5 CKD (using above definition).  
 
Note that these definitions were applied by year hence if a patient had CKD previously 
but no longer had CKD in 2008-2009 then they would be defined as miscoded. Note 
patients with biochemical CKD were defined by two blood results not a single blood 
result. 
3.3.4.Demographic and comorbid characteristics of these groups  
From the November 2009 THIN dataset, as of 1st April 2009, the following were 
ascertained for the general population: confirmed CKD, labelled CKD, appropriately 
coded, uncoded CKD and miscoded CKD groups. 
• Basic demographics such as age, gender and race 
• Deprivation index: latest Townsend score as defined in Chapter 2[154]  
• Smoking Status 
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• The following co-morbid conditions: 
• Cardiovascular Disease (Ischaemic Heart Disease, Stroke and Peripheral Vascular 
Disease) 
• Diabetes Mellitus 
• Hypertension 
• Hypercholesterolaemia 
The co-morbid conditions were extracted from Read codes for the specific conditions 
using QOF business codes for the disease definitions, from previous definitions and 
direct examination of the Read codes based on clinical experience.[45;182] 
3.3.5.Characteristics of CKD patients that were excluded from the QOF CKD register  
It was important to recognise the factors that may predict the inclusion of individuals 
onto the QOF register as inclusion on the register was likely to result in better 
management.[141] Identifying the predictors for inclusion on the CKD register would 
help us to target any populations in whom the CKD diagnosis was missed.  
Patients with confirmed CKD (based on 2 e-GFR results) were included in this analysis 
and the outcome was exclusion from the QOF register, i.e. a binary outcome. The co-
variables for this analysis were age, gender, race, Townsend Quintile, co-morbid 
conditions as detailed in the previous section and smoking status. The co-variables 
were entered into a mixed model in a backward stepwise selection process with α = 
0.05 as criteria for model inclusion using the SASV9.2 PROC GLIMMX with a logit link 
and practice location as random effects term.[183] Non linear functional forms were 
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considered for age (log transformation).[184;185] The final model contained the 
significant co- variables. Practices were included as a random effects term, as practice 
management and the characteristics are likely to be different and represent clustering 
which may not be captured in the other co-variables.[183] 
3.3.6.What are the differences between Uncoded and Miscoded patients – a mixed 
model 
It was of interest to determine the differences between miscoded and uncoded CKD 
patients. The same methodology as above was used. The outcome in this model was 
exclusion from the CKD QOF register. The co variables were the same as above with 
the exception of CKD stage which is not applicable to miscoded CKD patients. Practice 
location was fitted as random effects term for the reasons described above. The same 
model selection procedures as above were used.  
3.3.7.Comparison of QOF indicators between patients with labelled and confirmed 
CKD  
As discussed in the introduction to this chapter, it is possible that patients with a 
particular disease who were not on a QOF disease register may have worse 
management than those on the disease register.[141] The management of patients 
with appropriately coded CKD on the QOF register was therefore compared to those 
patients with uncoded CKD. In further exploratory analyses, the management of 
uncoded CKD patients was compared with miscoded patients to assess the influence of 
coding. 
Patients with labelled CKD and confirmed CKD with the appropriate QOF indicators 
were included in the analysis. The QOF indicators have been described earlier in this 
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chapter. The proportion of patients with labelled CKD, confirmed CKD, appropriately 
coded CKD, miscoded CKD and uncoded CKD with following indicators prior to April 
2009 were calculated:  
• The proportion who had a blood pressure in the last 18 months 
• The proportion who had a blood pressure ≤ 145/85 in the last 18 months 
• The proportion who had a urine ACR in the last 18 months  
• The proportion who had a urine ACR >30 units in the last 18 months 
• Those proportion coded with hypertension, an ACR above 30 units and on an 
ACE inhibitor in last 18 months 
The proportions of achieved indicators were compared between the uncoded and 
appropriately coded CKD patients and the uncoded and miscoded CKD groups using 
Pearson Chi-Square tests.[109] Cholesterol and blood pressure results were extracted 
and were compared using student’s T test if normally distributed or using the Mann 
Whitney Test if not. 
As a significant proportion of patients with CKD have diabetes, the appropriate 
Diabetes QOF indicators were compared between the same groups using the same 
statistical methods as above.  
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3.4. Results 
3.4.1.Who is on the Practice CKD register?  
The baseline population for analysis consisted of 2 701 730 patients aged over 18, alive 
and registered at their current practice for at least six months on the 1st April 2009 of 
whom 631 905 patients (23.4%) had two lab eGFR seven days apart.  
The flowchart in figure 3-1 demonstrates how patients were identified by biochemical 
criteria or having ‘CKD Read codes’ specific to QOF between 2008/2009 (Figure 3-1).  
There were 108 911 (4.0%) patients with stages 3 to 5 CKD (confirmed CKD) and the 
majority of these had CKD stage 3a (79 505, 73%), followed by CKD stage 3b (24 018, 
22%), then CKD stage 4 (5010, 4.6%) and lastly CKD stage 5 (872, 0.8%).(Figure 3-2)  
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Figure 3-1. Flowchart of how patients were defined with CKD for QOF analysis cohort 
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Figure 3-2. Proportion of patients with biochemical CKD versus classified CKD 
 
 
In 2009, 139 176 (5.1%) appeared on practice registers (labelled CKD) (Figure 19). Of 
those with biochemically confirmed CKD, 78 471/108 911 (72%) were labelled with a 
Read code for CKD 3-5. A further 60 705/139 176 (44%) of labelled CKD patients had a 
Read code but no biochemical evidence of CKD (i.e. were miscoded) and 30 440/108 
911 (28%) fulfilled biochemical criteria for CKD but were not on a practice CKD register 
(uncoded CKD).  
  
Confirmed CKD 
108 911 
Labelled CKD 
139,176 
Miscoded 
60705 
Uncoded 
30 440 
Appropriately coded 
78471 
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3.4.1.1.Characteristics of confirmed and labelled CKD patients 
The demographic and clinical characteristics of the general population compared to 
labelled or confirmed CKD patients are shown in Table 3-4. Patients with either 
labelled CKD or confirmed CKD in comparison with the general population were likely 
to be older, female, Caucasian, smoke and have more comorbidity. Uncoded patients 
in comparison with appropriately CKD patients were more likely younger, female, non-
diabetic, non-hypertensive, have no cardiovascular disease and be non-smokers (p 
<0.01). Uncoded CKD patients compared with miscoded patients were more likely to 
be older, women, be non-diabetic, hypertensive, have cardiovascular disease and 
smoke (p <0.01).  
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3.4.1.2.Multivariable analysis of predictors of exclusion and inclusion on Practice CKD 
register 
3.4.1.2.1.Uncoded versus appropriately coded 
In the multivariable analyses, the independent variables associated with exclusion 
from the practice register i.e. the odds of being uncoded patients versus appropriately 
coded) were younger age, female gender, and reduced co-morbidity (Table 3-5 and 
Figure 3-3)  
Table 3-5. Multivariate logistic regression model for significant predictors for exclusion from the CKD 
QOF register: Uncoded vs. appropriately coded 
Risk Factor Odds Ratio of Uncoded CKD compared to 
appropriately Coded CKD 
Odds Ratio (95 % CI) 
Age
I
 0.991(0.990-0.993) 
Female sex
II
 1.20(1.16-1.24) 
CKD stage 
3a 
III
 
3b 
4 
5 
 
1* 
0.37(0.35-0.38) 
0.24(0.22-0.27) 
0.24(0.19-0.31) 
Coronary Heart Disease
iv 0.81(0.76-0.86)* 
Hypertension
iv
 0.61(0.59-0.63)* 
Diabetes Mellitus 0.72(0.69-0.75)* 
Cardiovascular Disease 
(composite of Coronary Heart Disease, 
Peripheral Vascular Disease and Stroke) 
0.83(0.78-0.88)* 
Peripheral Vascular Disease
iv
 0.88(0.82-0.95)* 
Hypercholesterolaemia
iv
 0.80(0.76-0.84)* 
i. For an increase in years from the mean age 
ii. In comparison with male gender 
iii. Indicates the reference indicator 
iv. The presence of the disease in comparison to those without it * p < 0.0001 
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Figure 3-3. Forest plot of odds ratios: uncoded CKD versus appropriately coded CKD 
 
Note stage 3b, 4, 5 CKD are compared to stage 3a CKD 
3.4.1.2.2.Uncoded versus miscoded 
Uncoded patients were more likely to be older, have hypertension, have 
cardiovascular disease and to smoke compared to miscoded patients. They were less 
likely to have diabetes, coronary heart disease and hypercholesterolaemia. (Table 3-6 
and Figure 3-4) 
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Table 3-6. Multivariate logistic regression model for significant predictors for exclusion from the CKD 
QOF register: Uncoded vs. Miscoded 
Risk Factor Odds Ratio of Uncoded CKD compared to 
miscoded CKD 
Odds Ratio (95% CI) 
Age
I
 1.027(1.026-1.028)* 
Female sex
II
 1.23(1.17-1.26)* 
Coronary Heart Disease
iv 0.80(0.74-0.86)* 
Hypertension
iv
 1.11(1.02-1.15)* 
Diabetes mellitus 0.84(0.77-0.89)* 
Cardiovascular Disease 1.21(1.13-1.30)* 
Peripheral Vascular Disease
iv
 NS 
Hypercholesterolaemia
iv
 0.90(0.84-0.97)* 
Smoking
iv 1.21(1.16-1.30)* 
* p < 0.0001 
i. For an increase in years from the mean age 
ii. In comparison with male gender 
iii. Indicates the reference indicator 
iv. The presence of the disease in comparison to those without it. The disease was ascertained 
by having a Read code for the disease 
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Figure 3-4. Forest plot of odds ratios: uncoded CKD versus miscoded CKD 
 
 
3.4.2.QOF indicators: Comparison of Labelled and Confirmed CKD 
The management of CKD patients according to QOF is shown in Table 3-7. There was a 
trend for the confirmed CKD group of patients to have worse management compared 
to those with labelled CKD.  
There was significant underachievement in QOF outcomes in the uncoded CKD group 
versus the coded CKD group where CKD patients not on the practice CKD register were 
less likely to have a recorded blood pressure, a blood pressure on target or have a 
recorded ACR. Similarly uncoded patients were significantly less likely to achieve CKD 
QOF indicators in comparison to miscoded CKD patients.  
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The mean blood pressure was significantly different in patients in with uncoded CKD 
(mean systolic 136.2 mmHg, 95% CI 136.0 to 136.4 mm Hg/mean diastolic 75.8mmHg 
95% CI 75.7 to 75.9 mmHg, p < 0.0001 ) compared to those appropriately coded (mean 
systolic 136.0 mmHg, (95% CI 135.9 to 136.1 mmHg/mean diastolic 75.0 mmHg 95% CI 
75.0 to 75.1 mmHg, p < 0.001). The cholesterol was likely to be lower in the uncoded 
CKD group versus the coded CKD group (median cholesterol 5.0 vs. 5.1 mmol/l, p < 
0.005). Mean systolic blood pressure, in mmHg, was significantly higher in patients 
with uncoded CKD (136.2 (95% CI 136.0 to 136.4)/75.8 (75.7 to 75.9) compared to 
miscoded CKD 134.5 (134.3 to 134.6)/ 76.3 (75.0 to75.1), p <0.0001.  
Cholesterol was measured in 92% of individuals regardless of group. There was no 
difference in serum cholesterol level between miscoded and uncoded CKD (median 
cholesterol 4.7 vs. 4.7 mmol/l, p =0.9455). All patients with proteinuria as defined by 
an ACR ≥30 mg/mmol and with a Read code for hypertension (n=1018) were on 
angiotensin blockade regardless of CKD coding (Table 3-7). 
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3.4.2.1.Comparison of Diabetic QOF indicators in CKD patients 
In exploratory analyses of the subgroup of patients with diabetes and CKD (Table 3-8), 
similar patterns were observed where patients in the confirmed CKD group were less 
likely to have their BMI, HbA1c, and ACR measured in comparison to the labelled CKD 
group. These differences were highly significant when comparing the coded CKD and 
uncoded CKD group with the exception of blood pressure management. Similarly CKD 
management was better in miscoded patients versus uncoded patients with the 
exception of attaining the lower blood pressure target of 135/85 mmHg. There was a 
trend for better management in patient labelled and therefore on the CKD register 
compared to those with confirmed CKD.  
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3.5.Discussion 
3.5.1.Summary of Key Findings 
The age and gender standardised prevalence of labelled CKD (i.e. a QOF Read code for 
stages CKD 3-5) rose from 0.11% in 2005 to 5.05% in 2009. In 2009 out of 139 176 
many labelled CKD patients, 78 471 (56.0%) of patients were appropriately coded and 
60 705 (44%) were miscoded as having CKD. In 2009, 4% (108 911) of the total 
population had actual or ‘confirmed’ CKD (based on 2 lab e-GFRs) and of these 28% (30 
440) were uncoded i.e. not labelled with CKD by a Read Code on the computer system 
of the practice.  
Patients with CKD were less likely to be appropriately coded if they were younger, 
female and had less co-morbidity such as hypertension, diabetes mellitus, 
cardiovascular disease or hypercholesterolaemia. When comparing patients with 
uncoded CKD to miscoded CKD patients, uncoded patients were more likely to be 
older, female, have hypertension, cardiovascular disease and smoke. However they 
were less likely to have diabetes, coronary heart disease or hypercholesterolaemia. 
There were significant differences in the management of patients according to their 
coding: CKD patients who were appropriately coded were more likely to have their 
blood pressure checked, have their blood pressure on target and have an ACR 
compared to uncoded patients. Similarly management was better in patients with 
miscoded CKD versus uncoded CKD. In patients with diabetes and CKD, again those 
uncoded for CKD had worse management and were less likely to have a BMI or ACR 
recorded, have a HbA1c of less than 7 and 10 %, and have blood pressure to target in 
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comparison to CKD patients with a Read code (whether or not appropriate). The only 
exception was having a lower blood pressure target of 130/85 mmHg which was 
similar amongst all groups.  
 
3.5.2.Interpretation of results and comparison to existing literature 
These results suggest that in 2009 there was considerable inaccuracy in the practice 
CKD register. A substantial proportion of patients were inappropriately placed on the 
register, whilst many with a CKD diagnosis were omitted from the register. These 
findings were consistent with another study examining the sensitivity and specificity of 
CKD diagnosis by Read code in THIN.[186] They found poor sensitivity, approximately 
50% but good specificity of 90%. However they used non QOF Read codes for CKD to 
define CKD therefore coding for CKD would not lead to patients being recognised for 
incentivised management and therefore my work is novel.[186] Additionally 
‘undercoding’ patients with CKD exists in other health care systems, for example in US 
Veteran hospitals where patients biochemical evidence of CKD may not have the 
coding for the latter.[187] In patients with CKD, it was the younger, ‘healthier’ patients 
who were at higher risk of being unrecognised. This may be because CKD is 
unexpected in this cohort. However despite these patients lacking the usual risk 
factors for CVD, the CKD prognosis consortium, which adjusted for comorbidity, 
demonstrated that younger patients with CKD were still at greater risk for all-cause 
mortality (HR 2.79 for patients aged 18-54 with CKD stage 3 compared to those with 
eGFRs 75-89 ml/min/1.73m2). When comparing patients with uncoded CKD to 
miscoded CKD, patients with uncoded CKD were still likely to be at risk of 
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cardiovascular disease and mortality as they were more likely to be hypertensive and 
smoke.  
Though not interpreted as causal, patients with uncoded CKD were less likely to 
achieve QOF management targets in comparison with those on the register. This could 
suggest that GPs are only including patients more likely to achieve QOF indicators but 
also could signify that uncoded patients will not be automatically recalled for health 
checks. Further research to better understand the reasons for these results is needed. 
Patients who are excluded from QOF demonstrate that GPs need to direct resources to 
appropriately identify patients with CKD. 
Potential reasons for miscoding could be due methodological issues. It was not 
possible to tell when the code had lapsed and therefore practices may have amended 
the CKD diagnosis but I was unable to account for this in my analysis and therefore 
inflating the numbers of those who were miscoded. Other reasons were that practices 
may have calculated the GFR and determined patients with CKD by this method. 
However only another 0.77% of the population had CKD if calculated eGFRs were used 
to stage CKD 3-5 and the proportion of miscoded patients were 2.2%. Therefore 
hypothetically at least 1.43% of the population would have still remained uncoded. 
Another hypothesis is that patients are diagnosed with CKD by the practice based on a 
single blood result. Looking at the latest result in 2009 in patients with only one 
previous blood test, in the miscoded cohort, another 25.1 % of this cohort (n=15247, 
0.56% of the denominator population) had a lab eGFR below 60 ml/min/1.73m2.[188] 
These findings are consistent with evidence that the management in patients with type 
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2 Diabetes, excluded from the practice register was worse.[141] These results are also 
comparable to a US study where CKD patients without CKD (ICD) codes on hospital 
administrative systems were less likely to have markers for renal complications such as 
anaemia and renal bone disease checked.[154] Being labelled with disease may incur 
harm as well as benefit with loss of income reported in patients labelled with 
hypertension.[189] However on a positive note, the goals achieved in the UK are 
generally higher than some western cohorts.[190] 
3.5.3.Strengths and limitations 
It cannot be definitively proved by this thesis that CKD misclassification leads to poorer 
management as this was a retrospective cohort study. Patients may have better CKD 
classification due to unrecorded confounders that are associated with CKD 
misclassification and subsequent management. For example patients with 
hypertension are likely to receive angiotensin blockade and better CKD recognition as 
GPs should check patient’s renal function after instituting this. 
As mentioned earlier, patient information prior to registration at the practice and pre 
AMR date was excluded. This may have resulted in patients being misclassified as 
miscoded. Additionally it may have led to the loss of co-variables in the multivariable 
analysis. A further limitation is that patients without a Read code were assumed not to 
have the disease or condition. This seems a reasonable assumption given that smoking 
status and cardiovascular reporting in Primary care databases is reasonably 
accurate.[137;138;144;146] There may be unmeasured confounders that explain why 
management is worse in miscoded CKD patients.  
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This cohort had several advantages: firstly it was a large cohort representative of the 
general population.[136] Patients excluded from practice registers were included and 
therefore their management could be assessed. Finally THIN and other primary care 
databases lack recall bias because the data do not rely on patients or researchers to 
provide information. 
3.6.Executive Summary 
• Various international and national guidelines exist for CKD including NICE 
guidance in the UK. 
• The UK QOF incentivized management for CKD during the time period included 
in the analysis.  
• The impact of QOF coding on the management of CKD was previously 
unknown. 
• The CKD practice register is inaccurate as many patients with CKD are 
undiagnosed as having CKD and many patients are misclassified as having CKD 
without any evidence of CKD. 
• Uncoded CKD patients are likely to be younger and have less comorbid 
conditions in comparison with appropriately coded CKD patients. 
• Uncoded CKD patients are likely to be older than miscoded CKD patients. 
• Uncoded CKD patients are less likely to attain QOF targets.  
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CHAPTER 4. WHAT FACTORS PREDICT ALL-CAUSE MORTALITY IN STAGE 
3 CKD PATIENTS? A PROGNOSTIC MODEL  
This chapter describes risk factors for mortality in patients with stages 3-5 CKD 
according to contemporary literature. The chapter then describes the development of 
a prognostic model which aims to identify potential risk factors associated with all-
cause mortality using data routinely collected in primary care. The results may be used 
by general practitioners to target care to those at highest risk of an event.  
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4.1.Introduction 
4.1.1.Cardiovascular disease and mortality in CKD patients 
Cardiovascular (CVD) risk factors are abundant in patients with CKD because 
cardiovascular factors are associated with the development of CKD(reverse causality). 
Additionally the relationships between CVD risk factors and cardiovascular disease in 
patients with CKD are complex (eg raised blood pressure, cholesterol and body mass 
index) and may not always result in cardiovascular sequelae.[191] Furthermore renal 
failure results in other non-atherogenic cardiovascular abnormalities such as left 
ventricular diastolic dysfunction, left ventricular hypertrophy and arteriosclerosis.[192] 
The reasons for these include malnutrition, anaemia, hyperhomocysteinuria, bone 
mineral disorders and increased inflammation.[191] These risk factors also aggravate 
atherosclerosis. The following section will discuss the impact of traditional and non 
traditional risk factors on cardiovascular disease in CKD patients.  
4.1.1.1.Diabetes and other co-morbid conditions 
Risk factors such as hypertension, diabetes and atrial fibrillation are implicated in 
mortality and CVD in patients with CKD. Hypertension and blood pressure control are 
discussed in a separate section below. Diabetes is a known risk factor for CKD and CVD 
in the general population.[193] The Framingham study found that men with diabetes 
had double the risk of CVD compared to non-diabetics and this risk was three fold 
higher for women after 20 years follow-up.[194] Not only is diabetes implicated in CVD 
but it is directly associated with the development of CKD. 
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CKD due to diabetes mellitus is labelled as ‘diabetic nephropathy’. Diabetic 
nephropathy is associated with both type 1 (T1DM) and type 2 Diabetes Mellitus 
(T2DM).[195] In a study of patients with T1DM, diabetic nephropathy developed in 
25% of the population in a conventionally treated arm. In patients who had been 
treated with intensive insulin treatment, the proportion was lower at 17%.[106;107] 
Therefore diabetes is implicated both in the cause of CKD and the development of 
CKD. It is worth noting that although CKD patients with diabetes are more likely to be 
obese, have hypertension and lipid abnormalities, diabetes is still an independent risk 
factor for mortality across all stages of CKD.[196]  
Atrial Fibrillation (AF) is present in up to 15% of patients with CKD and is a known risk 
factor for stroke.[126;197;198] Risk stratification for anticoagulation in CKD patients is 
complicated as they are more likely to bleed, but in a subgroup analysis of CKD 
patients in the SPAFIII trial, ischaemic stroke was reduced by 76% in patients with CKD, 
randomised to warfarin versus placebo.[199] There are, however, no specific trials of 
warfarin therapy in CKD patients with AF.  
4.1.1.2.Hypertension and proteinuria: A complicated CVD risk factor in CKD patients 
Hypertension is one of the commonest risk factors for CVD in the general population 
and is defined as a systolic blood pressure and diastolic blood pressure greater than 
140 mmHg and 90 mmHg respectively. In the UK the Health Survey of England (HSE) in 
2010 found a prevalence of hypertension of 31.5% in Men and 29.0% in women.[200] 
The prevalence of hypertension has risen considerably and the current prevalence of 
hypertension was not anticipated until 2025.[201] In a large epidemiological meta-
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analysis of people with cardiovascular disease (i.e. stroke, ischaemic heart disease and 
other vascular disease) the risks of further cardiovascular events doubled for a rise in a 
systolic and diastolic blood pressure of 20 and 10 mmHg respectively.[202] 
The prevalence of hypertension in CKD patients is much higher. In the NHANES 
screening study: between 1999 and 2004, the proportion of patients with 
hypertension with stages 1-5 CKD was 75-85%.[203] There is an inverse linear 
relationship between GFR and systolic blood pressure as demonstrated by the MDRD 
study.[204] Furthermore development of CKD can lead to de novo hypertension and 
worsening hypertension.[205]  
The aetiology of hypertension in CKD patients may be different from the general 
population due to increased arterial stiffness,[206] salt and water retention,[207] 
increased activity of the renin angiotensin system due to local scarring and increased 
sympathetic activity.[208] Furthermore, secondary hyperparathyroidism, treatment 
with erythropoietin and dysregulated nocturnal blood pressure contribute to 
hypertension.[112;209] The relationship between hypertension in CKD and CVD is not 
linear but more J-shaped: individuals with a blood pressure of 120mmHg or less have 
an equivalent risk of death to those with a blood pressure of 180mmHg.[207;210] This 
may be due to reverse epidemiology where hypertension may result in greater blood 
flow to failing nephrons.[210] 
However hypertension as a risk factor for CVD in patients with CKD and BP control is 
confounded by proteinuria. In next section the management of hypertension in CKD 
patients and the impact of proteinuria will be discussed.  
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The majority of antihypertensive trials that have examined cardiovascular risk 
reduction in CKD patients are derived from post hoc analysis of subgroups with CKD 
from trials in the general hypertensive population or from diabetic nephropathy trials. 
Unfortunately unless such subgroup analysis has been specified a priori it is difficult to 
ascertain a causal association between intervention and outcome. Any results are 
hypothesis generating and should be interpreted with caution. As evidence for 
diabetics and non-diabetics with CKD differs it will be discussed separately. 
4.1.1.2.1.Diabetic Nephropathy 
Multiple trials have shown that antihypertensive treatment in diabetic nephropathy 
reduces renal morbidity, cardiovascular morbidity and all-cause 
mortality.[119;211;211-217] The Reduction Of Endpoints In NIDDM With The 
Angiotensin II Antagonist Losartan (RENAAL) study, where patients with diabetic 
nephropathy were randomised to either Losartan or placebo showed a 16% reduction 
in Renal Events (a composite outcome of ESRD or doubling of serum creatinine) and 
that an increase of blood pressure of 10mmHg led to an increase in the absolute risk of 
ESRD or death of 6.7% (p=0.007).[212;218] This study also found that the risk of first 
hospitalization for heart failure was reduced by 32 % (p=0.005), and though there was 
no reduction in other cardiovascular events, there was an increased risk of CVD 
associated with albuminuria.[219] Similar findings were observed in the Irbersartan 
Diabetic Nephropathy Trial (IDNT) with a 20 % reduction in renal morbidity in patients 
randomized to Irbersartan versus placebo as well as a reduction in heart failure and 
cardiovascular mortality.[116;211] 
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4.1.1.2.2.Non Diabetic Chronic Kidney Disease 
Subgroup Analysis of larger Blood pressure lowering trials 
Unfortunately there are no specific randomized control trials looking at whether 
antihypertensive treatment reduces CVD in non-diabetic CKD patients.[220] In a post 
hoc subgroup analysis of the Heart Outcomes Prevention Evaluation Study (HOPE) 
(Ramipril vs. placebo), renal dysfunction was found to be an independent predictor of 
CVD.[221] In the CKD subgroup, ramipril was associated with a reduction in 
cardiovascular death and a reduction in all-cause mortality by almost a third. Similarly 
in a CKD subgroup analysis of the “Avoiding Cardiovascular Events through 
Combination Therapy in Patients Living with Systolic Hypertension” study there was 
reduction in pre-specified renal event (doubling of serum creatinine) with Bezapril and 
Amlodipine. 
The MDRD and the AASK study 
Two landmark trials have examined blood pressure reduction in non-diabetic CKD 
patients. In the MDRD study of 840 CKD patients (predominantly non-diabetic CKD), 
were randomised to either a low ‘BP’ or ‘standard’ BP. They achieved a systolic blood 
pressure of 125.6 and 132.7 mmHg in the low versus standard blood pressure groups 
respectively. There was no difference in renal sequelae in either blood pressure group 
apart from patients with significant proteinuria and this may be explained by higher 
angiotensin blockade use in the lower BP group. In a longitudinal follow up study it was 
suggested that there were lower rates of death and ESRD in the ‘low BP’ group (HR 
[0.68 (95% CI 0.57 -0.82)].  
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In the African-American Study of Kidney Disease and Hypertension (AASK), African-
American patients with hypertensive kidney disease were randomised to similar blood 
pressure targets as the MDRD study.[222] There was no difference in renal events 
between the two groups. However in the subsequent longitudinal observational study, 
patients assigned to a lower BP had lower rates of ESRD or doubling of creatinine in 
those patients with proteinuria (Urine protein excretion > 300mg/day).[220] In both 
longitudinal studies of AASK and MDRD caution must be taken in interpretating the 
results as the low blood pressure and normal blood pressure group were no longer 
randomised.  
As the studies in diabetic and non diabetic CKD show that treating hypertension is 
beneficial in most groups it is worth discussing what is the optimal blood pressure 
target in CKD patients. 
4.1.1.2.3.The effect of target blood pressure 
In the UK, the most recent published guidelines are from the National Institute of 
Clinical Excellence (NICE).[161] 
They specify the following targets: 
Less than 140/90 mmHg for people with non-diabetic non proteinuric CKD 
Less than 130/80 mmHg for people with diabetes or proteinuria (Albumin Creatinine 
Ratio above 70) 
Target blood pressure in CKD is not a straightforward topic. Even in the general 
population, many previous trials did not achieve a low blood pressure on treatment. 
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For example, the mean blood pressure achieved in Systolic High blood pressure and 
Elderly Program, was 143/68 mmHg and in the large Hypertension and Outcomes Trial 
(HOT) there was no risk difference seen between those randomly assigned to a 
diastolic blood pressure of less than 80, 85 and 90 mmHg apart from the diabetic sub 
group. The blood pressures achieved in the HOT trial were 144/85, 141/83 and 140/80 
respectively.[114;119] 
In Diabetes, where there has been a reduction in microvascular or macrovascular 
events, the blood pressures achieved varied, with many higher than 130/80mmHg; for 
example in the UKPDS trial the target blood pressure was 154/82 mmHg achieved; the 
HOPE study achieved a mean systolic blood pressure of 134.5 mmHg and the RENAAL 
achieved a blood pressure of 146/78 mmHg in the treatment group.[212-214] In the 
IDNT trial, a systolic blood pressure below 120 mmHg was associated with the same 
cardiovascular risk as that for patients with a systolic of 180 mmHg. Similarly, a meta-
analysis suggested a blood pressure of below 110 mmHg was associated with worse 
renal outcomes.[223] It should be noted that only a few studies have compared 
specific blood pressure targets and they have not shown a benefit below 130/80 
mmHg in their main analysis.[119;217;222;224] A recent Cochrane review looking at 
target blood pressure to reduce cardiovascular and microvascular complications in the 
general population, evaluated 11 studies and found no benefit beyond lowering a 
blood pressure below 140/90 mmHg.[225] 
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4.1.1.2.4.The impact of different classes of blood pressure medication 
In diabetic nephropathy, the majority of trials have shown a reduction in both 
cardiovascular and renal morbidity with angiotensin blockade and predominantly 
angiotensin II blockers.[211;218;226;227] Similarly in non diabetic CKD the REIN 
studies showed that decline in renal function was reduced in those treated with 
Ramipril.[228] In the AASK study a risk reduction of 22% (95% CI 1-38%) of renal 
morbidity was seen in the Ramipril cohort.[222] These effects seem to be independent 
of blood pressure as confirmed by two meta-analyses evaluating cardiovascular 
disease and progression of renal disease.[117;229] Angiotensin blockade appears 
superior to calcium channel blockers and beta blockers. Dual blockade of the Renin 
Angiotensin system is not beneficial and may be harmful: the ONTARGET study 
considered cardiovascular risk reduction in high risk patients by dual blockade but 
found an increase in adverse events as well as lack of benefit from this.[230]  
Which adjunctive therapy is best is uncertain. Adding a calcium channel blocker to a 
ACE inhibitor in the REIN 2 study added no benefit in the treatment of CKD 
patients[231] but this conflicted with the ACCOMPLISH trial that may not have had the 
appropriate endpoint.[220;232] Direct renin inhibition may reduce risk as it has been 
shown to reduce urine albumin excretion in patients with diabetic nephropathy on 
losartan.[233]  
4.1.1.2.5.Is treatment of blood pressure related to reduction in proteinuria? 
Treatment of hypertension in CKD is likely to treat proteinuria as well. Even small 
amounts of proteinuria are associated with higher rates of morbidity and mortality. In 
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the collaborative meta-analysis, independent of blood pressure and eGFR patients with 
an ACR of 1.1mg/mmol, 3.43mg/mmol and 33.9mg/mmol were likely to have a hazard 
ratio for all cause mortality 1.2 (95% CI 1.15-1.26 ), 1.63 (1.50-1.77) and 2.22 (1.97-
2.51) compared to an ACR of 0.6mg/mmol. As discussed before most of the trials have 
taken place in patients with diabetic nephropathy and in the RENAAL trial 
cardiovascular risk fell by 18% if albumininuria fell by 50%.[219] In the MDRD and AASK 
study, blood pressure reduction was only effective if patients had proteinuria though 
these were subgroup analysis on very small number of patients. Another confounder is 
that most of the blood pressure studies in diabetic and non diabetic CKD that show 
reduction in cardiovascular events have used angiotensin blockade which reduce 
proteinuria directly as well as reducing blood pressure.[117] The only study to use an 
alternative or additional agent in CKD patients was the negative REIN 2 study.[231] 
4.1.1.3.Antiplatelet agents 
Aspirin and other anti-platelet agents have been shown to prevent recurrent 
cardiovascular disease in the general population. However there is a risk for increased 
bleeding.[234] CKD patients are at increased risk of bleeding due to platelet 
dysfunction and therefore at greater risk of harm then benefit.[235] There are no 
specific randomized control trials conducted for CKD patients and the available 
evidence comprises of post hoc analysis of other studies. In subgroup analyses of the 
HOT study, patients were stratified to categories of either a GFR of greater than or 
equal to 60ml/min/1.73m2 (n=14,977), CKD stage 3a (n=3083) and CKD stage 3b 
(n=536). In patients randomized to Aspirin there was a reduction in all forms of 
cardiovascular disease in CKD 3b patients but not CKD stage 3a, but CKD 3b patients 
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was a very small subgroup. In general there were increased risks of minor 
bleeding.[110] 
Further clarification came from a meta-analysis of 9969 CKD patients. Treatment with 
antiplatelet agents reduced the composite outcome of fatal or non fatal myocardial 
infarction patients with stable cardiovascular disease but also increased the risk of 
bleeding. There was no reduction in all cause mortality, hospitalisation or stroke. In 
patients with unstable coronary disease, antiplatelet agents showed no benefit.[236] 
This meta-analysis did not delineate risk for specific CKD groups. Therefore further 
trials need to be conducted in CKD specific populations to determine whether there is 
a benefit across all CKD groups and whether any benefits outweigh the harm of 
bleeding. 
4.1.1.4.Hypercholesterolaemia/other lipid abnormalities 
Patients with CKD often have other lipid abnormalities apart from 
hypercholesterolaemia such as hypertryglyceridaemia due to decreased lipoprotein 
lipase activity, raised apoliprotein A levels due to reduced renal clearance and 
decreased HDL cholesterol.[237] CKD patients may also have reduced cholesterol due 
to malnutrition and that is why low cholesterol is associated with mortality i.e. reverse 
causality.[123;237] Though it is well established that HMG CoA-Reductase inhibitors 
(statins) (by reducing LDL cholesterol) reduce cardiovascular disease in the general 
population, only recently has a randomized clinical trial specific to CKD been 
conducted with adequately powered end-points to determine the impact of statins. 
The Study of Heart and Renal Protection (SHARP) study randomized 9270 to 
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simvastatin and ezetimibe or placebo.[121] Two thirds of the patients were not on 
dialysis and in the treatment arm there was a 0.85mmol/l reduction in LDL cholesterol 
and 17% reduction in the composite end point of non fatal myocardial infarction, 
stroke or revascularization events. However statins reduce proteinuria as well and 
whether it is a statin specific effect or true reduction in cholesterol is difficult to 
discern as lower cholesterol is not always associated with reduced morbidity and 
mortality.[238] 
4.1.1.5.Age, Sex, Ethnicity and Deprivation 
The prevalence of CKD is higher in the elderly population. (see section 7) It has been 
debated whether decreased GFR is a normal part of ageing. The CKD Prognosis 
Consortium examined the impact of different age groups on mortality and ESRD in the 
general population and high risk cohorts. The risk of death rose with increasing age 
and the number of extra deaths rose from 9.0 to 27.2 extra deaths per 1,000 person-
years for patients aged 18–54 years and ≥75 years.(183) Men are more likely to die 
with CKD across all stages in comparison to women in the CKD prognosis consortium 
general population cohorts and there may be gaps in their treatment as prevalence of 
CKD is less in this cohort.[239] The prevalence of chronic kidney disease is variable in 
non Caucasians but African Americans or blacks have higher rates mortality.[54;240] 
South Asians and South East Asians with ESRD have lower rates of mortality in 
comparison to Caucasians despite age correction.[129;241] 
Chronic Kidney Disease is more prevalent in more deprived areas in both secondary 
care or primary care populations.[63;242] Deprivation is more common in ethnic 
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minority groups[243] and even despite improving healthcare is still associated with 
increased mortality.[130] 
4.1.1.6.Lifestyle 
Smoking is associated with the development of CKD and like the general population is 
associated with cardiovascular disease and mortality in CKD patients.[112;113] 
Although obesity is more common in CKD patients and obesity is associated with 
increased prevalence of CKD, patients with higher BMI (even in morbidly obese 
patients) may have lower mortality rates and the cause of this is uncertain.[128;244]  
4.1.1.7.Non-traditional risk factors 
Reduced renal function results in reduced erythropoietin production even with 
moderately reduced renal function.[245] The relationship between haemoglobin may 
not be linear as both anaemia (defined as less than 13mg/dl in men and less than 
12mg/dl in women) and very high haemoglobins are associated with cardiovascular 
events and mortality.[245;246] However intervention with Erythropoietin has not been 
beneficial in CKD patients and even harmful in some meta-analysis.[131;247] As renal 
function declines, bone mineral regulation becomes disordered and results in 
hyperphosphatemia, hypercalcemia or hypocalcaemia, decreased active Vitamin D and 
secondary hyperparathyroidism. Hyperphosphatemia is linked to vascular calcification, 
a risk factor for cardiovascular disease and in a recent meta-analysis was an 
independent risk factor for cardiovascular disease.[248] Phosphate binding drugs are 
used to reduce serum phosphate in CKD with hyperphosphatemia. In a recent study 
although the desired effect was achieved, phosphate binders resulted in worsening 
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vascular calcification but there was no change in CVD[249] Other modifications such as 
vitamin D supplementation and calcimimetics have uncertain effects and have not 
shown improvement in cardiovascular morbidity or mortality.[248;249]  
4.2. Rationale in modeling for death in patients with stage 3 CKD 
As discussed in Chapter 1.5, the mortality and morbidity is high patients with chronic 
kidney disease as many patients die of cardiovascular disease. The commonest stage of 
CKD is stage 3 and it is recommended that this cohort should be managed in Primary 
Care by NICE.[44;52] The previous section demonstrated that there was inconsistent 
evidence for that treatment of cardiovascular risk factors for patients with CKD and 
what demographic, clinical features and medication are associated with increased or 
decreased survival in patients with stage 3 CKD. 
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4.3.Methods 
4.3.1.Model development: A review of the literature 
Given the uncertainties described above, a prognostic model was generated to 
evaluate the relationship between non modifiable and modifiable risk factors and the 
composite outcome of CVD or all-cause mortality in CKD 3 patients. Modifiable risk 
factors included lowering blood pressure or using pharmacological agents such as 
aspirin or cholesterol lowering agents. The following is a review of literature of 
prognostic modelling that will be used in the methods.  
When considering modelling risk the following have to be considered:[250] 
• Model selection  
• Variable selection and overfitting 
• Conditional variable selection 
• Whether the relationship between variable and outcome is linear 
• Model fit 
• Missing data 
• Whether the model satisfies the assumption of the model 
• Data clustering and random effects 
4.3.1.1.Model Selection 
A Cox proportional hazards analysis was chosen over multivariate logistic regression as 
patients in the dataset had variable follow up and censored data. Logistic regression 
was considered unsuitable since it does not allow for censoring.[251] A simple survival 
probability for a group of individuals or survivor function at a particular time, t, is: 
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The above function when plotted yields a familiar survival graph known as the Kaplan 
Meier curve.[251] Survival analysis is unique since those individuals that do not 
experience the outcome of interest, are lost to follow up or alive at the end of the 
study period can be censored. There are several forms of censoring but in this study 
right censoring was used as it occurred after the individual had been entered into the 
study.[251] Univariate analysis such Kaplan Meier curves can be plotted for different 
groups in the study and compared using the log rank test; a non-parametric test. The 
log rank test assumes proportional hazards i.e. that the risk of events in each group is 
proportional throughout the study period.[109] 
To evaluate the effect of multiple covariates a Cox proportional hazards model was 
selected. This is a semi parametric analysis and again is based on the assumption that 
there are proportional hazards.[109] 
The hazards function ℎb which can be interpolated from the survival curve, is the risk 
of dying or suffering an event at time, t. If there are X1 to Xp variables then this 
function is given by: 
ℎb = ℎb × expdq + dq +…… .+dq) 
Where ℎb is the model where there are no covariables.[251] 
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4.3.1.2.Selection of co-variables and overfitting 
In order for any statistical model to fit the data properly it must include the 
appropriate explanatory co-variables. A pragmatic literature review was undertaken to 
identify potential items for inclusion as summarised in and described in the 
introduction to this chapter. 
The potential for overfitting was considered during model development.[250] 
Overfitting is where there are models with too many degrees of freedom i.e. too many 
variables in the model. In general terms between 10 and 20 events per co-variable are 
required. This allows for less than 5% optimism (i.e. negligible overfitting).[250] Given 
the large number of events under consideration for this study problems of overfitting 
were considered negligible. 
 
4.3.1.2.1.Conditional variable selection 
Conditional variable selection can take several forms but the commonest are forward 
conditional selection or backward conditional selection. In the former model, each 
variable is entered step by step and any co-variable that has a p value greater than 
0.05 is discarded from the model. In a backward selection process all the co-variables 
are entered in the model and non-significant co-variables i.e. those with a p value less 
than 0.05 are excluded. This is done in a hierarchal fashion where the least significant 
factor is discarded and then 2nd least factor is discarded and so on until the final 
model contains only significant co-variables. Forward conditional selection does not 
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allow us to assess all the co-variables together and interactions may be missed thus 
backward selection was selected as the method of choice for this study.[252;253] 
4.3.1.3.Non-linearity of variables 
A further consideration when entering continuous co-variables into a Cox regression 
analysis, is whether the relationship between the co-variable and hazard ratio is 
linear.[184] As discussed earlier in this chapter the relationship between blood 
pressure or BMI and risk may be non-linear. Several strategies can be applied to deal 
with this issue. Firstly the co-variable can be grouped into categorical variables, 
however this strategy can lead to loss of information and may not display the true 
form of the data.[254]  
Secondly data can be transformed: the simplest transformations are first degree 
polynomials where the variable can be raised to a particular power for example it can 
be squared [158], cubed or most commonly the natural log can be taken. So instead of 
variable X, the transformed variable in the form of X2 or Log(X) is entered into the 
model. However the co-variable may have a turning point in the relationship with risk 
and this will not be modelled by simple transformation.[184] Royston et al suggest that 
adding another polynomial term can appropriately model a continuous variable.[184] 
Although this looks inherently complex, most continuous variables can be modelled 
using to two fractional polynomials (FP)i.e. where Xp + Xp is added to the model where 
p is in the family (-2, -1, -0.5, 0, 0.5, 1, 2 and 3, where 0 is the terminology for 
log).[254] Royston and colleagues have devised a macro for SAS (MFP) that assesses 
which FP to include using a closed test procedure and does a stepwise comparison of 
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functional forms until the appropriate one is found.[255] This process was used to 
assess non-linearity of forms for age, BMI, blood pressure and cholesterol. The best 
model fit was selected as described below. 
4.3.1.4.Model fit 
Model fit in survival analysis is given by the likelihood function (L) that summarises 
unknown parameter information in the model.[251] When considering different 
models the largest likelihood function represents best model fit to the observed data. 
In practice the value of −2 log sis used and incorporated into Akaike Information 
Criteria (AIC) which is based on the likelihood statistic: 
CtZ = −2 log s – vw 
Where w is the unknown number of parameters, v is a constant usually set to between 
2-6 and generally 2 is used.[256] As the log likelihood statistic has been negatively log 
transformed, the smaller the AIC statistic the better the model fit. If two models are 
similar and one has more co variables, then AIC will not be much different and will 
penalize the model with more variables. Using fewer variables will avoid overfitting 
and improve the goodness of fit.[256] Usually a reduction of 4 in AIC between models 
is regarded as significant.[257]  
4.3.1.5.Missing data  
It was anticipated that there would be missing data as this is typical in primary care as 
shown in previous THIN studies.[144;258] If patients with missing data are excluded (a 
complete case analysis) then this can result in unstable and inaccurate models.[259] 
Complete case analysis is associated with loss of power in the study and may result in 
Page 159 of 375 
 
overfitting.[260] An additional challenge is that the missing data are generally related 
to patient and study characteristics, unless the missing data are genuinely independent 
of observed and unobserved characteristics of cohort (missing completely at random, 
MCAR). If data are missing due to observed characteristics then the data is deemed 
missing at random (MAR) and if data are missing due to unobserved characteristics 
then the missing data are deemed missing not at random.[260] An important 
assumption that is made when examining missing data is that the missing data are 
MAR.[261] 
In this study, complete case analysis may have led to selection bias and potentially 
could have excluded either well patients who have little illness and therefore fewer 
measurements and entries into the notes and also patients who are at greater risk of 
non-compliance who do not engage with their clinician and therefore also have fewer 
entries in their electronic record. Therefore missing data had to be considered when 
devising an outcome model and this will be discussed below.[261] 
4.3.1.5.1.Missing data in multivariable models and multiple imputation 
The threshold of missing data at which models become unrealistic and unpredictable is 
unclear but Harrell et al suggested that when more than 5% of data are missing that 
complete case analysis should no longer be considered.[262] Missing data in analyses 
can be handled by several different ways. Simple strategies such as mean or median 
substitution or creating a category that labels the variable as missing are inefficient 
and inaccurate.[260] More complex strategies such EM algorithms, single mean 
conditional imputations and multiple imputation can be used.[259] For the purposes of 
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this thesis, only multiple imputation will be discussed since this is the current method 
of choice.[259] 
4.3.1.5.2.Multiple imputation 
In single imputation, any missing data is assumed to be missing at random, and is 
replaced with a value generated using a multivariate regression model of existing non 
missing patient data. This allows analysis of the whole dataset. However the values 
imputed may have not been drawn from a representative dataset of the true 
population, and although small p values may be generated, the model may be over 
accurate, when in reality there is more uncertainty in how the data is imputed. To 
overcome this limitation, substituting multiple values for each missing value, using a 
regression analysis which has some random variation is preferable. This is called 
multiple imputation Each imputed dataset is analysed separately and then the 
regression estimates and coefficients are combined. Generally between 5-10 datasets 
yield optimum efficiency.[260] 
There are numerous regression models for calculating imputed variables, but as the 
missing data in my model were likely to be categorical as well as continuous, and the 
datasets were very large, then the simplest and most efficient way was to use chained 
equations. Here a series of univariate regression analyses were carried out to generate 
imputed values.[263] Although this feature is not directly available in SAS software 
researchers have developed a SAS, “callable” function called IVEWARE.[263] This 
function imputes missing values using linear, logistic, Poisson, or generalized logit 
regression depending on the nature of the missing variable.[263] 
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It was anticipated that there would be greater than 15% missing data for at least some 
variables from previous THIN studies and therefore multiple imputation was 
used.[250] Multiple imputed datasets were created, then they were analysed 
individually and regression coefficients combined to produce median regression 
coefficients.[259] 
4.3.1.6.Checking Cox Proportional Hazards assumption 
If the included co-variables in the model violate the proportional hazards function then 
the model is not valid. There are numerous methods to examine this but hazards are 
only proportional if the ratio of hazards are independent of time.[251] This assumption 
was tested graphically by examining plots of scaled Schoenfeld residuals of particular 
variables with survival time. If a non zero relationship was observed this the 
assumption was violated.[251] 
4.3.1.7.Frailty Model to assess for clustering 
A traditional Cox proportional model does not account for clustering of data at the 
practice level in the THIN dataset. A frailty model, an extension of the Cox Model, 
corrects for random effects i.e. unobserved heterogeneity in survival data.[264] The 
prognostic models in this thesis included general practices as a frailty term into the Cox 
proportional hazards model assuming the variable has a gamma distribution.[264] This 
was done in R software using the frailty package. 
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4.3.2.Step by Step discussion of the models. 
4.3.2.1.All cause mortality Model: Extracting the patients, co-variables and outcomes and 
step by step analysis plan 
4.3.2.1.1.Patient Selection 
Patients with CKD stage 3a and 3b were characterized by two consecutive estimated 
eGFRs calculated from serum creatinine at least seven days apart using the non IDMS 
MDRD equation[13], diagnosed between 2005 to 2008. Calculated eGFRs were used as 
lab eGFR reporting did not commence until 2006 and it was anticipated that a cohort 
based solely on lab based data would yield insufficient events for the model. Secondly 
two consecutive results of creatinine where the conservative estimate is taken, 
provide relatively good agreement with each other.[9] Patients had to have survived at 
three months following a diagnosis of stage CKD 3 to allow a model to be devised. 
Patients had to be 18 or over at time of diagnosis of CKD and registered at the practice 
for greater than 6 months. All data post the AMR date was considered for each 
practice.[150] Patients entry in the cohort was the time of their initial diagnosis of CKD 
i.e. the first CKD 3a or 3b staging. 
4.3.2.1.2.Outcome Measures 
The primary outcome in the all cause mortality model was time to death from the 
diagnosis of CKD. This was defined by patient registration data. 
4.3.2.1.3.Co-Variables 
The distribution of the variables is described below. For any independent variable, the 
closest measurement between three months before the diagnosis of CKD and one 
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month after were in the multivariable analysis. The table also demonstrates the files 
and methodology used to define the variables. Note when preparing the database, the 
same cleaning and preparation techniques were used as in chapter 2 and 3. In the 
absence of relevant Read Codes indicating smoking status or comorbidity it was 
assumed that that patient did not smoke or have a diagnosis for the condition of 
interest. 
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4.3.2.2.Step by Step Analysis for Normal Cox Regression Model (Figure 4-1) 
4.3.2.2.1.Preparing the dataset and multiple Imputation (performed by SAS) 
Step 1. Firstly the dataset was labelled for the co-variables as above. The 
database was examined to look at the proportion with complete cases. If the 
proportion of population with missing data was 15% then multiple imputation 
was carried out. 
Step 2. As IVEWARE uses methods that require normal distribution of 
continuous variables, the following transformations were performed to 
approximate to the normal distribution[263] 
a. Haemoglobin (Hb) was reflected and then log transformed 
b. Cholesterol was log transformed 
c. Body Mass Index (BMI)was log transformed 
Step 3. Survival times were calculated from the CKD diagnosis date to the 
outcome date and patients were censored if they were alive at the end of the 
study period and deregistered during the study period 
4.3.2.2.2.Analyzing each imputed data set and determining the final model 
Step 4. For each imputed dataset, linearity of continuous covariables was 
assumed and variables were entered into a Cox proportionally hazards model 
using the backwards elimination model. The median regression co-efficients 
and parameters for each co-variable from each imputed dataset analysis were 
combined. 
Step 5. For each imputed dataset, all the co-variables specified were entered in 
to a Cox – proportional hazards model using the MFP algorithm using MFP 
package in R with age, BMI, eGFR, cholesterol, systolic blood pressure, diastolic 
blood pressure, haemoglobin modelled by 2nd degree fractional polynomials 
(mfp). The MFP algorithm in R entered all the co-variables regardless of 
whether the variable was to be transformed into a mfp in a backward 
elimination variable selection procedure. The procedure then cycled through all 
the possible 36 transformations (up to 2nd degree fractional polynomial 
Page 169 of 375 
 
transformations) for each specified co variable and selected the optimal 
fractional polynomial using a closed test procedure.[255] The commonest mfp 
forms for each imputed dataset were noted. It was anticipated that fractional 
polynomials would be different between the analyses of imputed datasets 1-5. 
The commonest multiple fractional forms were recorded. 
Step 6. The commonest mfp for the continuous variables were entered with the 
other variables into a Cox proportional hazards model. The regression co-
efficients were combined. The median regression co-efficients and parameters 
for each co-variable from each imputed dataset analysis were combined. 
Step 7. Steps 4-6 were repeated with but with a frailty term for practice 
location added to each model. 
Step 8. The model fit statistic the AIC of all the models in steps 4-7 were 
compared to demonstrate the best fitting model. i.e. the final model 
Step 9. In the final model the proportional hazards assumption was examined 
for each co-variable using scaled Schoenfeld residuals against survival. The 
assumption was assumed to hold if there was a non zero slope. 
Step 10. A complete case analysis i.e. a Cox proportional hazards model 
performed on dataset without missing data performed with mfp and frailty 
term for practice location was also estimated. 
  
  
S
te
p
 1
.
D
a
ts
e
t 
la
b
e
ll
e
d
 f
o
r 
co
v
a
ri
a
b
e
s 
a
s 
a
b
o
v
e
 t
a
b
le
 
a
b
o
v
e
. 
O
u
tc
o
m
e
 v
a
ri
a
b
le
 
d
e
te
rm
in
e
d
. 
T
im
e
 t
o
 
o
u
tc
o
m
e
 c
a
lc
u
la
te
d
S
te
p
 2
.
M
is
si
n
g
 d
a
ta
 p
ro
p
o
rt
io
n
 
d
e
te
rm
in
e
d
S
te
p
 3
.
M
u
lt
ip
le
 i
m
p
u
ta
ti
o
n
 
p
e
rf
o
rm
e
d
 t
o
 c
re
a
te
 5
 
d
a
ta
se
ts
S
te
p
 4
C
P
H
M
 w
h
e
re
 l
in
e
a
ri
ty
 o
f 
co
n
ti
n
u
o
u
s 
v
a
ri
a
b
le
s 
a
ss
u
m
e
d
. 
M
o
d
e
l 
co
e
fi
ci
e
n
ts
 c
o
m
b
in
e
d
 f
ro
m
 
e
a
ch
 a
n
a
ly
se
d
 i
m
p
u
te
d
 
d
a
ta
se
t
F
ig
u
re
 4
-1
. 
S
u
m
m
a
ry
 o
f 
a
ll
 c
a
u
se
 m
o
rt
a
li
ty
 m
o
d
e
l.
 
D
a
ts
e
t 
la
b
e
ll
e
d
 f
o
r 
co
-
v
a
ri
a
b
e
s 
a
s 
a
b
o
v
e
 t
a
b
le
 
a
b
o
v
e
. 
O
u
tc
o
m
e
 v
a
ri
a
b
le
 
d
e
te
rm
in
e
d
. 
T
im
e
 t
o
 
o
u
tc
o
m
e
 c
a
lc
u
la
te
d
M
is
si
n
g
 d
a
ta
 p
ro
p
o
rt
io
n
 
M
u
lt
ip
le
 i
m
p
u
ta
ti
o
n
 
p
e
rf
o
rm
e
d
 t
o
 c
re
a
te
 5
 
C
P
H
M
 w
h
e
re
 l
in
e
a
ri
ty
 o
f 
co
n
ti
n
u
o
u
s 
v
a
ri
a
b
le
s 
a
ss
u
m
e
d
. 
M
o
d
e
l 
co
-
e
fi
ci
e
n
ts
 c
o
m
b
in
e
d
 f
ro
m
 
e
a
ch
 a
n
a
ly
se
d
 i
m
p
u
te
d
 
S
te
p
 5
.
C
P
H
M
 w
h
e
re
 f
ra
ct
io
n
a
l 
p
o
ly
n
o
m
ia
l 
tr
a
n
sf
o
rm
a
ti
o
n
 
(M
F
P
) 
o
f 
co
n
ti
n
u
o
u
s 
v
a
ri
a
b
le
 e
x
p
lo
re
d
S
te
p
 6
.
C
P
H
M
  
w
h
e
re
 c
o
m
m
o
n
e
st
 
m
fp
 u
se
d
 f
o
r 
e
a
ch
 
co
n
ti
n
u
o
u
s 
v
a
ri
a
b
le
S
te
p
 7
.
S
te
p
s 
4
-6
 r
e
p
e
a
te
d
 b
u
t 
w
it
h
 a
d
d
e
d
 f
ra
il
ty
 t
e
rm
 f
o
r 
p
ra
ct
ic
e
 l
o
ca
ti
o
n
 
S
te
p
 8
.
T
h
e
 m
o
d
e
l 
fi
t 
fo
r 
a
ll
 t
h
e
 
m
o
d
e
ls
 i
n
 S
te
p
 4
-7
 
co
m
p
a
re
d
 t
o
 d
e
ri
v
e
 t
h
e
 
b
e
st
 f
it
ti
n
g
 m
o
d
e
l
S
te
p
 9
. 
T
h
e
 c
o
x
 p
ro
p
o
rt
io
n
 
h
a
za
rd
s 
a
ss
u
m
p
ti
o
n
 t
e
st
e
d
 
g
ra
p
h
ic
a
ll
y
S
te
p
 1
0
.
C
o
m
p
le
te
 c
a
se
 a
n
a
ly
si
s
1
7
0
 o
f 
2
9
1 
 
h
a
za
rd
s 
a
ss
u
m
p
ti
o
n
 t
e
st
e
d
 
C
o
m
p
le
te
 c
a
se
 a
n
a
ly
si
s
 
 
4.4.Results 
This section of the chapter
using routinely collected general practice 
were included in the model from th
Figure 4-2. D
4.4.1. Step 1: All cause mortality outcomes and description
The median follow up for the cohort was 1064 days (range 90 to 1079 days). There were 
13 083 deaths. The cohort 
median age was 72.9 years and the majority of patients were female (62.2%). The majority 
of patients had either no recorded ethnicity or Caucasian race (98.3%), followed 
Caribbean (0.8%), Indian Sub
majority of the cohort had the most affluent Townsend quintile. 
Thin Cohort November 
2009
(N=9 720 702)
Adult patients registered 
at practice for a minimum 
of 6 months on 1st
November 2009
(N = 6 581 419)
Patients with at least one 
serum creatinine post 
AMR date and 6 months 
registration at practice
(N= 1 982 568)
 describes the results of a model to predict all
data in CKD 3 patients. In total 109 017 patients 
e THIN cohort (Figure 4-2).  
erivation of THIN CKD cohort for all cause mortality model
 
demographics and co-morbidities are shown in 
-continental (0.9%) and South East Asian (0.1%) (
 
CKD stage  determined 
using higher eGFR 
Patients with two 
consecutive blood results 
seven days apart 
(N=1 202 293)
eGFR calculated using pre 
IDMS MDRD equation
Patients who survived for 
3 months and who had 
CKD during the cohort 
Cox proporrtional hazard 
model predicting time to 
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Table 4-2. The 
by African 
Table 4-2). The 
follow up
(N = 109 017)
death
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4.4.1.1.Risk factors/Medications  
Patients had a median eGFR of 54.32 mmol/litre/1.73m2, median cholesterol of 4.9mmol/l, 
median BMI of 27.9 kg/m2 and had mean blood pressure of 140.9/78.5 mmHg. The majority 
of patients with a urine dip or ACR had a high level of proteinuria (75.4%) followed by those 
with no proteinuria (17.6%) (Table 4-2). Patients had the following co-morbidities: 22.3% had 
diabetes mellitus, 11.5% had atrial fibrillation, 8.7% had heart failure and 19.8% were either 
currently smoking or had previously smoked.(Table 4-2) Many patients had some form of 
cardiovascular disease; 13.1% had Read codes for cerebro vascular accident (CVA), 25% had 
coronary heart disease (CHD) and 6.6% had peripheral vascular disease (PVD). Patients were 
on the following medications: anti-platelet agents (37.6%), angiotensin blockers (41.7%), 
beta-blockers (28.8%), diuretics (44.5%) and lipid lowering medication (41.6%) (Table 4-2) 
Nearly one in five (19.2%) patients had been prescribed non steroidal anti inflammatory 
drugs (NSAIDS) recently. (Table 4-2) 
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Table 4-2. Demographics and clinical features of the whole for all cause mortality cohort (n= 109 017) 
Demographic feature Figure or proportion (either range or percentage in 
brackets) 
Median Age in years at time of diagnosis (years) 72.9(18-107) 
Gender – Female 68725(62.2) 
Not recorded/Caucasian Race 
African –Caribbean 
Indian Subcontinent 
South East Asian 
107178(98.3) 
813(0.8) 
975(0.9) 
81(0.1) 
Townsend quintiles (95.5) * 
1 
2 
3 
4 
5 
 
26174(25.1) 
24810(23.8) 
21654(20.8) 
19066(18.3) 
12407(11.0) 
Diabetes Mellitus 24259 (22.3) 
Atrial Fibrillation 12555(11.5) 
Heart Failure 9504(8.7) 
Ever Smoked 21571(19.8) 
CVA 14231(13.1) 
CHD 27284(25.0) 
PVD 7178(6.6) 
Median eGFR in mmol/min/1.73m2 54.2 (3.6-59.9) 
Median Cholesterol (mmol/l) 
(66.1)* 
4.9(1.7-13.9) 
Median Body Mass Index (kg/m2) 
(41.2)* 
27.9(11.2-59.5) 
Median Haemoglobin (g/dl) 
(62.7)* 
13.4(3.3-25.8) 
Mean Systolic blood pressure (mmHg) 
(84.8)* 
140.9(20.6) 
Mean Diastolic blood pressure (mmHg) 
(84.8)* 
78.5(11.4) 
Proteinuria levels (14.9)* 
None 
High 
Very High 
 
2852(17.6) 
12225(75.4) 
1134(7.0) 
Anti platelets 
#
 41004(37.6) 
Anticoagulation 
#
 7056(6.5) 
Angiotensin Blockade 
#
 51289(47.1) 
Beta blockers 
#
 31378(28.8) 
Calcium Channel Blockers 
#
  22510(20.7) 
Diuretics 
#
 48525(44.5) 
Other Anti-hypertensives 
#
 6959(6.4) 
Lipid lowering medication 
#
 45320(41.6) 
Iron Supplementation 
#
 6614(6.1) 
Vitamin D 
#
 9357(8.6) 
Non Steroid Anti Inflammatory Drugs 
#
 20968(19.2) 
* Proportion with available data # All medications prescribed between 3 months prior to and 
one month after CKD diagnosis  
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4.4.2.Step 2: Missing data 
Only 5777 patients had a complete set of variables and the relative proportions are shown in 
Table 4-2. Townsend Quintiles (derived from postcode) and blood pressure had the highest 
proportion of complete data with proteinuria having the least complete data. 
4.4.3. Step 3: Multiple imputation 
Most records had missing data and so the pattern by which the data were missing was 
analysed and found to have an arbitrary missing pattern. In preparation for imputation, the 
incomplete data were graphed to assess normality. Serum cholesterol and BMI were 
positively skewed, hence log transformed and appeared normally distributed afterwards 
(Appendix A. Figures 1 to 2). Systolic and diastolic BP were normally distributed and Hb was 
negatively skewed and hence reflected and then log transformed (Appendix A. Figures 3 to 
5). Subsequently multiple imputation of data in 5 datasets (Table 4-3) was undertaken using 
multiple chained equations. The distribution of imputed variables was examined and are 
shown in Table 4-3. 
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Table 4-3. Variables with imputed data through imputation for all cause mortality model 
Variable with imputed 
data 
Original Data Imp 1* Imp 2 Imp 3 Imp 4 Imp 5 
Median Cholesterol 
(mmol/l) 
4.9 
(1.7-13.9) 
5.09 5.08 5.08 5.07 5.08 
Median Body Mass 
Index (kg/m2) 
27.9 
(11.2-59.5) 
27.40 27.4 27.39 27.42 27.39 
Median Haemoglobin 
(g/dl) 
13.4 
(3.3-25.8) 
13.50 13.50 13.50 13.50 13.50 
Mean Systolic blood 
pressure (mmHg) 
140.9 
(20.6) 
140.48 140.54 140.52 140.51 140.50 
Mean Diastolic blood 
pressure (mmHg) 
78.5 
(11.4) 
78.54 79.59 78.56 78.56 79.56 
Proteinuria levels 
None 
  
High 
 
Very High 
 
2852 
(17.6)* 
12225 
(75.4) 
1134 
(7.0) 
 
10740 
(9.9) 
90092 
(82.6) 
8185 
(7.5) 
 
10516 
(9.7) 
90236 
(82.7) 
8265 
(7.6) 
 
10095 
(9.3) 
91118 
(83.6) 
7804 
(7.2) 
 
10342 
(9.5) 
90473 
(83.0) 
8202 
(7.5) 
 
10366 
(9.51) 
90368 
(82.9) 
8283 
(7.6) 
Townsend quintiles 
1 
 
2 
 
3 
 
4 
 
5 
 
26174 
(25.1)* 
24810 
(23.8) 
21654 
(20.8) 
19066 
(18.3) 
12407 
(11.0) 
 
27347 
(25.1) 
25982 
(23.8) 
22680 
(20.8) 
19998 
(18.3) 
13010 
(11.9) 
 
27390 
(25.1) 
25931 
(23.8) 
22727 
(20.9) 
19956 
(18.3) 
13013 
(11.9) 
 
27339 
(25.1) 
25994 
(23.8) 
22683 
(20.8) 
19974 
(18.3) 
13027 
(12.0) 
 
27367 
(25.1) 
25934 
(23.8) 
22694 
(20.8) 
19997 
(18.3) 
13025 
(12.0) 
 
27372 
(25.1) 
25897 
(23.8) 
22699 
(20.8) 
19981 
(18.3) 
13068 
(12.0) 
 *abbreviation for imputation 
(Note range will be the non imputed as minimum and maximum and proportions are in 
brackets (%)) 
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4.4.4.Step 4. Results of analyses where the relationship between continuous co-variable 
and time to outcome was assumed linear. 
The following sections detail the Cox proportional hazards model where the continuous co-
variables were assumed to be linearly associated with time to outcome. The Cox regression 
analysis for each imputation is shown in Appendix A: Tables 1 to 5 and the combined 
estimates are shown in Table 4-4. 
4.4.4.1. Predictors associated with worse outcomes 
Increasing age (for every 100 years HR 513.7, 95%CI 414.2 to 637.1), male gender (compared 
to female HR 1.62, 95% CI 1.56 to 1.68), increasing Townsend quintile (Table 4-4), diabetes 
(HR 1.18, 95% CI 1.10 to 1.25), heart failure (HR 1.62, 95% CI 1.55 to 1.70), atrial fibrillation 
(HR 1.07, 95% CI 1.02 to 1.13) and patients who had previously smoked (HR 1.16, 95% CI 
1.11 to 1.20) were independently associated with increased risk of death. In patients with 
CKD all forms of cardiovascular disease were associated (CHD HR 1.07, 95% CI 1.02 to 1.11, 
CVA 1.25, 95% CI 1.19 to 1.30, PVD 1.18, 95% CI 1.12 to 1.24) with poorer survival. Very but 
not high albuminuria was associated with worse survival. Anti-platelet medication (HR 1.08, 
95% CI 1.04 to 1.27), anticoagulation (HR 1.29, 95% CI 1.21 to 1.38), diuretic use (HR 1.22 
95% CI 1.18 to 1.27), iron supplements (HR 1.14, 95% CI 1.08 to 1.21) and vitamin D 
supplementation (HR 1.25, 95% CI 1.19 to 1.32) were associated with poorer survival (Table 
4-4). The variables removed in backward selection were diastolic BP and NSAIDS. In the 
analysis of imputed dataset 3, calcium channel blockers were not significant but were 
significant in the overall combined model. 
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4.4.4.2.Predictors associated with better outcomes 
African Caribbean ethnicity (HR 0.61, 95% CI 0.42 to 0.89) and Indian Sub-continental 
ethnicity (HR 0.47, 95% CI 0.35 to 0.63) were associated with better survival.(Table 4-4) 
Increasing haemoglobin (HR for every increase in 10g/dl 0.20, 95% CI 0.18 to 0.23), GFR (For 
an increase in 100ml/min/1.73m2 HR 0.12, 95% CI 0.10 to 0.15), cholesterol (for an increase 
in 10mmol/l HR 0.50, 95% CI 0.43 to 0.59), systolic blood pressure (for an increase in 
100mmHg, HR 0.51, 95% CI 0.46 to 0.55) and BMI (for an, increase in 10 kg/m2, HR 0.83, 95% 
CI 0.80 to 0.86) were associated with improved survival. Angiotensin blockade (HR 0.85, 95% 
CI 0.81 to 0.88), beta blockade (HR 0.86, 95% CI 0.82 to 0.88), calcium channel blockers (HR 
0.96, 95% CI 0.92 to 0.99) and other antihypertensive medication (HR 0.87, 95% CI 0.82 to 
0.94) were associated with better survival. Lipid lowering medication was significantly 
associated with improved outcomes (HR 0.73, 95% CI 0.70 to 0.76). The Akaike Information 
Criteria (AIC), an indicator of model fit, improved with each model from a baseline of 293297 
(Table 4-5).  
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Table 4-4. All cause mortality: combined coefficients from Cox proportional hazards model and linear risk is 
assumed of numerical terms 
Risk factor /Medication 
 
Beta SE Hazard 
Ratio 
95% CI 
Lower 
95% CI 
Upper 
Age 6.242 0.110 513.685 414.181 637.093 
Male Gender 0.481 0.020 1.618 1.557 1.682 
Race
a
 
African Caribbean 
Indian Subcontinent 
South East Asian 
 
-0.494 
-0.763 
-1.183 
 
0.190 
0.151 
1.000 
 
0.610 
0.466 
0.306 
 
0.421 
0.347 
0.043 
 
0.885 
0.628 
2.176 
Townsend Quintile
b
 
2
nd
  
3
rd
  
4
th
  
5
th
 
 
0.116 
0.157 
0.176 
0.158 
 
0.026 
0.027 
0.027 
0.031 
 
1.123 
1.170 
1.192 
1.172 
 
1.067 
1.110 
1.129 
1.103 
 
1.183 
1.233 
1.258 
1.245 
Diabetes Mellitus 0.168 0.023 1.183 1.130 1.239 
Heart Failure 0.483 0.024 1.622 1.546 1.701 
Atrial Fibrillation 0.070 0.025 1.073 1.021 1.126 
Coronary Heart Disease 0.063 0.021 1.065 1.021 1.110 
Cerebrovascular Accident 0.221 0.022 1.248 1.194 1.303 
Peripheral Vascular Disease 0.161 0.029 1.175 1.109 1.244 
Ever Smoked 0.146 0.023 1.157 1.106 1.210 
Systolic BP -0.680 0.045 0.507 0.464 0.553 
BMI -0.186 0.019 0.830 0.800 0.862 
Haemoglobin -1.602 0.056 0.202 0.181 0.225 
Glomerular Filtration Rate -2.131 0.101 0.119 0.097 0.145 
Cholesterol -0.687 0.084 0.503 0.427 0.594 
Albuminuria
c
 
High 
Very High 
 
0.029 
0.217 
 
0.035 
0.044 
 
1.030 
1.243 
 
0.961 
1.141 
 
1.103 
1.354 
Anti-platelets 0.078 0.021 1.081 1.037 1.126 
Anticoagulation 0.255 0.033 1.291 1.210 1.377 
Angiotensin Blockade -0.169 0.020 0.845 0.813 0.878 
Beta blockade -0.151 0.021 0.860 0.825 0.896 
Calcium Channel Blocker -0.045 0.022 0.956 0.916 0.998 
Diuretic use 0.200 0.019 1.221 1.176 1.269 
Other Antihypertensive -0.140 0.038 0.870 0.808 0.937 
Lipid lowering agent -0.312 0.023 0.732 0.700 0.765 
Iron supplements 0.135 0.029 1.144 1.081 1.211 
Vitamin D supplementation 0.223 0.026 1.250 1.187 1.316 
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Table 4-5. AIC for each analysed imputed dataset for analysis in Table 4-4 
Imp Dataset Akaike Information Criteria 
1 278848.2 
2 278842.3 
3 278887.3 
4 278909 
5 278946.2 
 
4.4.5.Step 5: Analysis of transformed variables.  
This section details the Cox proportional hazard models where continuous variables were 
transformed up to 2 fractional polynomial terms (Xp + Xp where p is in the family 2, -1, -0.5, 0, 
0.5, 1, 2 and 3, where 0 is the terminology for log). Each imputed model was analysed using 
the MFP algorithm in R. The details of each individual coefficient derived from each analysed 
imputed dataset are in Appendix A: Tables 11-15. The algorithm suggested a different 
transformation for the variables of, haemoglobin, BMI, cholesterol and GFR (Table 4-6). 
Table 4-6. Suggested transformation of variables from mfp algorithm in R for each imputation for mortality 
model 
 Imputed Dataset 
Variable 1 2 3 4 5 
Age/100 X + X*Log X X + X*Log X X + X*Log X X + X*Log X X + X*Log X 
Systolic BP 
/100 
X + X2 X + X2 X + X2 X + X2 X + X2 
Hb/10 X-1+X-1 x 
LogX 
 
X-1+X-1 x 
LogX 
 
X-1+X-1 x 
LogX 
 
X-1+X-1 x 
LogX 
 
X-1+X-1 x LogX 
 
BMI/10 X+X3 LogX + X2 X2 + X2 x 
LogX 
X2 + X2 x 
LogX 
X2 + X2 x 
LogX 
GFR/100 X2 X X2 X2 X2 
Cholesterol 
/10 
X2 + X3 X2 + X3 X2 + X3 X2 + X3 X2 + X2* Log 
X 
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4.4.5.1.Results: log relative hazard ratio for each transformation 
Using the coefficients for each variable, the log relative hazard ratio was plotted for all 
transformed co-variables against the original scale for each analysis of  
• Age (Figure 4-3) 
• Systolic blood pressure (Figure 4-4) 
• Hb (Figure 4-5) 
• BMI (Figure 4-6) 
• Cholesterol (Figure 4-7) 
For age the relationship was identical for each imputation (Figure 4-3) and the log relative 
hazard ratio increased as age increased.  
Figure 4-3. Age versus Log relative Hazard Ratio for each imputation for mortality model (without frailty 
term) 
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For systolic blood pressure (Figure 4-4), though the values were different, the log relative 
hazard ratio decreased until a systolic of 166mmHg and then increased slightly above this 
threshold. 
Figure 4-4. Log relative Hazard Ratio versus Systolic BP for each imputation for mortality model (without 
frailty term) 
 
For haemoglobin (Figure 4-5), the values across imputations (imps) 1 to 3 and 5 are similar 
where the log relative hazard ratio decreased as haemoglobin increased. For the analysis of 
imputed dataset 4 the relationship is the same but the log relative hazard ratio was less.  
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Figure 4-5. Haemoglobin versus Log relative Hazard Ratio for each imputation (without frailty term)  
 
 
For the variable BMI (Figure 4-6), across Imps 1 to 5, the log relative hazard ratio decreased 
until BMI reaches 36 and then the log relative hazard ratio started to rise. However though 
the direction of the log relative hazard ratio was the same, the value for the beta coefficient 
for the log relative hazard ratio was different.  
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Figure 4-6. Body Mass Index versus log relative hazards ratio for Imps 1-5 (no frailty term) for mortality 
model 
 
Similar to the above plot, as cholesterol increased from 2 to 8 mmol/l the log relative hazard 
ratio fell and then started to increase again through all the imputed datasets. (Figure 4-7) 
Figure 4-7. Cholesterol versus log relative hazards ratio for Imps 1-5 (no frailty term) for mortality model  
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4.4.5.2.Other non transformed continuous and categorical co variables 
Like the combined model results from step 4 in the results, diastolic blood pressure and 
NSAIDS were not significant and removed from the models for imputed datasets 1 to 5. 
Additionally calcium channel blockers were no longer significant and removed from the 
model. For each model for each imputation, with the exception of transformed variables, 
coefficients for each co-variable showed the same direction as the model in Step 4. Male 
gender, increasing Townsend quintile, diabetes mellitus, heart failure, atrial fibrillation, CHD, 
CVA, PVD, patients who smoke or had previously smoked, very high albuminuria, anti-
platelets, anticoagulation, diuretic use, iron and vitamin D supplementation were associated 
with worse outcomes.  
Patients with African-Caribbean race, Indian-Sub continental race, increasing GFR (at a 
squared rate were associated with improved survival), treatment with angiotensin blockers, 
beta-blockers, other anti-hypertensives and other lipid lowering agents were associated with 
improved survival. The AIC for the analysis for each imputation is shown in Table 4-7 and is 
significantly better than previous models in Step 4. 
Table 4-7. AIC for each analysed imputed dataset: comparing non linear and linear terms for mortality model 
Imp Dataset Akaike Information Criteria for 
models analysed in Step 4: No 
transformation of continuous co-
variable 
Akaike Information Criteria for 
models analysed in Step 5: Where 
transformations of co-variable in 
for each continuous co-variable 
1 278848.2 278528.2 
2 278842.3 278507.4 
3 278887.3 278556.3 
4 278909 278604.1 
5 278946.2 278596.5 
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4.4.6. Step 6. Selection of the model with the most consistent transformations i.e. the 
alternative model 
The analysis imputed dataset using the MFP algorithm suggests a different transformation 
for the BMI, Hb, cholesterol and GFR. As specified in the methods each imputed model was 
analysed using the commonest suggested transformation. The model fit statistic AIC of this 
model, the ‘alternative’ model was compared to the AIC of original model with mfp. The 
following were the commonest mfp for the transformed variable. 
• Age - X + X*Log X (all Imps) 
• Systolic BP - X + X2 (all Imps) 
• Hb - X-1+X1- x Log X (1 to 3, 4) 
• BMI - X2+X2*Log X (Imps 3 to 5) 
• GFR - X2 (Imps 1, 3 to 5) 
• Cholesterol - X2+X3 (all Imps) 
4.4.6.1.Model fit statistic comparing the original mfp modes and the ‘alternative’ model 
To see if the ‘alternative’ model was significantly worse than the original mfp model then AIC 
had to increase by 4 (p < 0.05). However the model with the commonest transformation 
(alternative) model and the original mfp models were no different and the model fit 
improved for the best model in comparison with the original model. 
Table 4-8. A comparison between the original model with mfp and alternative model (no frailty term) 
Imp 
Dataset 
Akaike Information Criteria for 
original mfp models  
Akaike Information for 
‘alternative’ mfp model 
1 278528.2 278528.0 
2 278507.4 278501.3 
3 278556.3 278557.2 
4 278604.1 278604.8 
5 278596.5 278598.2 
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4.4.6.2.The final combined (without frailty) (Table 4-9) 
The following co-variables were associated with poorer survival; male gender (HR 1.64, 95% 
CI 1.58 to 1.71), Increasing Townsend quintile (for e.g. 5th quintile versus the first quintile, HR 
1.16, 1.10 to 1.24, diabetes mellitus (HR .1.19, 1.13 to 1.25), heart failure (HR 1.69, 1.59 to 
1.79), atrial fibrillation (HR 1.18, 1.13 to 1.24). 
Again as in the previous steps, all cardiovascular disease was associated with increased 
death (CHD HR 1.07, 1.02 to 1.13, CVD HR 1.24, 1.18 to 1,29, PVD HR 1.17, 1.11 to 1.24) 
Patients who were current or previous smokers (HR 1.26, 1.21 to 1.32), very high 
albuminuria but not high levels of proteinuria (very high albuminuria versus no proteinuria 
HR 1.24, 1.14 to 1.35), anti-platelets prescription (HR 1.08, 1.03 to 1.12), anticoagulation (HR 
1.30, 1.22 to 1.39), diuretic use (HR 1.22, 1.17 to 1.26), iron supplementation (HR 1.13, 1.06 
to 1.19) and vitamin D supplementation (HR 1.24, 1.18 to 1.31) were associated with lesser 
survival also. 
African-Caribbean ethnicity (HR 0.58, 0.40 to 0.84), Indian Sub-continental ethnicity (HR 
0.46, 0.34 to 0.62), angiotensin blockade (HR 0.85, 0.82 to 0.89), beta-blockade (HR 0.86, 
0.83 to 0.90), other antihypertensives (HR 0.89, 0.82 to 0.96) and lipid lowering medication 
(HR 0.75, 0.71 to 0.78) were associated with better survival. Increasing GFR (for an increase 
in (100 mls/min/1.73m2)2, HR 0.10, 0.08 to 0.13) was associated with increased survival.  
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Table 4-9. The combined coefficients using the ‘alternative’ models (No frailty term) 
Risk factor/Prescription  Beta SE  HR  95% CI 
Age/100 7.75 0.76 2328.55 529.29 10244.19 
Age/100 x log(Age/100) 0.69 0.54 2.00 0.70 5.71 
Male Gender 0.50 0.02 1.64 1.58 1.71 
African –Caribbean
a
 
Indian Subcontinent 
South East Asian 
-0.54 
-0.77 
-1.25 
0.19 
0.15 
1.00 
0.58 
0.46 
0.29 
0.40 
0.34 
0.04 
0.84 
0.62 
2.03 
2
nd
 Townsend Quintile
b
 
3
rd
 Townsend Quintile
b
 
4
th
 Townsend Quintile
b
 
5
th
 Townsend Quintile
b
 
0.12 
0.15 
0.17 
0.15 
0.03 
0.03 
0.03 
0.03 
0.12 
1.16 
1.18 
1.16 
1.07 
1.10 
1.12 
1.10 
1.18 
1.23 
1.25 
1.24 
Diabetes Mellitus 0.17 0.02 1.18 1.13 1.24 
Heart Failure 0.46 0.02 1.59 1.52 1.67 
Atrial Fibrillation 0.07 0.02 1.07 1.02 1.13 
Coronary Heart Disease 0.06 0.02 1.07 1.02 1.11 
Cerebrovascular Accident 0.21 0.02 1.24 1.18 1.29 
Peripheral Vascular Disease 0.16 0.03 1.17 1.11 1.24 
Ever Smoked 0.15 0.02 1.16 1.11 1.22 
Systolic BP/100 -3.41 0.31 0.03 0.02 0.06 
(Systolic BP/100)
2
 0.97 0.11 2.64 2.13 3.26 
(BMI/10)
2 
x log (BMI/10) 0.18 0.02 1.20 1.16 1.24 
(BMI/10)
2
 -0.32 0.03 0.73 0.69 0.77 
(Hb/10)
-1 
x log(Hb/10) 4.74 0.36 114.66 56.40 233.12 
(Haemoglobin/10)
-1
  6.38 0.35 588.06 293.33 1178.92 
(Glomerular Filtration Rate/100)2 -2.29 0.12 0.10 0.08 0.13 
(Cholesterol/10)
2
 -2.56 0.34 0.08 0.04 0.15 
(Cholesterol/10)
3
 2.24 0.36 9.36 4.59 19.09 
 High Albuminuria 
c
 
Very High Albuminuria  
0.03 
0.22 
0.04 
0.04 
1.03 
1.24 
0.96 
1.14 
1.10 
1.35 
Anti-platelets 0.07 0.02 1.08 1.03 1.12 
Anticoagulation 0.26 0.03 1.30 1.22 1.39 
Angiotensin Blockade -0.17 0.02 0.85 0.82 0.88 
Beta blockade -0.15 0.02 0.86 0.83 0.90 
Diuretic use 0.20 0.02 1.22 1.17 1.26 
Other -0.14 0.04 0.87 0.80 0.93 
Lipid lowering agent -0.29 0.02 0.75 0.71 0.78 
Iron supplements 0.12 0.03 1.13 1.06 1.19 
Vitamin D supplementation 0.22 0.03 1.24 1.18 1.31 
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4.4.6.3.Fractional polynomials in Model 
The relationship between log hazard ratios in age (Figure 4-8) is the same as for the original 
transformed mfp (Figure 4-3), as age increases the log relative hazard ratio increases. The log 
relative hazard decreased as systolic blood pressure started to decrease but when blood 
pressure was above 172 mmHg the risk started to increase (Figure 4-8). As haemoglobin 
increased the log relative hazard ratio decreased. When BMI increased from 15 to 36 kg/m2 
the log relative hazard ratio fell sharply and increased after this (Figure 4-9). As the 
cholesterol increased the log relative hazard ratio decreased until after a cholesterol of 7.6 
mmol/l the log relative hazard ratio started to increase again. (Figure 4-9) 
 
Figure 4-8. Age versus log relative hazard ratio (no frailty term) in model using most consistent mfp for all 
cause mortality 
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4.4.7.Step 7. Frailty Models 
Steps 4 to 6 were repeated with a frailty term (a random effects term) for practice 
location added to each model. These steps will be named Step 4F to 6F. 
4.4.7.1.Step 4F. Analysis of co-variables where relationship between continuous co-variable 
and time to outcome is assumed to be linear. 
When a frailty term (a random effects term) for practice was added to each 
imputation, similar to the model in step 4 without frailty, diastolic blood pressure and 
NSAIDs were not significant and removed from the final model. (Appendix A: Tables 11 
to 15). Calcium channel blockers were included despite not being significant in 3rd Imp 
but were significant in the combined model. (Table 4-10).  
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Table 4-10. Combined coefficients for all cause mortality model where linear risk is assumed of 
numerical terms with practice location as frailty term 
Risk factor /Prescription Beta SE HR 95% CI 
AGE 6.248 0.111 516.823 416.099 641.928 
MALE GENDER 0.480 0.020 1.617 1.555 1.681 
African –Caribbean
a
 
Indian Subcontinent 
SOUTH EAST ASIAN 
-0.498 
-0.750 
-1.197 
0.191 
0.153 
1.001 
0.608 
0.473 
0.302 
0.418 
0.350 
0.043 
0.884 
0.638 
2.148 
TOWNSEND QUINTILE
B
 
2ND  
3RD  
4TH  
5TH 
 
0.113 
0.152 
0.169 
0.154 
 
0.027 
0.027 
0.028 
0.032 
 
1.119 
1.164 
1.184 
1.166 
 
1.062 
1.103 
1.121 
1.096 
 
1.179 
1.228 
1.251 
1.242 
DIABETES MELLITUS 0.165 0.024 1.179 1.126 1.234 
HEART FAILURE 0.484 0.024 1.622 1.546 1.701 
ATRIAL FIBRILLATION 0.065 0.025 1.067 1.016 1.121 
CORONARY HEART DISEASE 0.063 0.022 1.065 1.021 1.111 
CEREBROVASCULAR ACCIDENT 0.218 0.022 1.243 1.190 1.299 
PERIPHERAL VASCULAR DISEASE 0.156 0.030 1.169 1.103 1.239 
EVER SMOKED 0.144 0.024 1.154 1.101 1.210 
SYSTOLIC BP -0.679 0.045 0.507 0.464 0.554 
BMI -0.187 0.019 0.830 0.800 0.861 
HAEMOGLOBIN -1.603 0.056 0.201 0.181 0.225 
GLOMERULAR FILTRATION RATE -2.152 0.102 0.116 0.095 0.142 
CHOLESTEROL -0.682 0.085 0.506 0.428 0.597 
ALBUMINURIA
C
 
HIGH 
VERY HIGH 
 
0.028 
0.228 
 
0.035 
0.044 
 
1.029 
1.257 
 
0.960 
1.153 
 
1.103 
1.369 
ANTI-PLATELETS 0.077 0.021 1.080 1.036 1.126 
ANTICOAGULATION 0.258 0.033 1.295 1.213 1.381 
ANGIOTENSIN BLOCKADE -0.168 0.020 0.845 0.813 0.879 
BETA BLOCKADE -0.150 0.021 0.861 0.826 0.897 
CALCIUM CHANNEL BLOCKER -0.047 0.022 0.954 0.914 0.997 
DIURETIC USE 0.198 0.020 1.219 1.173 1.266 
OTHER -0.139 0.038 0.870 0.808 0.937 
LIPID LOWERING AGENT -0.309 0.023 0.734 0.702 0.768 
IRON SUPPLEMENTS 0.133 0.029 1.142 1.079 1.208 
VITAMIN D SUPPLEMENTATION 0.224 0.027 1.250 1.187 1.318 
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The combined model with frailty was similar to the model above (Step 4. Non frailty 
models) To recap; increasing age, male gender, increasing Townsend quintile, diabetes 
mellitus, heart failure, atrial fibrillation, patients who had previously smoked, all 
cardiovascular disease, very high albuminuria, anti-platelets, anticoagulation, diuretic 
use, iron and vitamin D supplementation were associated with poorer survival.(Table 
4-10)  
African-Caribbean ethnicity, Indian sub-continental ethnicity, increasing systolic blood 
pressure, body mass index, Haemoglobin, GFR and cholesterol were associated with 
better survival. Treatment with Angiotensin blockade, beta blockers, calcium channel 
blockers, other anti-hypertensives and lipid lowering medication were also associated 
with better survival. The AIC for each model for each imputed dataset was better than 
the previous model without a frailty term for practice location (Table 4-11).  
Table 4-11. AIC for each model for all cause mortality model with and without frailty term 
Imp Dataset Akaike Information 
Criteria for models 
analysed in Step 4: No 
transformation of 
continuous co-variable 
without frailty 
Akaike Information 
Criteria for models 
analysed in Step 4f: No 
transformation of 
continuous co-variable 
with frailty 
1 278848.2 278760.6 
2 278842.3 278745.9 
3 278887.3 278801.7 
4 278909 278814.9 
5 278946.2 278857.7 
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4.4.7.2.Step 5f. Models with transformation 
When practice location was added to the algorithm to determine the best fitting 
fractional polynomial in Cox proportional hazards model for each imputed dataset; 
with the exception of calcium channel blockers, the same co-variables were significant 
and same transformation of continuous co variables as in Step 5 were suggested (Cox 
proportional hazards model are in Appendix A Tables 16 to 20) The plots of the 
transformed co-variables were almost identical to figure 4-8 and figure 4-9 and are 
shown in Appendix A Figures 6 to 10. The AIC for each imputation substantially 
improved in comparison with all previous models in step 2.(Table 4-12) 
Table 4-12. AIC for each model for all cause mortality with original suggested fractional polynomial 
with frailty term 
Imp Dataset Akaike Information 
Criteria for models 
analysed in Step 5: : 
Variables transformed 
according to Table 4-6 
without frailty 
Akaike Information 
Criteria for models 
analysed in Step 5f: 
Variables transformed 
according to Table 4-6 
with frailty 
1 278528.2 278447.3 
2 278507.4 278418 
3 278556.3 278477.1 
4 278604.1 278516 
5 278596.5 278514.9 
 
4.4.7.3.Step 6f. Finding the most consistent transformations of continuous co-variables 
across the Imps 
Like the non frailty models (Step 6 non frailty model), the ‘mfp’ transformations 
suggested for Hb, BMI, Cholesterol and GFR differed across each Imp and therefore the 
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commonest transformations were compared against the original suggested 
transformations.  
The commonest transformations to recap were: 
Age/100 + Age/100 x log Age + Systolic blood pressure/100 + systolic blood 
pressure/1002 + Haemoglobin -1 + Haemoglobin/10-1 x log Haemoglobin/10 + BMI 2 + 
BMI/102 x log BMI/10 + GFR/1002 + Chol/102 + Chol/103 
Like in step 6 in the non frailty model, the AIC statistic did not differ by 4 between 
models for each imputation except for the analysis of imputed dataset 3 where by the 
model improved with the most consistent transformations.(Table 4-13) 
Table 4-13. A comparison between the original model with mfp and the best model with a frailty term 
Imp 
Dataset 
Akaike Information 
Criteria for original Model 
Akaike Information for 1st 
‘alternative’ Model 
1 278447 278447 
2 278418 278410 
3 278477 278477 
4 278516 278517 
5 278515 278515 
As the ‘alternative’ imputed model seemed the best fit across all analysed imputed 
datasets this was chosen as the final model and coefficients were combined for each 
imputation.  
4.4.7.4.Final combined model with mfp and frailty term for practice location 
The same co variables are significant in ‘best model’ without frailty (Step 3) and the 
‘best model’ with frailty (Step 6f). The direction of the risk/protection did not change 
and the coefficients changed slightly (Table 4-14) especially for the transformed 
variables. 
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Table 4-14. Combined all cause model for each imputation using the alternative model 
incorporating a frailty term of practice location 
Risk factor /Prescription Beta SE HR 95% CI 
Age/100 7.76 0.76 2339.28 529.49 10334.8 
Age/100 x log(Age/100) 0.70 0.54 2.00 0.70 5.75 
Male Gender 0.50 0.02 1.64 1.58 1.71 
African –Caribbean
a
 
Indian Subcontinent 
-0.55 
-0.76 
0.19 
0.15 
0.58 
0.47 
0.40 
0.35 
0.84 
0.63 
2
nd
 Quintile
 b
 
3
rd 
Quintile
 b
 
4
th 
Quintile
 b
 
5
th
 Quintile
 b
 
0.11 
0.15 
0.16 
0.15 
0.03 
0.03 
0.03 
0.03 
1.12 
1.16 
1.17 
1.16 
1.06 
1.10 
1.11 
1.09 
1.18 
1.22 
1.24 
1.23 
Diabetes Mellitus 0.16 0.02 1.18 1.13 1.23 
Heart Failure 0.46 0.02 1.59 1.52 1.67 
Atrial Fibrillation 0.06 0.03 1.07 1.02 1.12 
Coronary Heart Disease 0.06 0.02 1.07 1.02 1.11 
Cerebrovascular Accident 0.21 0.02 1.23 1.18 1.29 
Peripheral Vascular Disease 0.15 0.03 1.17 1.10 1.24 
Ever Smoked 0.15 0.02 1.16 1.11 1.22 
Systolic BP/100 -3.35 0.31 0.04 0.02 0.06 
(Systolic BP/100)
2
 0.95 0.11 2.58 2.08 3.19 
(BMI/10)
2 
x log (BMI/10) 0.18 0.02 1.20 1.16 1.24 
(BMI/10)
2
 -0.32 0.03 0.73 0.69 0.77 
(Hb/10)
-1 
x log(Hb/10) 4.74 0.36 114.53 56.27 233.11 
(Hb/10)
-1
  6.38 0.36 588.87 293.37 1182.02 
(Glomerular Filtration Rate/100)2 -2.32 0.12 0.10 0.08 0.12 
(Cholesterol/10)
2
 -2.52 0.35 0.08 0.04 0.16 
(Cholesterol/10)
3
 2.20 0.37 9.04 4.42 18.50 
High Albuminuria
c
 
Very High Albuminuria 
0.03 
0.23 
0.04 
0.04 
1.03 
1.26 
0.96 
1.15 
1.10 
1.37 
Anti-platelets 0.07 0.02 1.08 1.03 1.12 
Anticoagulation 0.26 0.03 1.30 1.22 1.39 
Angiotensin Blockade -0.17 0.02 0.85 0.82 0.88 
Beta blockade -0.15 0.02 0.86 0.83 0.90 
Diuretic use 0.19 0.02 1.21 1.17 1.26 
Other -0.14 0.04 0.87 0.80 0.93 
Lipid lowering agent -0.29 0.02 0.75 0.71 0.78 
Iron supplements 0.12 0.03 1.12 1.06 1.19 
Vitamin D supplementation 0.22 0.03 1.24 1.18 1.31 
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Reference for analysis a. Caucasian race b. 1st Townsend Quintile c. No Albuminuria 
4.4.8. Step 8. Is model fit improved after incorporating mfp transformation and 
frailty terms? 
The table below compares the model fit statistic AIC combined models from Step 4 
(model without mfp and frailty), Step 6(model with ‘best mfp’) and Step 6f (model with 
‘best mfp’ and frailty). A lower AIC implies a better model fit and a difference of 4 
between the value of AIC for each model means there is a significantly better model (p 
< 0.05) and if this difference is 11 then the significance increases to p < 0.001. 
Incorporating fractional polynomials for age, systolic blood pressure, Hb and BMI, GFR 
and cholesterol led to a significantly better model. Incorporating the frailty term 
resulted in an even better fitting model. (Table 4-15) 
Table 4-15. Comparison of the AIC for the original all cause mortality model without frailty/mfp and 
then models with mfp and frailty 
Imp 
Dataset 
AIC for original Model 
i.e. no transformation 
or frailty term 
(Step 4) 
AIC for alternative mfp 
model with but no 
frailty term 
(Step 6) 
AIC for alternative mfp 
model with but with 
frailty term 
(Step 6f) 
1 278848 278528(-320) 278447(81) 
2 278842 278501(341) 278410(91) 
3 278887 278557(330) 278477(80) 
4 278909 278604(304) 278517(87) 
5 278946 278598(348) 278515(83) 
*The value in brackets is the difference between the current column and the previous 
column 
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4.4.9.Step 9. Testing the proportional hazards assumption 
The best most informative model is described in step 7 (Model in step 6f). The scaled 
Schoenfeld residuals against time are shown in Appendix B for Imputed dataset 3 
analysis. All the graphs show a non zero slope hence maintain the proportional hazards 
assumption.  
4.4.10.Step 10. Complete Case Analysis 
As specified in the methods a complete case analysis was carried out for the dataset. 
This included 5777 patients who had a complete set of data for analysis. The median 
age was lower in the complete case analysis, but the gender proportion and ethnic mix 
was similar to the full dataset (Table 4-16).  
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Table 4-16. Demographics of the whole all cause mortality cohort and cohort with complete data 
Demographic feature Figure or proportion for 
entire Cohort 
(109 017)* 
Figure or proportion 
Complete cohort 
analysis 
(n=5777) 
Median Age in years at time of diagnosis 
(years) 
72.9(18-107) 71.8(23.4-99.8) 
Gender – Female 68725(62.2) 3005(55.0) 
Not recorded/Caucasian Race 
African –Caribbean 
Indian Subcontinent 
South East Asian 
107178(98.3) 
813(0.8) 
975(0.9) 
81(0.1) 
5617(97.2) 
60(1.0) 
97(1.7) 
3(0.1) 
Median eGFR mmol/min/1.73m
2
 54.2 (3.6-59.9) 55.1(4.4-59.9) 
Diabetes Mellitus 24259 (22.3) 3307(57.2) 
Atrial Fibrillation 12555(11.5) 703(12.2) 
Heart Failure 9504(8.7) 561(9.7) 
Ever Smoked 21571(19.8) 1478(25.6) 
Antiplatelet agents 41004(37.6) 3054(52.9) 
Anticoagulation 7056(6.5) 431(7.5) 
Angiotensin Blockade 51289(47.1) 3752(65.0) 
Beta blockers 31378(28.8) 1996(34.6) 
Calcium Channel Blockers 22510(20.7) 1535(26.6) 
Diuretics 48525(44.5) 2736(47.4) 
Other Anti-hypertensives 6959(6.4) 266(9.8) 
Lipid lowering medication 45320(41.6) 3870(67.0) 
Iron Supplementation 6614(6.1) 469(8.1) 
Vitamin D 9357(8.6) 395(6.8) 
Non Steroid Anti Inflammatory Drugs 20968(19.2) 1018(17.6) 
Median Cholesterol (mmol/l) 
(66.1) 
4.9(1.7-13.9) 4.5(1.7-10.4) 
Median Body Mass Index (kg/m2) 
(41.2) 
27.9(11.2-59.5) 28.4(14-59.3) 
Median Haemoglobin (g/dl) 
(62.7) 
13.4(3.3-25.8) 13.5(3.9-20.8) 
Mean Systolic blood pressure (mmHg) 
(84.8) 
140.9(20.6) 139.0(13.8) 
Mean Diastolic blood pressure (mmHg) 
(84.8) 
78.5(11.4) 76.7(11.5) 
Proteinuria levels (14.9) 
None 
High 
Very High 
 
2852(17.6)* 
12225(75.4) 
1134(7.0) 
 
1088(18.8) 
4389(80.0) 
300(5.2) 
Townsend quintiles (95.5) 
1 
2 
3 
4 
5 
 
26174(25.1)* 
24810(23.8) 
21654(20.8) 
19066(18.3) 
12407(11.0) 
 
1373(23.8) 
1273(22.0) 
1191(20.6) 
1150(20.0) 
790(13.7) 
* Proportion within available data 
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The median eGFR was slightly higher and more patients had diabetes and smoked but 
similar proportions had heart failure and atrial fibrillation (Table 4-16). In general 
patients were more likely to be on relevant prescription medication with the exception 
of Vitamin D supplementation and NSAID prescription (Table 4-16).  
4.4.10.1.Cox proportional hazards model for complete case analysis 
The median follow up was 967 days (90 to 1785) which is less than the previous 
analysis and 526 patients died during the study period. As models with frailty and 
transformation of variables had previously shown better fit, only this model is shown 
(Table 4-17) 
Age and BMI will be discussed later but like the previous analysis the following were 
associated with worse survival; male gender, heart failure, 4th Townsend quintile, 
diabetes mellitus, heart failure, CVA, PVD, patients who had previously smoked, had 
very high albuminuria, diuretic use, anticoagulation, vitamin D supplementation. 
Increasing haemoglobin, systolic blood pressure, and GFR and angiotensin blockade 
were associated with improved survival. Initially as age increased so did the log relative 
hazard ratio but when age reached 50 years then the rate at which the log relative 
hazard ratio increased fell and levelled out. As BMI increased the log relative hazard 
ratio decreased but not quite in a linear fashion. 
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Table 4-17. Cox model with frailty term and fractional polynomials complete case analysis for all cause 
mortality model 
Risk Factor/Prescription Beta SE HR 95% CI Lower  
Age/100
-1
 9.85 1.45 18940.0
0 
1113 322274. 
Age/100
-0.5
 -0.38 3.88 0.00 0.00 0.00 
Gender 0.58 0.10 1.78 1.48 2.15 
Townsend Quintile compared 
to 1st Quintile 2
nd
  
3
rd 
4
th 
5
th
  
 
0.06 
0.09 
0.31 
0.17 
 
0.14 
0.14 
0.13 
0.15 
 
1.06 
1.10 
1.37 
1.19 
 
0.81 
0.84 
1.06 
0.88 
 
1.40 
1.44 
1.77 
1.60 
Diabetes Mellitus 0.42 0.10 1.53 1.25 1.87 
Heart Failure 0.76 0.11 2.13 1.72 2.63 
Cerebrovascular Accident 0.25 0.10 1.28 1.04 1.57 
Peripheral Vascular Disease 0.28 0.12 1.33 1.05 1.67 
Ever Smoked 0.34 0.10 1.40 1.16 1.70 
Systolic BP/100 -0.94 0.23 0.39 0.25 0.61 
Haemoglobin/10 -1.70 0.27 0.18 0.11 0.31 
BMI/10
0.5
 -18.83 2.91 0.00 0.00 0.00 
BMI/10 5.30 0.84 200.60 38.64 1040.65 
GFR/100 -1.87 0.54 0.15 0.05 0.45 
High Albuminuria 
Very High Albuminuria 
0.12 
0.85 
0.13 
0.18 
1.12 
2.34 
0.88 
1.63 
1.44 
3.35 
Anticoagulation 0.31 0.13 1.37 1.06 1.77 
Angiotensin Blockade -0.24 0.10 0.79 0.65 0.96 
Diuretic use 0.30 0.10 1.35 1.12 1.64 
Vitamin D supplementation 0.39 0.15 1.47 1.11 1.96 
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4.5. Discussion  
4.5.1. Summary Of Results 
This chapter has summarised the development of a model that examined which 
routinely collected primary care data are associated with survival in patients with CKD. 
The model development went through several iterations and included 109 017 
patients with a median follow-up of 1064 days (i.e. about three years). Firstly the 
dataset had a high proportion of missing data and multiple imputations of missing data 
were undertaken with multiple chained equations to create five datasets with imputed 
data for blood pressure, cholesterol, haemoglobin, and body mass index. The first 
models included continuous co-variables linearly in the models. The 2nd iteration in the 
models were where the continuous variables were transformed up to 2nd degree 
fractional polynomials (fp) and the commonest and best fractional polynomials were 
determined. The 3rd iteration included models with fractional polynomials and a frailty 
term for practice location. The final model found to have the lowest AIC was the 3rd 
iteration. (Figure 4-10) 
The forest plot in Figure 4-11 shows the co-variables that were not transformed in 
Model 3 and the model shows that African-Caribbean and Indian Sub-continental 
ethnicity, angiotensin blockers, beta blockers, other anti hypertensive drugs and anti 
lipid agents were associated with increased survival. Increasing Townsend quintile, AF, 
HF, diabetes, CHD, CVD, PVD, smoking, anti-platelets agents, anticoagulation, iron and 
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Vitamin D supplementation were all associated with worse survival. The non significant 
variables are described in (Figure 4-11). 
With the exception of age where the risk of death approximately increases linearly as 
age increases, the relationship with systolic blood pressure, haemoglobin, cholesterol 
and BMI were more complex. The relationship with systolic blood pressure and hazard 
for death was inverse J shaped. As Hb increased generally the risk of death decreased. 
The relationship between BMI and risk was U shaped where this risk of death 
decreased until BMI of 36 kg/m2 and then subsequently increased. This was similar to 
the relationship between the risk of death and cholesterol. When GFR increased the 
risk of death increased at squared rate. This model satisfied the non proportional 
hazards model as the co-variables had a non zero slope on Scaled Schoenfeld residual 
plots.  
The complete case analysis consisted only of 5777 patients and the patients were 
younger than the whole cohort (Median age in years 71.8 vs. 72.9) and less likely to be 
female (55% vs. 62.2%). The median follow up was 967 days. The model was very 
similar to 1st Model (Figure 4-10) however which contained a reduced number of 
protective factors. 
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4.5.2. Interpretation of Results 
To ascertain the optimal model to determine co-variables associated with survival, the 
development underwent several iterations and ultimately the best model included the 
whole database with multiple imputations with fractional polynomials for age, systolic 
blood pressure, GFR, haemoglobin, cholesterol and BMI included in addition to a frailty 
(random effects) term for practice location. The suggested fractional polynomial for 
these co-variables differed across each model, however plots of these transformations 
with the log relative hazard ratio revealed very similar relationships. When the 
commonest transformations were used in the analysis for each imputed dataset, it was 
only for the analysis of 4th imputed dataset that the model fit was worse than original 
suggested mfp. Additionally there was in improvement in model fit for dataset 2 
analyses. 
Before discussing each co-variable individually it is worth discussing the relationship 
between transformed co-variables and log hazard ratio. If a variable is linear or ordinal 
then the exponentiation of the log hazard ratio will be the hazard ratio, however when 
log relative hazard ratio is modelled on fractional polynomials especially 2nd degree 
mfp then exponentiation will change this relationship and therefore further 
adjustment is required. However as log relative hazard ratio increases or decreases 
then there is a likewise change in hazard ratio.[251]  
4.5.3.Comparison to existing literature 
The relationship between age and log hazard ratio was almost linear and an increase in 
age was associated with increasing risk of death. This is similar to existing literature 
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where absolute risk for mortality and ESRD increased as age increased.[265] Male 
gender was associated with an increased risk of death and this is similar to existing 
literature in CKD patients and the general population.[239] Though ethnicity was 
missing in the majority of the population, non Caucasian patients were more likely to 
survive than those with unrecorded/Caucasian ethnicity. This may be due to several 
reasons. Ethnicity reporting in primary care electronic records software is either 
recorded by staff or volunteered by patient. Such patients are therefore more likely to 
consult their GP, have registered more recently and patients with under recorded 
ethnicity could have worse outcomes. Conversely these patients may be healthier and 
do not need to consult their GP. Favourable outcomes in Indian sub-continentals with 
CKD stage 3 have not been reported before but have been reported in patients on 
Renal replacement therapy.[129;241] The relationship with African – Caribbean 
patients with CKD is more complex. American studies suggest that Black patients with 
CKD are more likely to die in comparison with Caucasian patients.[240] However 
American Black patients have increased social deprivation and decreased access to 
health care. Though similar disparities exist in the UK, healthcare is free at the point of 
access and this group may relatively have better access to health care.[134] 
Additionally deprivation is accounted for in the model. Increased deprivation is 
associated with increased mortality and this may account for the differences in ethnic 
groups. The deprivation data is generally complete in the THIN dataset because it is 
derived from the post code from census data.[136] 
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As expected, all co-morbid conditions included in the analysis; diabetes, CVD, CHD, 
PVD, heart failure and atrial fibrillation were associated with increased 
mortality.[102;196;272;273] These conditions represent the most vulnerable of CKD 
patients as they predispose patients to CKD and also increased mortality. 
4.5.3.1.Transformed Variables and the relationship with medication 
4.5.3.1.1.Body Mass index, Anaemia, GFR and Proteinuria 
So far the results have not proven contradictory to current medical opinion. However 
the transformed continuous variables do not behave predictably. Patients who have a 
body mass index of 25 kg/m2 or above in the general population are more likely to die 
or suffer from cardiovascular disease.[128] However, in patients with CKD the 
relationship is less clear as there is some evidence to suggest a U shaped relationship 
with mortality, i.e. being underweight or morbidly obese may be associated with 
worse outcomes but patients with overweight and obese body mass indices may have 
the best survival.[108;274;275] In my analysis body mass index convincingly showed a 
U shaped or inverse J shaped relationship with mortality. One possible hypothesis is 
that the MDRD equation may underestimate eGFR in obese individuals. This 
particularly happens in patients over a BMI over 29 kg/m2.[276;277] and is particularly 
salient to the CKD cohort in my analysis as the median BMI was 29 kg/m2. If the GFR is 
better at higher BMIs, then this may offset the increased risk of death usually 
associated with higher BMIs and explain the improved survival.  
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It is predictable that as haemoglobin rises the risk of death falls. A lower haemoglobin 
is associated with a higher risk of death in the general population.[132] In patients 
with CKD anaemia is primarily due to erythropoietin deficiency but may also be due to 
inflammation, iron deficiency and increases oxidative stress.[278] Patients treated with 
iron supplementation may be at greater risk for death as they are more likely to be 
anaemic. This is a form of confounding by indication,[279] where anaemia a risk factor 
of death and or CVD pre disposes to iron use and therefore death. This analysis also 
suggests that oral iron supplementation may not be effective at correcting iron 
deficiency anaemia and this may be due to impaired oral absorption of iron in CKD 
patients.[280] 
The risk of death associated with decreasing GFR and increasing proteinuria is well 
documented by several other studies and this likely due to worsening metabolic 
complications as renal function worsens.[34;43;43;93-95;159;196;265;265]  
Lipid and Lipid Lowering 
The relationship in this analysis between cholesterol, cholesterol lowering agents and 
the risk of death was complex. This analysis showed on one hand that an increasing 
cholesterol until a relatively high total cholesterol is associated with reduced risk of 
death but on the other hand that cholesterol lowering agents such as statins are 
associated with reduced risk of death. Evidence from dialysis patients (i.e. those 
patients with the most severe form of kidney disease), suggests that they are more 
likely to survive if the cholesterol increases and this relationship was consistent with 
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my analysis.[124] However in patients with ESRD this is likely to be because a lower 
cholesterol is associated with systemic inflammation and malnutrition.[281] CKD 
patients, regardless of stage, are more likely to have systemic inflammation and other 
lipid abnormalities such as high triglycerides and lower HDL cholesterol. An increase in 
total cholesterol may represent patients with increased HDL cholesterol which is 
protective.  
Patients treated with lipid lowering agents are more likely to survive than those not 
treated.[121] This contradicts the relationship between total cholesterol and mortality 
in my study but supports earlier trial evidence from the Study of Heart and Renal 
Protection where patients randomised to simvastatin and ezetimibe on average 
experienced LDL reduction and vascular risk reduction.[121] Interestingly, there was 
no reduction in mortality as perhaps this study was not powered to detect this. 
Treatment with statins may have additional effects other than lowering LDL 
cholesterol which may be protective.[105] This may partially explain the complex 
relationship between total cholesterol and risk of death. Patients with a total 
cholesterol above 5 mmol/l are more likely to be treated with lipid lowering agents 
and that is why the risk appears to reduce as cholesterol decreases at this threshold. 
However in treated patients the risk would increase if the cholesterol is very high and 
that is why there is U shaped relationship. This is another form of confounding by 
indication.  
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Blood pressure and Anti-hypertensives 
The relationship between systolic blood pressure and mortality has always been 
described in the literature as U or J shaped.[119] In the general population the risk of 
cardiovascular disease and mortality increases above a systolic blood pressure of 135 
mmHg in patients with diabetes and 145mmHg in those with hypertension.[111;225] 
However in my analysis, the turning point for where risk increases was considerably 
higher occurring at approximately a systolic blood pressure of 166mmHg. The 
recommendations for lowering systolic blood pressure beyond 140 mmHg are derived 
from patients with diabetic nephropathy.[116] In CKD patients, limited studies do not 
show a reduction below targets of 140 mmHg as either beneficial or harmful as shown 
in a meta-analysis.[282]  
In a CKD Collaborative meta-analysis, patients with or without hypertension (defined 
as systolic blood pressure above 140mmHg) had a similar risk of mortality when their 
GFR fell below 95 ml/min/1.73m2 and although not significant, the risk of death or 
ESRD was higher in those without hypertension.[283] A recent study examined the 
impact of blood pressure on mortality in 651 749 patients with CKD.[284] The group 
split blood pressure into 10mmHg groups and found that the risk of death was the 
same for patients with a blood pressure in the range of 130-160mmHg. The author of 
the study hypothesized that it was reduction in a normal diastolic blood pressure that 
was associated with greater mortality; however this was not significant in my 
analysis.[284] 
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This evidence from the literature conflicts with the protective use of some anti-
hypertensives observed in my analysis (with the exception of diuretics and calcium 
channel blockers).[115] Angiotensin blockers have been shown in large meta-analysis 
to reduce cardiovascular outcomes in patients with CKD and my analysis shows that 
the risk of death is reduced in CKD patients on angiotensin blockers.[229] Angiotensin 
blockers reduce proteinuria in CKD patients.[117] As increasing proteinuria increases 
risk of death in my analysis, angiotensin blockers may reduce the risk of death 
independently of lowering blood pressure by reducing proteinuria.[117] Beta-blockers 
again may have additional protective effects, as CKD patients may have increased 
sympathetic activity and suppression of this may provide other benefits additional to 
blood pressure lowering agents.[120] Beta-blockers may additionally reduce the 
progression of renal disease in CKD patients and this may also protect from death, as 
worsening eGFR is associated with poorer survival and increased cardiovascular 
risk.[222;285]  
Calcium Channel blockers were not significant in protecting from mortality in the final 
model and this is contradictory to previous evidence in the general population that 
showed a protective effect.[115] However in some studies with CKD patients this 
relationship has not been demonstrated.[222;231] The anti-hypertensive agents 
associated with better survival reduce blood pressure by blocking the renin 
angiotensin aldosterone system (RAAS) and calcium channel inhibitors act 
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independently of this. Blocking RAAS is reno-protective and therefore calcium channels 
may demonstrate no benefit.[286] 
Another surprising finding is that diuretics (including thiazide and loop diuretics) were 
associated with increased death.[115] This may be because diuretics are more likely 
used in patients with fluid retention and or heart failure and therefore are a marker of 
increased co-morbidity.[7] More surprisingly, is that those on other hypertensives, i.e. 
mostly patients on Doxazosin, were more likely to survive than those not on these 
agents. This is again contrary to the ALLHAT study in the general population and there 
is no evidence that this agent is any less or more effective than other agents in 
reducing mortality. Perhaps it is confounding by indication as Doxazosin is not 
tolerated in patients with postural hypotension (a marker for mortality in its own right) 
and therefore healthier individuals may be on this drug and men due to use prostatic 
hypertrophy.[287] This may require further investigation. It is worth discussing 
confounding by indication in the context of these results. Treated patients may differ 
from those who not treated for example characteristics that to lead patients being 
selected for particular agents may increase or decrease their survival. 
Remaining risk factors 
Confounding by indication may also explain the fact that treatment with anti-platelet 
agents, anticoagulation (warfarin) and Vitamin D supplementation, was associated 
with poorer survival. Though anti-platelet agents and anti-coagulation are associated 
with better survival in some randomised trials and meta-analysis, these patients are 
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more likely to have co-morbidity that may not be accounted for in the 
analysis.[110;120] Additionally patients on vitamin D supplementation may be patients 
at risk for falls on Vitamin D3 replacement or patients with renal bone disease on 
alphacalcidol.[248] These factors are associated with increased mortality.[248] NSAID 
use was not significant in this study, even though widely used during the time of CKD 
diagnosis. NSAID use may only be significant in the very elderly and in higher 
cumulative doses.[288] Diastolic blood pressure was not a significant co-variable in the 
analysis and this supports evidence that systolic blood pressure is a better predictor of 
cardiovascular risk from trials in the general population.[289;290] This may also be the 
case in patients with CKD.[291] 
In terms of prognostic models for mortality: this is one of the largest models 
conducted in CKD using routinely collected data.[292] All previous models have less 
candidate predictors then my model and may reflect the smaller sample sizes involved. 
In the complete case analysis the size of the study population was very small and there 
were far less significant predictors and they did not change direction or shape when 
analysed. This may be due to lack of power as optimism decreases when there are 
events per co-variable and this reduces overfitting. This emphasizes the use of the full 
cohort is preferential to discern the best predictors.[260] 
4.5.4.Limitations and Strengths 
This analysis had several limitations which will be discussed further in this section. The 
first is the generic bias associated with health care databases and UK primary care 
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databases.[146] There is a form of selection bias where patients with recorded 
information may be different from the general population.[144] Patients who attend 
for blood tests, blood pressure checks and who request repeat prescriptions are more 
likely to do better than non-compliant and non-engaging individuals.[293] However 
conversely healthy and well patients are less likely to have a check-up i.e. inverse care 
law. Additionally there was no linked data to secondary care and CKD 3 patients with 
complications may have been managed differently. Despite these limitations, patients 
selected from primary care are more likely to be representative of the general 
populations than those from hospital populations where selection bias mentioned 
above is likely to be more extreme.[125] 
There were missing data especially for more ‘specialised’ measurements such as urine 
ACR but blood pressure data were quite complete. Multiple imputations were 
performed but assumptions were made that that the data were missing at random. 
This dataset relied heavily on Read code recording, and we have previously shown that 
for QOF CKD recording this may be inaccurate.(Chapter 3) However I used non QOF 
Read codes to identify comorbidities and it is known that for cardiovascular disease, 
Read code recording is reasonably accurate.[138;155]  
There is poor recording of ethnicity, endemic to all GP computer systems and 
therefore THIN, GPRD and QRESEARCH and previous work has shown that this may 
result in non-coding of up to half of patients of non-white origin.[294] This may lead to 
the associations of better survival in ethnic minorities being questioned. There may be 
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patients with newer registrations included. The impact of ethnicity on CKD recognition 
will be discussed later. A further limitation is that although the THIN database provides 
an accurate record of prescribing there is no evidence that the drugs were dispensed 
and or taken. 
In a complex multivariable analysis presented in this whether co-variables cause or 
prevent death cannot be determined. Firstly this is a retrospective observational study 
(although the data is prospectively collected). The information was not collected a 
priori for the specific analysis of outcomes in CKD patients and therefore only 
association of the co-variables with the outcome not causation.[109] This is because 
patient demographics collection, patient measurements and patient treatments are 
not determined by the investigators. This is exemplified by treatment assignment. 
Treatment is not randomly assigned and patient characteristics and clinician 
preference will govern this. This is confounding by indication and may lead to unusual 
relationships between co –variables and outcome for example blood pressure and 
death. [279]  
Additionally in a large model like this interactions between co-variables were not 
assessed. However this would have been conceptually difficult as fractional 
polynomials were used and found to have a better fit in the model. Interaction terms 
between fractional polynomials and other polynomials and other co-variables are very 
complex to analyse and were outside the scope of this thesis. This could be considered 
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in the future using stata software which can analyse interactions between fractional 
polynomials and co-variables using the MFP gen algorithm. 
Limitations specific to this analysis are firstly CKD recognition: this has been discussed 
earlier (Chapter 2) but this paragraph will reiterate the issues of method of creatinine 
analysis and the lack of black ethnicity data. To explain the first point, by using the 
lower creatinine of two blood tests at least seven days apart and using the non IDMS 
MDRD equation to calculate the eGFR led to under classification of CKD. However 
using two blood tests seven days apart will have increased the precision of creatinine 
measurement.[276] Regarding the question of black ethnicity: between 2001 and 2011 
the UK national census reported that black ethnicity was between 2.2% and 3.3% and 
even if ten percent of these patients had CKD, the prevalence would only fall by 0.3%.  
Additional limitations were that patients were censored after they had de registered 
leading to unequal lengths of follow up. Patient information were excluded before 
AMR date and after at least 6 registration at the practice. This was because it was 
unlikely that their records would be accurate prior to this, however this could have led 
to patients with CKD being excluded.[150] The cause of death was unknown as THIN 
was not linked to ONS. The model predominantly examined cardiovascular risk factors 
and an assumption was made that the majority of deaths were due to cardiovascular 
disease.  
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The major strengths of this study are that this was a large cohort generally 
representative of the UK population. Although there may be some selection bias i.e. 
those who got blood tests, measurements and prescriptions, the selection bias is likely 
to be less than in patients from hospitals and volunteers for screening studies.[136] 
The other advantage of this CKD population is that it is a UK primary care based cohort 
where health care is free at the point of access and therefore this makes this one of 
largest generalisable CKD cohort studies in the world. There is no recall bias as clinical 
data are collected prospectively. The prescribing information is accurate and has been 
verified for research.[146]  
In many prognostic CKD studies when data is missing it is excluded or substituted with 
common values such as the mean or median.[284;292] Excluding patients with missing 
data can lead to considerably smaller sample sizes and their analyses may lose power 
and miss important predictors. Therefore multiple imputation was necessary in this 
analysis. Continuous data were not dichotomized and nor were they analysed linearly. 
By using fractional polynomials, important non-linear relationships were exposed and 
these transformed variables models had better fit than if analysed linearly. A random 
effects term for practice further improved model fit and again shows that this is 
important in such analyses where there may fundamental differences in clinical 
practice and case mix. The model included enough events to avoid substantial 
overfitting.[250]  
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4.6.Executive Summary 
• Cardiovascular Disease and mortality in CKD patients are associated with 
traditional and CKD specific risk factors 
• Cox proportional hazards model allow multivariable analysis of censored 
outcomes. 
• When considering models: missing data and non linear functional forms 
have to be considered. 
• In clustered data frailty models have to be considered. 
• This dataset had greater than 15% missing data for several variables and 
therefore five imputed datasets were created. 
• The optimal model was one that incorporated fractional polynomials and 
a frailty term. 
• The model confirmed the association between traditional risk/prognostic 
factors for mortality such as increasing age, GFR, angiotensin blockage 
and statins. 
• However other risk /prognostic factors such as blood pressure, 
cholesterol, blood thinning agents had an unconventional relationship 
with mortality. 
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CHAPTER 5. CAN ROUTINELY COLLECTED PRIMARY CARE DATA PREDICT 
CARDIOVASCULAR DISEASE OR ALL CAUSE MORTALITY IN STAGE 3 CKD 
PATIENTS? 
This Chapter describes the development of a new prognostic model which aims to 
identify potential predictors of the composite outcome of CVD or all cause mortality in 
CKD3-5 patients. No separate introduction and a brief overview of the methods are 
provided since the issues and approach used was similar to that in Chapter 4. The 
results are discussed in the context of the current literature. 
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5.1.Methods 
5.1.1.Model Cohort 
Patients with CKD stage 3a and 3b were characterized by two consecutive estimated 
Glomerular filtration rates (calculated from serum creatinine at least seven days apart 
using the non IDMS MDRD equation[13]). Patients had to have survived or suffered no 
cardiovascular events in subsequent three months to be included in the model. 
Patients were aged 18 or over at time of diagnosis of CKD and registered at the 
practice for greater than 6 months. All data post the AMR date was considered for the 
practice.[150] Patients entry in the cohort was the time of their initial diagnosis of CKD 
i.e. the first CKD 3a or 3b staging. 
5.1.2.Outcome Measures:  
The model outcome was a composite of time to cardiovascular event or all cause 
mortality. CVD or all-cause mortality was predefined by Read codes including the QOF 
business Read codes and additional codes identified by the doctoral researcher using 
her clinical expertise.[45] It was assumed that the absence of Read code or time of 
death meant that the patient did not incur an event. Patients were censored if they 
were alive at the end of the study period, had not suffered a CVD event or when they 
deregistered from the practice. Patients had to have survived a minimum of three 
months to allow appropriate modelling of risk factors. 
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5.1.2.1.Co-Variables 
The same covariables were included in the model as identified in the previous chapter 
(all-cause mortality model) (Table 4-1) with the exception of CVD as this was included 
in the composite outcome.  
5.1.2.2.Cox Proportional hazards-Model 
The same method of model development was adopted as described in Chapter 4 and is 
summarised in Figure 5-1.  
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 5.2. Results 
Cohort demographics
The cohort was derived from patients with two consecutive serum creatinines (N= 1 
202 293) seven days apart where both calculated eGFRs were below 60 and 
patient had survived a minimum o
patients with CKD 3 who were free of CVD at the time of diagnosis who were used for 
this analysis.(Figure 5
Figure 
Patient demographics
majority of patients were female (67.6%). The majority of patients had either no 
recorded ethnicity or were of Caucasian ethnicity (98.1%) (
cholesterol was 5.3 
haemoglobin (Hb) was 13.5 g/dl, blood pressure (BP) was 142.5/79.7 mmHg. 
Thin Cohort November 
2009
(N=9 720 702)
Adult patients registered at 
practice for a minimum of 
6 months on 1st November 
2009
(N = 6 581 419)
Patients with at least one 
serum creatinine post AMR 
date and 6 months 
registration at practice
(N= 1 982 568)
 
f 3 months (N = 109 017). There were 74 731 
-2)  
5-2. Derivation of THIN CKD cohort for composite outcome
 are shown in Table 5-1. The median age was 71.3 years and the 
Table 
mmol/l, the body mass index (BMI) was 28.1 kg/m
CKD stage  determined 
using higher eGFR 
Patients with two 
consecutive blood results 
seven days apart 
(N=1 202 293)
eGFR calculated using pre 
IDMS MDRD equation during the cohort follow up
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5-1). The median 
2, the 
 
Patients who survived for 3 
months and who had CKD 
(N = 109 017)
Patients free from CVD 
Disease at time of 
diagnosis
(N= 74 731)
Cox regression model 
predicting time to 
death/CVD from CKD 
diagnosis
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Table 5-1. Demographics of the composite model cohort (if not stated in brackets then proportion of 
data complete) 
Demographic feature Figure or proportion 
Median Age in years at time of diagnosis (years) 71.3 (23-107) 
Gender – Female 50517 (67.6%) 
Not recorded/Caucasian Race 
African –Caribbean 
Indian Subcontinent 
South East Asian 
73317(98.1%) 
683 (0.9%) 
690(0.9%) 
41(0.1%) 
  Townsend quintiles (95.7%)* 
1 
2 
3 
4 
5 
 
18855(26.4%) 
17477(24.4%) 
14762(20.6%) 
12569(17.6%) 
7857(11.0%) 
Median eGFR in mmol/min/1.73m
2
 54.3 (3-64) 
Median Cholesterol (mmol/l) 
(60.8%)* 
5.3(1.7-13.9) 
Median Body Mass Index (kg/m2) 
(38.2%)* 
28.1(11.2-59.5) 
Median Haemoglobin (g/dl) 
(64.2%)* 
13.5(3.3-25.8) 
Mean Systolic blood pressure (mmHg) 
(82.5%)* 
142.5(20.5) 
Mean Diastolic blood pressure (mmHg) 
(82.5%)* 
79.7(11.3) 
Proteinuria levels (13.6%)* 
None 
High 
Very High 
 
1876(18.5%) 
7586(74.8%) 
675(6.7%) 
Angiotensin Blockade 30716(41.1%) 
Beta blockers 16522(22.1%) 
Calcium Channel Blockers 13143(17.6%) 
Diuretics 30826(41.3%) 
Other Anti-hypertensives 4421(5.9%) 
Lipid lowering medication 21455(28.7%) 
Iron Supplementation 3882(5.2%) 
Vitamin D 6153(8.2%) 
Non Steroid Anti Inflammatory Drugs 15301(20.2%) 
*PROPORTION OF DATA AVAILABLE 
 
Patients had a median eGFR of 54.3 mmol/litre/1.73m2, 20.1% had diabetes mellitus, 
8.5% had atrial fibrillation, 5.0% had heart failure and 17.4% were current or ex 
smokers (Table 5-1). A significant proportion of patients were on anti-platelets 
medication (22.6%), angiotensin blockade (41.1%), beta-blockers (22.1%), diuretics 
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(41.3%) and lipid lowering medication (28.7%) Interestingly 20.2% of patients had a 
recent prescription of non-steroidal anti-inflammatory drugs (NSAIDS) (Table 5-1).  
5.2.1. Step 1. Outcomes experienced by the Cohort 
The median follow up for the cohort was 1034 days (range 90 to 1079 days). There 
were 12 048 events, of which 6511 were deaths and 5537 cardiovascular events (i.e. 
first ever Read code for cardiovascular event). In patients who incurred cardiovascular 
events, there were 2859 patients who had a Read code for CHD, 2127 with a Read 
code for cerebrovascular accident and 947 patients who had a Read code for 
peripheral vascular disease. Please note that the total number of events were more 
than 5537 cardiovascular events as some patients had 1 or more new Read codes. 
5.2.2.Step 2. Variables with missing data 
Only 3247 patients had a complete set of variables and the relative proportions are 
shown in Table 5-1. 
5.2.3. Step 3. Missing data analysis and subsequent imputation 
High proportions of data were missing and found to have an arbitrary missing pattern 
(data not shown). The incomplete data were graphed to see if they were normally 
distributed. Serum cholesterol and BMI were positively skewed and hence were log 
transformed and following this they appeared normally distributed. (Appendix C. 
Figures 1 to 2). Systolic and diastolic BP were normally distributed but Hb was 
negatively skewed and hence reflected and then log transformed to generate a normal 
distribution (Appendix C. Figures 3 to 5). After multiple imputation was undertaken 
using multiple chained equations, the distribution of imputed variables were examined 
and are shown in Table 5-2.  
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Table 5-2. Imputed datasets for composite model: The distribution of imputed variables 
Variable with imputed 
data 
Original Data Imp 1 Imp 2 Imp 3 Imp 4 Imp 5 
Median 
Cholesterol (mmol/l) 
5.3(1.7-13.9) 5.37 5.38 5.37 5.37 5.38 
Median 
Body Mass Index 
(kg/m2) 
28.1(11.2-
59.5) 
27.57 27.50 27.59 27.60 27.53 
Median  
Haemoglobin (g/dl) 
13.5(3.3-25.8) 13.51 13.50 13.51 13.50 13.50 
Mean 
Diastolic blood pressure 
(mmHg) 
142.5(20.5) 79.92 79.89 79.90 79.91 79.88 
Mean 
Systolic blood pressure 
(mmHg) 
79.7(11.3) 141.92 141.87 141.96 141.88 141.87 
Proteinuria levels 
None 
 
High 
 
Very High 
 
1876 
(18.5)* 
7586 
(74.8) 
675 
(6.7) 
 
7827 
(10.5) 
61085 
(81.7) 
5819 
(7.8) 
 
7738 
(10.4) 
61695 
(82.6) 
5298 
(7.1) 
 
7751 
(10.4) 
61408 
(82.2) 
5572 
(7.46) 
 
7711 
(10.3) 
61345 
(82.1) 
5675 
(7.6) 
 
8102 
(10.8) 
61321 
(82.1) 
5308 
(7.1) 
Townsend quintiles 
1 
 
2 
 
3 
 
4 
 
5 
 
18855 
(26.4)* 
17477 
(24.4) 
14762 
(20.6) 
12569 
(17.6) 
7857 
(11.0) 
 
19696 
(26.4) 
18247 
(24.4) 
15412 
(20.6) 
13141 
(17.5) 
8235 
(11.0) 
 
19637 
(26.3) 
18289 
(24.4) 
15434 
(20.6) 
13138 
(17.6) 
8225 
(11.0) 
 
19700 
(26.4) 
18277 
(24.5) 
15406 
(20.6) 
13138 
(17.6) 
8210 
(11.0) 
 
19719 
(26.4) 
18238 
(24.4) 
15422 
(20.6) 
13136 
(176) 
8216 
(11.0) 
 
19656 
(26.3) 
18242 
(24.4) 
15462 
(20.7) 
13111 
(17.5) 
8260 
(11.1) 
 (Note range will be the same as whole cohort as min and maximum specified in 
imputation) 
  
Page 228 of 375 
 
5.2.4. Step 4. Analysis of co-variables where the relationship between continuous co-
variables and time to outcome is assumed to be linear. 
The following section details the results of a Cox proportional hazards model where 
the continuous co-variables were assumed to be linearly associated with time to 
outcome. The results of the Cox regression analyses for each imputation are shown in 
Appendix C: Tables 1-5 and the combined estimates are shown in Table 5-3. The 
variables removed in backward selection in each Imputation were diastolic BP, NSAIDS, 
beta-blockers and calcium channel blockers. As lipid lowering agents were significant 
only in the fifth Imputation, this co-variable was removed from the analysis. 
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Table 5-3. Combined coefficients from Cox proportional hazards model for composite outcome where 
linear risk of numerical variables is assumed. (no frailty term) 
Risk factor/Prescription Beta Standard 
Error 
Hazard 
Ratio 
95% CI 
Lower 
95% CI 
Upper 
 
Age 0.05 0.00 1.05 1.05 1.05 
Male Gender -0.49 0.02 1.64 1.56 1.69 
Race with Caucasian race as 
reference 
African –Caribbean 
-0.43 0.16 0.65 0.48 0.89 
Indian Subcontinent -0.26 0.12 0.77 0.61 0.97 
South East Asian -0.51 0.58 0.60 0.19 1.87 
Townsend Quintile compared to 1st 
Quintile  
2
nd
  
0.09 0.03 1.09 1.04 1.15 
3
rd
 0.12 0.03 1.13 1.07 1.19 
4
th
 0.15 0.03 1.16 1.10 1.23 
5
th
  0.20 0.03 1.22 1.14 1.30 
Diabetes Mellitus 0.17 0.02 1.18 1.12 1.24 
Heart Failure 0.54 0.03 1.72 1.62 1.82 
Atrial Fibrillation 0.22 0.03 1.25 1.18 1.32 
Ever Smoked 0.23 0.02 1.26 1.21 1.33 
Systolic BP 0.00 0.00 0.9976 0.9967 0.9985 
BMI -0.02 0.00 0.98 0.98 0.99 
Haemoglobin -0.11 0.01 0.89 0.88 0.90 
Glomerular Filtration Rate -0.02 0.00 0.98 0.98 0.99 
Cholesterol -0.03 0.01 0.97 0.96 0.99 
Proteinuria levels with none as 
reference 
High 
0.15 0.03 1.16 1.09 1.24 
Very High 0.45 0.04 1.57 1.44 1.71 
Aspirin 0.22 0.02 1.25 1.20 1.30 
Anticoagulation 0.20 0.04 1.22 1.13 1.32 
Angiotensin Blockade -0.17 0.02 0.85 0.81 0.88 
Diuretic use 0.08 0.02 1.08 1.04 1.13 
Other -0.12 0.04 0.88 0.82 0.95 
Iron Medication 0.14 0.03 1.15 1.08 1.23 
Vitamin D supplementation 0.17 0.03 1.19 1.12 1.26 
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5.2.4.1.Covariables associated with worse outcomes (Table 5-3) 
Increasing age (for every year HR 1.05, 95% CI 1.05 to 1.05), male gender (compared to 
female HR 1.64, (1.56 to 1.69), increasing Townsend quintile diabetes (HR 1.18, 1.12 to 
1.24), heart failure (HR 1.72, 1.62 to 1.82), atrial fibrillation (HR 1.25, 1.18 to 1.23) and 
patients who had previously smoked (HR 1.26, 1.21 to 1.33) were independently 
associated with increased rate of events (Table 5-3), Increasing proteinuria was 
associated with worse survival. Anti-platelet agents (HR 1.25,1.20 to 1.30), 
anticoagulation (HR 1.22,1.13 to 1.32), diuretic use (HR 1.08 1.04 to 1.13), iron 
medication (HR 1.15,1.08 to 1.23) and vitamin D supplementation (HR 1.19,1.12 to 
1.26) were all associated with worse survival.  
5.2.4.2.Predictors associated with less CVD/Death (Table 5-3) 
African Caribbean ethnicity (HR 0.65, (95% CI 0.48 to 0.89) and Indian Sub-continental 
ethnicity (HR 0.77, 0.61 to 0.97) were associated with better survival but South East 
Asian ethnicity was not. Increasing haemoglobin (HR for every unit increase 0.89, 0.88 
to 0.90), eGFR (HR 0.99, 0.98 to 0.99), cholesterol (HR 0.97, 0.96 to 0.99) systolic blood 
pressure (HR 0.9976, 0.9967 to 0.9985) and body mass index (HR 0.98, 0.98 to 0.99) 
were associated with better survival. Angiotensin blockade (HR 0.85, 0.81 to 0.88) and 
other anti-hypertensive medication (HR 0.88, 0.82 to 0.95) were also associated with 
better survival. The Akaike Information Criteria (AIC), in indicator of model fit, was 
improved with each model with a baseline of 260757. (Table 5-4).  
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Table 5-4. AIC for each imputed dataset for Table 5-3 
Imp Dataset Akaike Information Criteria 
1 252133. 
2 252125. 
3 252220. 
4 252204. 
5 252139. 
 
5.2.5.Step 5: Analysis of transformed variables.  
This section details the Cox proportional hazard models where continuous variables 
were transformed up to 2 fractional polynomial terms (Xp + Xp where p is in the family 
2, -1, -0.5, 0, 0.5, 1, 2 and 3, where 0 is the terminology for log). Each imputed model 
was analysed using the MFP algorithm in R. The detail of each individual coefficient 
derived from each analysed imputed dataset are shown in Appendix C: Tables 6-10. 
The algorithm suggested a different mfp transformation for the variables of systolic 
blood pressure, haemoglobin, body mass index and GFR (Table 5-5). 
Table 5-5. Suggested transformation of variables from mfp algorithm in R for each imputation for 
composite model 
Variable Imputation 1  Imputation 2 Imputation 3 Imputation 4 Imputation 5 
Age Age squared Age squared Age squared Age squared Age squared 
Systolic blood 
pressure 
(x/100)
0.5
 + 
(x/100)
1
 
(x/100)
2
+ 
(x/100)
2
* 
log(x/100) 
(x/100)
1
 + 
(x/100)
2
 
 
(x/100)
1
 + 
(x/100)
2
 
 
(x/100)
1
+ 
(x/100)
1
* 
log(x/100) 
Haemoglobin (x/10)
-2
+ 
(x/10)
-1
 
(x/10)
3
+ 
(x/10)
3
* 
log(x/10) 
(x/10)
3
+ 
(x/10)
3
* 
log(x/10) 
(x/10)
3
+ 
(x/10)
3
* 
log(x/10) 
(x/10)
3
+ 
(x/10)
3
* 
log(x/10) 
BMI (x/10)
-0.5
+ 
(x/10)
3
 
log(x/10)+ 
(x/10)
3
 
(x/10)
-2
 
 
(x/10)
-0.5
+ 
(x/10)
3
 
(x/10)
-2
 
 
GFR None squared None None None 
Cholesterol None None None Not 
significant 
None 
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5.2.5.1.Plotting the log relative hazard ratio for each transformation 
Using the coefficients for each variable, the log relative hazard ratio was plotted 
against the original untransformed variable for the following variables: 
• Age (Figure 5-3) 
• Systolic blood pressure (Figure 5-4) 
• Hb (Figure 5-5) 
• BMI(Figure 5-6) 
The relationship between age and the hazard function was identical for each 
imputation (Table 5-5) and the log relative hazard ratio increased at a squared rate as 
age increased.  
Figure 5-3. Age versus Log relative Hazard Ratio for each imputation (without frailty term) 
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For systolic blood pressure (Figure 5-4), though the values were different for each 
imputation, the log relative hazard ratio decreased until a systolic of 166mmHg and 
then increased slightly above this threshold. 
Figure 5-4. Log relative Hazard Ratio versus Systolic BP for each imputation (without frailty term) 
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Figure 5-5. Haemoglobin versus Log relative Hazard Ratio for each imputation (without frailty term)  
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Figure 5-6. Body Mass Index versus log relative hazards ratio for Imps 1 to 5 (no frailty term)  
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Townsend quintile, diabetes mellitus, heart failure, atrial fibrillation, patients who 
smoke or had previously smoked, increasing proteinuria, aspirin, anticoagulation, 
diuretic use, iron and vitamin D supplementation were associated with worse 
outcomes.  
Patients with African-Caribbean ethnicity, Indian-Sub continental ethnicity, increasing 
eGFR, lipid lowering agents, angiotensin blockers and other antihypertensives had 
better outcomes. The AIC for the analysis for each imputation is shown in (Table 5-6) 
and was significantly better than previous model results from step 4. 
Table 5-6. AIC for each model with original suggested fractional polynomial for composite model (no 
frailty term) 
Imp Dataset Akaike Information Criteria for 
models analysed in Step 4: No 
transformation of continuous 
co-variable 
Akaike Information Criteria for 
models analysed in Step 5: 
Where transformations of co-
variable in Table 5-5 for each 
continuous co-variable 
1 252133.5 251977 
2 252125.2 251989 
3 252220.3 252108 
4 252204.9 252071 
5 252139.4 252010 
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5.2.6.Step 6. The (‘alternative’) model with the most consistent transformation 
As the analysis of each imputed dataset showed a different a transformation for the 
systolic blood pressure, BMI, GFR, and Hb it was decided to explore if there was effect 
on model fit (AIC), if each imputed model was analysed using the commonest 
suggested transformation. The commonest transformations were: 
• Systolic blood pressure - Systolic blood pressure + systolic blood pressure2 
(Imps 3 and 4),  
• Haemoglobin - haemoglobin3+haemoglobin/103*log haemoglobin (Imps 2-5) 
• Body Mass Index - BMI-2 (Imps 3 and 5) or BMI-0.5+BMI3 (Imps 2 and 4) 
•  Age - Age2  
• GFR and cholesterol no transformation. 
Therefore two models for each imputation were carried out as BMI had two 
suggested mfp. The AIC was then compared between the original mfp model, and 
the two ‘alternative’ models.  
5.2.6.1.Model fit statistic for each model 
The 1st alternative model had a lower AIC for each analysed imputed dataset compared 
to the 2nd alternative model. When original mfp model was compared to the 1st 
alternative model, there was a significant difference between the model of imputed 
dataset 1 (Χ2= 6.0, 1df p <0.02) and model of imputed dataset 2 (Χ2= 11.0, 1df p 
<0.001), (Table 5-7). However for the analysis of imputed datasets 3 to 5 there was no 
significant difference between the AIC of the original mfp model and 1st alternative 
model. 
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Table 5-7. A comparison between the original mode for composite outcome with mfp and the 1
st
 and 
2
nd
 best model (no frailty term) 
Imp 
Dataset 
AIC for original 
Model 
AIC for 1
st
 
‘alternative’ Model 
AIC for 2
st
 
‘alternative’ Model 
1 251977 251983 251988 
2 251989 252000 252021 
3 252108 252108 252116 
4 252071 252069 252071 
5 252010 252011 252025 
 
5.2.6.2.The final combined model using mfp but without frailty 
The final combined model is represented in Table 5-8. The following co variables were 
associated with poorer survival; male gender(HR 1.65, 95% CI 1.58 to 1.71), increasing 
Townsend quintile (for e.g. 5th quintile versus the first quintile, HR 1.21, 1.14 to 1.29, 
diabetes mellitus (HR .1.19, 1.13 to 1.25), heart failure (HR 1.69, 1.59 to 1.79), atrial 
fibrillation (HR 1.24, 1.17 to 1.31), current/ex-smokers(HR 1.26, 1.21 to 1.32), 
increasing proteinuria (high versus no proteinuria HR 1.17, 1.09 to 1.25, very high 
versus no proteinuria HR 1.55, 1.43 to 1.69), anti-platelet prescription (HR 1.25, 1.20 to 
1.30), anticoagulation (HR 1.23, 1.14 to 1.33), diuretic use (HR 1.09, 1.05 to 1.13), iron 
supplementation (HR 1.12, 1.05 to 1.20) and vitamin D supplementation (HR 1.17, 1.11 
to 1.25).  
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Table 5-8. Combined model for each Imputation for first alternative model for all Imputations. (No 
frailty term) 
Risk factor/Prescription Beta SE HR 95% CI 
(Age/100)
2
 3.33 0.07 27.97 24.57 31.84 
Male Gender 0.50 0.02 1.65 1.58 1.71 
Race with African Caribbean 
Race as reference 
African –Caribbean 
-0.46 0.16 0.63 0.47 0.86 
Indian Subcontinent -0.27 0.12 0.77 0.61 0.96 
South East Asian -0.54 0.58 0.58 0.19 1.81 
Townsend Quintile compared to 
1st Quintile  
2
nd
  
0.09 0.03 1.09 1.04 1.15 
3
rd
 0.12 0.03 1.12 1.06 1.19 
4
th
 0.15 0.03 1.16 1.10 1.23 
5
th
  0.19 0.03 1.21 1.14 1.29 
Diabetes Mellitus 0.17 0.02 1.19 1.13 1.25 
Heart Failure 0.52 0.03 1.69 1.59 1.79 
Atrial Fibrillation 0.21 0.03 1.24 1.17 1.31 
Ever Smoked 0.23 0.02 1.26 1.21 1.32 
(Systolic BP/100)
1
 -2.19 0.34 0.11 0.06 0.22 
(Systolic BP/100)
2
 0.66 0.12 1.94 1.55 2.43 
(BMI/10)
-2
 1.66 0.15 5.29 3.96 7.06 
(Haemoglobin/10)
3
 -0.69 0.05 0.50 0.46 0.55 
(Haemoglobin/10)
3 
x log 
(Haemoglobin) 
0.76 0.07 2.13 1.87 2.43 
Glomerular Filtration Rate/10 -1.43 0.11 0.24 0.19 0.30 
Cholesterol/10 -0.28 0.08 0.76 0.65 0.89 
Proteinuria compared to normal 
High 
Very High 
 
 
0.15 
 
 
0.03 
 
 
1.17 
 
 
1.09 
 
 
1.25 
0.44 0.04 1.55 1.43 1.69 
Aspirin 0.22 0.02 1.25 1.20 1.30 
Anticoagulation 0.21 0.04 1.23 1.14 1.33 
Angiotensin Blockade -0.16 0.02 0.85 0.82 0.89 
Diuretic use 0.08 0.02 1.09 1.05 1.13 
Other -0.12 0.04 0.89 0.82 0.96 
Iron Medication 0.11 0.03 1.12 1.05 1.20 
Vitamin D supplementation 0.16 0.03 1.17 1.11 1.25 
 
African-Caribbean ethnicity (HR 0.63, 0.47 to 0.86), Indian Sub-continental Ethnicity 
(HR 0.77, 0.61 to 0.96), angiotensin blockade (HR 0.85, 0.82 to 0.89) and use of other 
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antihypertensive (HR 0.89, 0.82 to 096) were associated with improved survival. 
Increasing GFR (for an increase in 100 mls/min/1.73m2, HR 0.24, 0.19 to 0.30), and 
cholesterol (for an increase in 10mmol/l, HR 0.76, 0.65 to 0.89) were associated with 
increased survival. Beta blockade, diastolic blood pressure, calcium channel blockers 
and lipid lowering drugs were all non-significant and were removed from the final 
models.  
5.2.6.3.Fractional polynomials in final model 
The relationship between log hazard ratios and age is shown in Figure 5-7. When age 
increased, the log relative hazard ratio increased at a squared rate. The log relative 
hazard decreased as systolic blood pressure started to increase but when blood 
pressure is above 166 mmHg the risk started to increase (Figure 5-7). As Hb increased 
the log relative hazard ratio decreased but at a Hb of 17.5 g/dl the log relative hazard 
ratio started to rise (Figure 5-7). When BMI increased between 15 to 27 kg/m2 the log 
relative hazard ratio fell sharply and then plateaued (Figure 5-7). 
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5.2.7.Step 7: Frailty Models 
Steps 4 to 6 were repeated with a frailty term (a random effects term) for practice 
location added to each model. These steps were named Step 4F – 6F. 
5.2.7.1.Step 4F. Analysis of co-variables where relationship between continuous co-variable 
and time to outcome is linear and a frailty term . 
When a frailty term (a random effects term) for practice was added to each imputation 
analysis diastolic blood pressure, NSAIDs, beta blockers and calcium channel blockers 
were removed from the final model. (Appendix B: Tables 11 to 15). Lipid lowering 
agents were significant only in the fifth Imputation and removed from combined 
model (Table 5-9). This is consistent with the findings observed in the model without 
the frailty term. 
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Table 5-9. Combined coefficients from composite outcome model where linear risk of numerical 
variables is assumed with practice location as frailty term 
 
Risk factor 
/Prescription 
Beta Standard 
Error 
Hazard Ratio 95% 
Confidence 
intervals 
Lower Limit 
95% 
Confidence 
intervals 
Upper Limit 
Age 0.05 0.00 1.05 1.05 1.05 
Male Gender 0.49 0.02 1.64 1.57 1.70 
Race with African 
Caribbean Race as 
reference 
African –Caribbean 
-0.38 0.16 0.68 0.50 0.93 
Indian Subcontinent -0.22 0.12 0.80 0.63 1.02 
South East Asian -0.51 0.58 0.60 0.19 1.87 
Townsend Quintile 
compared to 1st 
Quintile  
2
nd
  
0.08 0.03 1.09 1.03 1.14 
3
rd
 0.11 0.03 1.12 1.06 1.18 
4
th
 0.14 0.03 1.15 1.09 1.22 
5
th
  0.19 0.03 1.21 1.13 1.30 
Diabetes Mellitus 0.16 0.03 1.17 1.12 1.23 
Heart Failure 0.55 0.03 1.73 1.63 1.84 
Atrial Fibrillation 0.23 0.03 1.26 1.19 1.33 
Ever Smoked 0.24 0.03 1.27 1.20 1.33 
Systolic BP 0.00 0.00 0.997 0.996 0.998 
BMI -0.02 0.00 0.98 0.98 0.99 
Haemoglobin -0.11 0.01 0.89 0.88 0.90 
GFR -0.01 0.00 0.99 0.98 0.99 
Cholesterol -0.03 0.01 0.97 0.96 0.99 
High Albuminuria 0.16 0.03 1.18 1.10 1.26 
Very High albuminuria 0.46 0.04 1.59 1.46 1.73 
Aspirin 0.22 0.02 1.24 1.19 1.29 
Anticoagulation 0.18 0.04 1.19 1.10 1.29 
Angiotensin Blockade -0.17 0.02 0.84 0.81 0.88 
Diuretic use 0.07 0.02 1.07 1.03 1.12 
Other -0.12 0.04 0.89 0.82 0.96 
Iron Medication 0.15 0.03 1.16 1.08 1.24 
Vitamin D 
supplementation 
0.16 0.03 1.17 1.11 1.25 
The combined model with frailty was similar to the model in step 4 above with the 
exception of Indian Sub-continental ethnicity which was no longer significant. To recap 
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increasing age, male gender, increasing Townsend quintile, diabetes mellitus, heart 
failure, atrial fibrillation, patients who had previously smoked, increasing proteinuria, 
aspirin, anticoagulation, diuretic use, iron and vitamin D supplementation were 
associated with poorer survival. African-Caribbean ethnicity, increasing systolic blood 
pressure, body mass index, haemoglobin, GFR and cholesterol were associated with 
better survival. Angiotensin blockade and other anti-hypertensives were associated 
with better survival also. The AIC for each model for each imputed dataset was better 
the previous model without a frailty term for practice location (Table 5-10).  
Table 5-10. AIC for each model for Table 5-9 
Imp Dataset Akaike Information 
Criteria for models 
analysed in Step 4: No 
transformation of 
continuous co-variable 
without frailty 
Akaike Information 
Criteria for models 
analysed in Step 4f: No 
transformation of 
continuous co-variable 
with frailty 
1 252133.5 251900.1 
2 252125.2 251895.2 
3 252220.3 251993.8 
4 252204.9 251979.6 
5 252139.4 251924.6 
 
5.2.7.2.Results Step 5f. Models with transformation 
When a frailty term was added to the mfp algorithm to determine the best fitting 
fractional polynomial in Cox proportional hazards model for each imputed dataset, the 
with exception of Indian sub-continental ethnicity, the same co-variables were 
significant and same transformation of continuous co variables as in Table 5-5 were 
suggested (the results of the Cox proportional hazards model are presented in 
Appendix C Tables 16 to 20). The plots of the transformed co-variables were almost 
identical to those in Figure 36 to Figure 39 and are shown in Appendix C Figures 6 to 9. 
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The AIC for each imputation substantially improved in comparison with all previous 
models (Table 5-11). 
Table 5-11. AIC for each model with original suggested fractional polynomial with frailty term 
Imp Dataset Akaike Information Criteria for 
models analysed in Step 5: Where 
co variable is transformed as per 
Table 5-5 
Akaike Information Criteria for 
models analysed in Step 5f: 
Where co variable is transformed 
as per Table 5-5 with frailty 
1 251977 251745 
2 251989 251760 
3 252108 251884 
4 252071 251846 
5 252010 251797 
 
5.2.7.3.Results Step 6f. Finding the most consistent transformations of continuous co-
variables across the Imputations 
Like the non frailty models, the mfp transformations suggested for age, systolic blood 
pressure, Hb and BMI differed across each Imputation and therefore the commonest 
transformations were compared against the original suggested transformations.  
The commonest transformations to recap were (Table 5-5): 
1st alternative Model: Age2 + Systolic blood pressure + systolic blood pressure2 + 
haemoglobin3+haemoglobin/103*log haemoglobin + BMI-2 
2nd alternative Model: Age2 + Systolic blood pressure + systolic blood pressure2 + 
haemoglobin3+haemoglobin/103*log haemoglobin + BMI-0.5+BMI3 
For the frailty models again the 1st alternative Model had better fit compared to 2nd 
alternative Model. (Table 5-12) 
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Table 5-12. A comparison between the ordinal model with mfp and the 1
st
 and 2
nd
 best model with 
frailty term for composite outcome 
Imp 
Dataset 
Akaike Information 
Criteria for original 
Model 
Akaike Information 
for 1
st
 ‘alternative’ 
Model 
Akaike Information 
for 2
st
 ‘alternative 
Model 
1 251745 251751 251983 
2 251760 251769 252000 
3 251884 251884 252108 
4 251846 251845 252069 
5 251797 251798 252011 
 
Similar to the analysis of the non frailty models in step 6, there was a significant 
difference in the fit in the analysis of imputation 1 (Χ2= 6.0, 1df p <0.02) and analysis of 
imputation 2 (Χ2= 9.0, 1df p <0.01) between the 1st best alternative model. There was 
no significant difference between models for imputed datasets 3-5. (Table 5-12) As the 
1st alternative imputed model seemed the best fit across all imputed datasets using 
common transformations this was chosen as the final model and coefficients were 
combined for each imputation.  
5.2.7.4.Final model 
In the model with a frailty term for practice, Indian sub-continental ethnicity was no 
longer significantly protective (HR 0.80, 0.63 to 1.02), but as observed in the model 
produced in step 3 the remaining co-variables were still significant, the direction of the 
risk/protection did not change and the coefficients changed very slightly (Table 5-13). 
(The graphs for the data are not shown) 
  
Page 247 of 375 
 
Table 5-13. Combined model for composite outcome for each imputation using the 1
st
 best model 
incorporating a frailty term of practice location 
Risk factor/Prescription Beta Standard 
Error 
Hazard 
Ratio 
95% 
Confidence 
intervals 
Lower Limit 
95% 
Confidence 
intervals 
Upper Limit 
(Age/100)
2
 3.31 0.07 27.34 23.97 31.19 
Male Gender 0.50 0.02 1.65 1.58 1.71 
Race with Caucasian Race as 
reference 
African-Caribbean 
Indian-Subcontinent 
South East Asian 
 
 
-0.40 
-0.22 
-0.54 
 
 
0.16 
0.12 
0.58 
 
 
0.67 
0.80 
0.58 
 
 
0.49 
0.63 
0.19 
 
 
0.92 
1.02 
1.82 
Townsend Quintile compared to 
1st Quintile 
2 
3 
4 
5 
 
 
0.08 
0.11 
0.14 
0.18 
 
 
0.03 
0.03 
0.03 
0.03 
 
 
1.08 
1.12 
1.15 
1.20 
 
 
1.03 
1.06 
1.08 
1.12 
 
 
1.14 
1.18 
1.22 
1.29 
Diabetes Mellitus 0.16 0.02 1.18 1.12 1.24 
Heart Failure 0.53 0.03 1.70 1.60 1.80 
Atrial Fibrillation 0.23 0.03 1.25 1.18 1.32 
(Systolic BP/100)
1
 -2.19 0.34 0.11 0.06 0.22 
(Systolic BP/100)
2
 0.64 0.12 1.90 1.52 2.39 
(BMI/10)
-2
 1.71 0.15 5.53 4.13 7.40 
(Haemoglobin/10)
3
 -0.69 0.05 0.50 0.46 0.55 
(Haemoglobin/10)
3 
x log 
(Haemoglobin) 
0.77 0.07 2.17 1.90 2.48 
Glomerular Filtration Rate -1.34 0.11 0.26 0.21 0.33 
(Cholesterol/10) -0.29 0.08 0.75 0.64 0.88 
Albuminuria compared to 
normal 
High 
Very High 
 
 
0.16 
0.45 
 
 
0.03 
0.04 
 
 
1.18 
1.57 
 
 
1.10 
1.44 
 
 
1.26 
1.71 
Ever Smoked 0.24 0.03 1.27 1.20 1.33 
Aspirin 0.22 0.02 1.24 1.19 1.30 
Anticoagulation 0.19 0.04 1.20 1.11 1.30 
Diuretic use 0.07 0.02 1.08 1.04 1.12 
Other -0.12 0.04 0.89 0.82 0.96 
Angiotensin Blockade -0.16 0.02 0.85 0.82 0.89 
Iron Medication 0.12 0.03 1.12 1.05 1.20 
Vitamin D supplementation 0.15 0.03 1.16 1.10 1.23 
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5.2.9. Step 8. Is model fit improved after incorporating mfp transformation and 
frailty terms? 
The table below compares the model fit statistic AIC combined models from Step 4, 
Step 6 and Step 6f. A lower AIC implies a better model fit and a difference of 4 
between the value of AIC for each model means there is a significantly better model (p 
< 0.05) and if this difference was 11 then the significance increased to p < 0.001. 
Therefore incorporating fractional polynomials for age, systolic blood pressure, Hb and 
BMI led to a significantly better model. However incorporating the frailty term results 
an even better fitting model. (Table 5-14) 
Table 5-14. Comparison of the AIC for the original model without frailty/mfp and models with mfp 
and frailty. The value in brackets is the difference between the current column and the previous 
column 
Imp 
Dataset 
AIC for original 
Model i.e. no 
transformation or 
frailty term 
(Step 4) 
AIC for Model with 
mfp transformation 
(1st alternative 
Model) but no 
frailty term 
(Step 6) 
AIC for Model with 
mfp transformation 
(1st Best Model) 
with frailty term 
(Step 6f) 
1 252133.5 251983(-150.5) 251751(232) 
2 252125.2 252000(-125.2) 251769(-231) 
3 252220.3 252108(112.3) 251884(-224) 
4 252204.9 252069(-135.9) 251845(-224) 
5 252139.4 252011(-128.4) 251798(-213) 
 
5.2.10. Step 9: Testing the proportional hazards assumption 
The best fitting, most informative model is described in step 6f and the scaled 
Schoenfeld residuals against time are shown in Appendix D. All the graphs showed a 
non zero slope hence maintaining the proportional hazards assumption. 
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5.2.11.Step 10. Complete Case Analysis 
As specified in the methods a complete case analysis (CCA) was carried out for the 
dataset. This included 3243 patients who had a complete set of data for analysis. The 
Median age was lower in the complete case analysis, but the gender proportion and 
ethnic mix was similar (Table 5-15).  
Table 5-15. Demographics of the whole cohort and complete case cohort for composite outcome 
analysis 
Demographic feature Figure or proportion 
Whole Cohort 
(N=74 731) 
Figure or proportion 
Complete cohort 
(n=3243) 
Median Age in years at time of 
diagnosis (years) 
71.3 (23.-107) 69.8 (23-95) 
Gender – Female 50517 (67.6%) 1957 (67.4%) 
Not recorded/Caucasian Race 
African –Caribbean 
Indian Subcontinent 
South East Asian 
 
73317(98.1%) 
683 (0.9%) 
690(0.9%) 
41(0.1%) 
 
3136(96.7%) 
44 (1.4%) 
62(1.9%) 
1(0.03%) 
Townsend quintiles 
1 
2 
3 
4 
5 
 
18855(26.4%)* 
17477(24.4%) 
14762(20.6%) 
12569(17.6%) 
7857(11.0%) 
 
790(24.33) 
1529(22.76) 
2209(20.94) 
2824(18.94) 
423(13.03) 
Median eGFR in 
mmol/min/1.73m2 
54.3 (3-64) 55.0 (4-60) 
Diabetes Mellitus 15039(20.1%) 1904(58.7%) 
Atrial Fibrillation 6341(8.5%) 263(8.1%) 
Heart Failure 3705(5.0%) 144(4.4%) 
Ever Smoked 12999(17.4%) 729(22.5%) 
Aspirin 16875(22.6%) 1168(36.0%) 
Anticoagulation 3281 (4.4%) 149 (4.6%) 
Angiotensin Blockade 30716(41.1%) 1961(60.5%) 
Beta blockers 16522(22.1%) 757(23.3%) 
Calcium Channel Blockers 13143(17.6%) 717(22.1%) 
Diuretics 30826(41.3%) 1416(43.6%) 
Other Anti-hypertensives 4421(5.9%) 301(9.3%) 
Lipid lowering medication 21455(28.7%) 1804(55.7%) 
Iron Supplementation 3882(5.2%) 234(7.2%) 
Vitamin D 6153(8.2%) 214(6.6%) 
 
The median eGFR was slightly higher in the complete case cohort and more patients 
had diabetes and smoked but a similar proportion had heart failure and atrial 
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fibrillation (Table 5-15). In general patients were more likely to be on the prescription 
medication with the exception of Vitamin D supplementation and NSAID prescription 
(Table 5-15).  
Table 5-16. Variables with missing data and their mean, median value or proportion for the composite 
outcome analysis cohort  
Variable with Missing Data 
(Proportion of population 
with complete data) 
Figure or proportion 
  Whole Cohort 
(N=74 731)* 
Figure or proportion 
Complete cohort 
(n=3243) 
Median Cholesterol 
(mmol/l) 
(60.8%) 
5.3(1.7-13.9) 4.8(1.9-10.4) 
Median Body Mass Index 
(kg/m2) 
(38.2%) 
28.1(11.2-59.5) 28.8(14-59.3) 
Median Haemoglobin 
(g/dl) 
(64.2%) 
13.5(3.3-25.8) 13.5(4.7-20.8) 
Mean Systolic blood 
pressure (mmHg) 
(82.5%) 
142.5(20.5) 78.6(11.9) 
Mean Diastolic blood 
pressure (mmHg) 
(82.5%) 
79.7(11.3) 141.5(20.19) 
Proteinuria levels (13.6%) 
None 
High 
Very High 
 
1876(18.5%)* 
7586(74.8%) 
675(6.7%) 
 
680(20.9) 
2402(74.0) 
165(5.1) 
* Proportion within available data 
5.2.11.1.Cox proportional hazards model for complete case analysis 
The median follow-up was 914 days which was less than the previous analysis. As 
models with frailty and transformation of variables have previously shown better fit 
only this model is shown (Table 5-17). Like the previous analysis, male gender, heart 
failure, patients who had previously smoked, having very high albuminuria, diuretic 
use, anticoagulation and iron medication were all associated with worse survival.  
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Table 5-17. Cox model for composite outcome of complete case analysis with frailty term and 
fractional polynomials 
Risk factor/Prescription Beta Standard 
Error 
Hazard 
Ratio 
95% CI 
Lower  
95% CI  
Upper  
(Age/100)
-1
 -6.80 1.09 0.00 0.00 0.01 
(Age/100)
-1 
x 
log(Age/100) 
-3.55 0.63 0.03 0.01 0.10 
Male Gender 0.51 0.10 1.66 1.36 2.02 
Heart Failure 0.82 0.16 2.28 1.67 3.12 
Ever Smoked 0.23 0.11 1.26 1.01 1.58 
(BMI/10)
-1
 36.01 7.95 4.35E+15 7.40E+08 2.56E+22 
(BMI/10)
-0.5
 -41.66 9.75 0.00 0.00 0.00 
Glomerular Filtration 
Rate ml/min/1.73m
2
 
-0.01 0.01 0.99 0.97 1.00 
Proteinuria compared to 
normal 
High 
Very High 
-0.09 0.13 0.91 0.71 1.16 
0.72 0.20 2.05 1.38 3.05 
Diuretics 0.26 0.10 1.30 1.06 1.59 
Anticoagulation 0.45 0.17 1.57 1.11 2.20 
Iron Medication 0.44 0.15 1.56 1.15 2.10 
 
 
A higher eGFR and increasing BMI were protective. Initially as age increased so did the 
log relative hazard ratio but when the age reached 50 then the rate at which log 
relative hazard ratio increased fell and plateaued (Figure 5-8). As the BMI increased 
the log relative hazard ratio decreased sharply but then plateaued after the BMI 
reached over 35 (Figure 5-9).  
  
Page 252 of 375 
 
Figure 5-8. Age versus log relative hazard ratio in complete case analysis 
 
Figure 5-9. Body mass Index versus log relative hazard ratio in complete case analysis 
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5.3.Discussion 
5.3.1.Summary of Results 
The models have identified a number of potentially modifiable risk factors associated 
with CVD or all-cause mortality in CKD patients assessed routinely in primary care. 
There were 74 731 patients with CKD free from CVD at the time of diagnosis and the 
median follow up was 1034 days. Like the models in Chapter 4, there was a high 
proportion of missing data and 5 imputed datasets were created using chained 
equations. The model with transformed variables and frailty term for practice location 
had the best fit; i.e. the lowest AIC. In this model the relationship between age, systolic 
blood pressure, BMI and Hb were non-linear and are shown in Figure 5-7. As age 
increased the log relative hazard ratio increased at a squared rate. Blood pressure had 
an inverse J shaped relationship with log relative hazard ratio which was consistent 
with findings from Chapter 4. Particular to this model Hb had an inverse J shaped 
relationship with log relative hazard ratio. Initially, as BMI increased the log relative 
hazard ratio decreased but plateaued after a BMI of 30 kg/m2. 
The association of the rest of the risk factors with hazard for the composite outcome 
model are shown in the forest plot below (Figure 5-11). The predictors with the 
exception of cholesterol had similar risk profiles to the final model in Chapter 4. The 
complete case analysis consisted of 3243 patients who had a follow-up of 914 days. 
Very few variables had significance in this model, (Figure 5-10) but the direction or risk 
did not change for each of the co-variables. 
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In this chapter, time to the composite outcome of cardiovascular disease or death was 
modelled. The results for this model were consistent with the findings from Chapter 4 
(outcome all cause mortality). These were gender, diabetes, AF, heart failure, treatment 
with angiotensin blockade, diuretics, other anti-hypertensives, anticoagulation, anti-
platelet agents, Townsend quintiles, and vitamin D and iron supplementation. 
Additionally the relationship between systolic blood pressure and risk was the same 
between the two models. These factors and comparison to literature has been discussed 
and will not be revisited. Additionally NSAIDs, calcium channel blockers and diastolic 
blood pressure were also not significant and excluded from this analysis as well as the 
previous analysis and will not be discussed as they have been discussed before.(Chapter 
4: Discussion) 
Factors that are no longer significant in this analysis in comparison to the death model in 
chapter 4 were beta-blockers, lipid lowering agents, and Indian Sub-continental ethnicity. 
The relationships between haemoglobin, BMI and cholesterol and the risk of outcome 
were different in this analysis. There were less high risk individuals in this cohort and 
therefore there were less patients on beta blockade and lipid lowering agents. For 
example in the death model there were 42% of patients on lipid lowering agents versus 
29% in the composite outcome model and 29% versus 22% on a beta-blocker 
respectively. Exclusion of patients in which these agents could provide secondary 
prevention of cardiovascular deaths, could lead to them appearing insignificant in this 
composite outcome analysis. Additionally, as less people are on these agents then the 
analysis will have less power to detect a difference. In the SHARP study the absolute risk 
difference though highly significant was only 2%. 
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Indian sub continental ethnicity may also be insignificant in this analysis for two reasons. 
Firstly perhaps higher risk patients with this ethnicity were removed as patients were free 
from cardiovascular disease. Secondly there may have been a loss of power in the second 
study as the sample size is smaller. Why cholesterol and BMI lost their J shaped 
relationship with risk of the composite outcome versus death alone is likely due to a loss 
of power or a more select group of patients in this analysis. Note when the MFP algorithm 
was run for this analysis, in the analysis of two of the imputed datasets a ‘U’ shaped 
relationship was suggested for BMI.  
Like the complete case analysis for the death model there were fewer predictors in the 
complete case analysis of the composite outcome. The direction of the predictors did not 
change. 
5.3.2. Limitations and Strengths 
The limitations and strengths of this analysis have been discussed in the limitations and 
strengths of the death model in Chapter 4. The composite outcome is a smaller model 
with slightly fewer events and therefore may lack the power to detect the differences 
found in the death model.  
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5.4.Executive Summary 
• Multiple imputations had to be implemented in this model consistent with the 
models in the previous chapter 
• The optimal model was one that incorporated fractional polynomials and a 
frailty term. 
• This model was similar to the all cause mortality model with the exception that 
beta blockers and statins lost their protective association. The relationship of 
BMI and log relative hazard ratio was no longer U shaped. 
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CHAPTER 6. OVERALL DISCUSSION 
The analyses presented in this thesis shows several important findings relating to the 
prevalence of CKD in the general population, the diagnosis and management of CKD in 
primary care and the use of a very large primary care dataset to identify potential risk 
factors associated with mortality or CVD and mortality in CKD patients. In this chapter, I 
summarise the key findings and discuss their implications. 
6.1.Summary of Key Findings 
Chapter 2. Main objective: to determine the prevalence of CKD in the UK from a very 
large primary care database. 
Adapting the definition for stages 3-5 CKD from the NKDOQI and QOF guidelines, the 
prevalence of stages 3-5 CKD in the UK was 4.67% in 2009. The prevalence of stages 1-2 
CKD was 0.34% using urine dip (with trace and above on urine dip as to define high 
albuminuria) and 0.33% using urine ACR. The overall prevalence of stages 1-5 CKD as 
identified was 5.01% (using urine dip data). 
Chapter 3. Main objectives: 1) to determine if patients with stages 3-5 CKD were correctly 
diagnosed by primary care practitioners as required by the Quality Outcomes Framework 
and 2) to assess the impact of classification on indicators of quality of care. 
A substantial proportion of patients with stages 3-5 CKD had not been placed on the 
practice CKD register; only 72% of patients with stages 3-5 CKD were appropriately coded 
for CKD. Furthermore, 44% of those on the practice CKD register did not have CKD. This 
indicates substantial over-classification and misclassification. Patients who were excluded 
from the practice CKD register were more likely be older and to have more co-morbidity 
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in a multivariable analysis. The likelihood of achieving QOF CKD indicators decreased in 
the following order; appropriately coded CKD patients, miscoded CKD patients; uncoded 
CKD patients. Although there were similar trends in the achievement of diabetic QOF 
indicators, diabetic patients were more likely to achieve QOF indicators regardless of the 
presence of CKD. 
Chapter 4. Objective: to develop an optimal model to identify which routinely collected 
primary care data were associated with all cause mortality in stage 3 CKD patients. As 
there were a high proportion of missing data, which had the potential to exclude more 
than 15% of the cohort from the development of this model, 5 imputed datasets were 
generated using chained equations.  
The best fitting model incorporated fractional polynomials for age, eGFR, systolic blood 
pressure, serum cholesterol, haemoglobin, body mass index and a frailty term for 
practice. In this model, male gender, increasing Townsend quintile, heart failure, AF, all 
CVD, smokers/ex-smokers, very high proteinuria, anti-platelet agents, anticoagulation, 
diuretics, vitamin D treatment and iron supplementation were associated with decreased 
survival. Non Caucasian race, angiotensin blockade, beta blockade, other hypertensive 
medication and anti-lipid drugs were associated with increased survival. NSAIDS, diastolic 
blood pressure and calcium channel blockers and high proteinuria had no relationship 
with survival.  
Systolic blood pressure and body mass index had an inverse J shaped relationship with 
mortality where the risk of death decreases until a certain point (Systolic BP 166mmHg 
and BMI of 36 kg/m2) and then started to rise. There was a similar relationship with log 
hazard ratio and cholesterol.  
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Chapter 5. Objective: to ascertain the optimal model for predicting the composite 
outcome of all cause mortality or cardiovascular disease using routinely collected primary 
care data in patients with stages 3-5 CKD (patients free from cardiovascular disease at the 
time of CKD diagnosis). Like the mortality model, there was a substantial proportion of 
missing data and five datasets with imputed data were generated.  
The best model incorporated fractional polynomials for age, systolic blood pressure, 
haemoglobin and BMI. Consistent with the mortality model, there was an increased risk 
of the composite outcome with: male gender, increasing Townsend quintile, diabetes, 
heart failure, AF, previous/current smokers, increasing proteinuria (high or very high), 
anti-platelet agents, anticoagulation, diuretics, iron and vitamin D supplementation. The 
risk of the composite outcome was reduced with African–Caribbean ethnicity, angiotensin 
blockade and other anti-hypertensive usage. The relationship between blood pressure 
and the composite outcome was similar to the previous mortality model.  
Some differences were observed when compared to the mortality model: Indian sub-
continental race, beta blockers and lipid lowering agents were not significant in this 
model. This model also differs from the original model in that there was an inverse 
relationship between the cholesterol level and the risk of the composite outcome; 
interestingly, there was no inverse J shaped relationship with the outcome. The 
relationship between haemoglobin and the composite outcome was U shaped. The 
relationship between BMI and log relative hazard ratio was similar to the mortality model 
but when the BMI was greater than 36, the log relative hazard ratio for the composite 
outcome did not increase. NSAIDs, calcium channel blockers and diastolic blood pressure 
had no significant relationship with the composite outcome.  
Page 262 of 375 
 
6.2.Clinical implications of the results reported in this thesis 
6.2.1.Prevalence of CKD 
The prevalence of stages 3-5 CKD in this large study population was lower than other UK 
estimates.[49;63;67] As discussed in the Chapter 2, this was because of two reasons. 
Firstly the number of patients with two blood tests was considerably less than those with 
single blood test used to identify CKD in screening or database studies.(Chapter 2.1) 
Secondly, as shown in the sensitivity analysis, using a single blood result to ascertain 
prevalence resulted in a higher prevalence of CKD and this was comparable to other 
studies.(Chapter 2.1) There is inherent variation in GFR; transient decreases in eGFR can 
occur due to medication, acute kidney injury, protein loading, hydration state or intra-
assay variability in the creatinine measurement.[43] A further variation can be associated 
with different methods of measuring serum creatinine.[31] This is why all the 
international and national guidelines state that stages 3-5 CKD should be defined using 
two blood results.[1;43;44] In this study two blood results were used to stage CKD. 
Although the QICKD investigators did partially incorporate this definition when 
ascertaining stages 3-5 CKD prevalence, they also included patients where there was only 
a single blood test available.[49] Therefore this thesis is the only study to date that has 
ascertained the prevalence of CKD using two blood results to produce a reliable estimate 
of the burden of stages 3-5 CKD.  
The estimates in this study for utilising two eGFRs may be conservative: the CKD stage 
was based on the blood test with the lower eGFR from the two blood tests and it was 
assumed that the creatinine analysis method was non IDMS and therefore could result in 
a higher eGFR if the creatinine analysis method was IDMS aligned.[31] Conversely the 
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whole population was assumed to be Caucasian and this may lead to overestimation of 
CKD, though the effects are likely to be negligible. 
Despite these limitations he reduced prevalence of CKD found in this thesis could have a 
major impact on primary and secondary care. These reduced estimates could allow for 
more accurate planning of treatment and future financial planning of budgets for CKD 
care.[97] 
The prevalence of stages 1-2 CKD was very low in comparison to previous 
estimates.[1;33;43;44] This was because only a small minority of the population with an 
eGFR above 60ml/min/1.73m2 had two urine dips (8.34% by 2009) or two urine ACRs 
(2.16% by 2008). There is considerable variation in urine protein excretion and all the 
guidelines state that high or very high albuminuria should be confirmed on two separate 
occasions.[1;33;43;44] Many of the studies only used a single urine protein test and 
where studies report on a single test, larger proportions of patients had this 
measured.[62;71;295] The work from this thesis suggests that stages 1-2 CKD is under-
recognised in primary care, even though the presence of albuminuria/proteinuria is 
common in patients with cardiovascular comorbidities including diabetes and associated 
with increased mortality and morbidity.[93] One important implication from my work is 
to focus on the need to test for urinary protein in patients: firstly in those with stages 3-5 
CKD to stratify for risk and inform management (BP targets) and secondly screen people 
with an eGFR ≥ 60 ml/min for proteinuria where they are at risk i.e. those with diabetes, 
hypertension, cardiovascular disease and structural renal disease, as proteinuria is a 
marker for progression to stage 3 CKD and we can intervene to reduce this progression. 
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6.2.2.Recognition and management of patients with stages 3-5 CKD in primary care 
The implication of this part of my research is that a significant proportion of people are 
being identified as having CKD without confirmation. Just through day to day biological 
variability and the measurement uncertainty associated with the assay a patient may 
receive a CKD diagnosis. However, a single eGFR as low as 54 ml/min cannot indicate 
stage 3 CKD without a repeat test, as this level is within the variability of an eGFR of 60 
ml/min or more.[9] With the large numbers of patients with receiving a CKD diagnosis this 
has important consequences. For the individual patient this can mean an inappropriate 
disease label and on a population basis, the misuse of resources. 
The current guidelines for primary care practitioners lack clarity in defining CKD. The 
summary NICE guidelines do not mention that two blood results are required to define 
stages 3-5 CKD and are mentioned in a footnote in the full guidelines.[161] This study may 
allow more accurate prediction of the costs of CKD, as previous estimates were based on 
QOF Read coded CKD.[97] 
The Quality Outcomes Framework has incentivised stages 3-5 CKD recognition and 
management in primary care. However, my research shows that CKD recognition is poor 
as many patients are missed. Of note, patients who are less likely to be appropriately 
coded for CKD are younger patients or patients with less comorbidities and these patients 
may not be managed as well. Though it would seem intuitive that this subgroup would 
seem less likely to benefit from treatment, these patients have a far higher risk of death 
compared to the age-matched general population and therefore intervention may 
improve their outcomes as shown in the mortality models. 
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Patients with uncoded CKD were less likely to have attained CKD QOF indicators then 
those on the practice CKD register. Although this study, as a retrospective analysis, cannot 
confirm that under-recognition of CKD results in poorer management of uncoded 
patients, previous research in diabetes indicators suggests that this may be true.[141]   
Although the differences in actual blood pressure between uncoded and those with 
coded CKD were only slightly higher (a difference in 1-2 mmHg), this resulted in significant 
differences in QOF achievement. One could speculate that patients at or just above the 
threshold BP of 140/85 may be recorded as lower. Primary care practices have to review 
the way CKD is recorded on a regular basis and actually target the high risk patients 
(young and older people with comorbidity) for inclusion into the QOF CKD register. 
Practically as primary care is all computerised, it would not be difficult to identify 
miscoded and uncoded individuals, as they can search for patients with 2 eGFRs under 60 
ml/min/1.73m2 and examine those who have the correct coding.This thesis is the first 
research to examine QOF recognition and achievement in patients with CKD and suggests 
that primary care practitioners may not utilise QOF appropriately.  
Additionally there were no difference in cholesterol and only small differences in blood 
pressure between the uncoded and coded cohorts to suggest that primary care 
practitioners are managing hypertension and cholesterol to national guidelines. However, 
it is difficult to discern whether being labelled as a hypertensive or having hypertension 
may affect coding in the first place. For example patients with hypertension coding with 
CKD were more likely to be on the practice CKD register but have a lower blood pressure 
and therefore these subtle differences in blood pressure may reflect those preferentially 
managed.  
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6.2.3.Prognostic Models 
The all cause mortality prognostic model has been developed from the largest cohort of 
stage 3 CKD patients to date. The analysis of this cohort and prognostic/risk factors 
associated with mortality reasserts the association of beta-blockers, angiotensin blockers, 
other antihypertensives, lipid lowering agents and possibly non Caucasian race with 
reduced mortality. However, paradoxically, the results suggest that only very high blood 
pressure and cholesterol is associated with mortality. The results presented in this thesis 
also suggest that calcium channel blockers, any blood thinning agents and diuretics may 
be associated with increased harm. Although these effects can partly be explained by 
confounding by indication, the association or risk with much higher blood pressure are 
supported by other large epidemiological studies.[283;284] Therefore this thesis suggests 
that beta blockers, other anti-hypertensives (mainly Doxazosin) and angiotensin blockade 
may reduce mortality independently of blood pressure. This may support the strong 
pathophysiological evidence that mortality and CVD in CKD patients are not all due to 
atherosclerotic disease; as kidney function becomes more advanced arterial stiffness and 
cardiac fibrosis becomes increasingly important.[112;206] Beta blockers and angiotensin 
blockers can reduce arterial stiffness independently of blood pressure.[296;297] 
CKD patients are more likely to have gastrointestinal blood loss and this may explain why 
anti-platelet agents may cause more harm.[298] Additionally aspirin was found only to be 
efficacious in hypertensive patients and this cohort had relatively lower blood pressure 
than previously described.[112] Increased total cholesterol (7.6mmol/l) is associated with 
increased atherosclerosis but risk may be attenuated in patients with CKD.[105] It is also 
worth noting that this was an all-cause mortality model and therefore all deaths could not 
be attributed to atherosclerotic disease; CKD patients may suffer from increased 
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arrhythmogenic disease and sudden cardiac deaths, therefore reduction in cholesterol 
and blood pressure may not have the same effect.[112]  
The composite outcome model had similar findings to the above model. This model only 
included CKD patients free from CVD at the time of CKD diagnosis. As discussed before 
there is a smaller number of significant risk/prognostic factors identified in this analysis 
compared to the all cause mortality model. This may be due to reduced power as this 
model had a smaller population.[250] This model also depended on coding from primary 
care practitioners and although cardiovascular disease recording is regarded as accurate, 
as described previously, that CKD coding is less accurate all CVD events may not be 
captured.[138;299] Nevertheless, the model reinforces previously described associations 
including the U shaped relationship of blood pressure and risk of morbidity and mortality.  
Reassuringly primary care practitioners are using drugs such as angiotensin blockers, beta 
blockers and statins that appear to be associated with benefit in a high proportion of 
patients. (Though cause can not be inferred) 
The models developed show that traditional risk/prognostic factors for mortality and 
cardiovascular morbidity in the general population may not be associated with the same 
risk/benefits in patients with stage 3 CKD suggesting alternative approaches against non-
traditional risk factors as well as management with conventional therapies may be 
required to improve clinical outcomes. These include the reduction of arterial stiffness by 
agents such as Spironolactone, aggressive treatment of complications such as bone 
mineral disorders and acidosis and treatment of specific conditions such as adult 
polycystic kidney disease.[267;300-302] 
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6.3.Strengths and Limitations 
During this thesis, I had the privilege to analyse an extremely large database and 
interrogate for CKD prevalence and CKD outcomes. The large majority of the remit of CKD 
patient care is with primary care in the UK and the care received is important as it 
concerns a clinically significant proportion of the population. This thesis provides reliable 
estimates of CKD prevalence and is the only study that critically examines the care 
received in primary care especially regarding QOF. The results reported should help 
primary care practitioners to redirect resources to appropriately diagnose and manage 
CKD patients. The model development is novel; this is the largest UK dataset and one of 
the largest internationally to examine mortality and morbidity in stage 3 CKD patients 
using prospectively collected data. Missing data were managed through multiple 
imputation and data transformation. This avoided the analysis of a much smaller dataset 
and the potential loss of association between key risk and prognostic factors. Also if data 
had not been transformed then spurious relationships between blood pressure, BMI and 
cholesterol may have been shown. 
However the research reported in this thesis has limitations as it is a retrospective study 
(although it lacks recall bias as the data was prospectively collected). For example CKD 
prevalence was based on those with blood tests. Additioanlly there is likely confounding 
by indication.[279] Additionally as reverse causality can confound these results as the CKD 
disease state can modify the relationship of risk factors and outcomes such hypertension 
and cholesterol.[210] 
6.4.Future Research 
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In preparation of this thesis it was found that there was a lack of prospective, 
appropriately powered, randomised control studies regarding key interventions in 
patients with CKD. There was inconclusive evidence regarding the blood pressure target 
and even adjunctive blood pressure agents.[118;282;303] Other agents that reduce 
cardiovascular risk such as aspirin may not be as efficacious and may cause harm by 
excess bleeding.[110]. This may be why risk predictive instruments such as Framingham 
and QRISK are ineffective in delineating risk to specific CKD stages.[51;125] 
This thesis raises some thought provoking questions about how CKD is managed in 
primary care and the impact of demographic, clinical features and interventions in this 
group. There are numerous ideas and avenues for research and the following are a few 
limited examples.  
• A prospective screening study to ascertain the prevalence of stages 1-5 of CKD in the 
UK, using two blood samples and two urine samples over 3 months to ascertain the 
exact prevalence of CKD. This could involve a follow up study of the Health Survey of 
England. This could alternatively be ascertained by using the THIN additional 
information services. Firstly those with a blood test in the last year could have a 
follow up blood test and urine test to assess what stage of CKD they have. Additionally 
high risk groups such as diabetics, those with CVD, AF and HTN could be screened 
using two consecutive blood and urine tests. 
• Assessing strategies for enhancing the accuracy of disease registers for CKD and 
identify if further development of the CKD QOF has the potential to improve care for 
those surrogates that are associated with better long-term outcomes. Also to assess 
key interventions recommended by NICE should also be assessed. 
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• A randomised control study to determine which blood pressure target reduces 
morbidity and mortality in patients by CKD in primary care. As discussed in chapter 1 
and 3, patients with stage 3 CKD are more likely to be managed in primary care and 
therefore this would be the ideal forum to conduct this research. This could be 
achieved by standard randomised control studies or novel trial designs such as 
prospective randomized open, blinded end-point cluster randomised control studies.  
• Though this thesis concentrates primarily on stage 3 CKD, there is even less evidence 
in patients with stage 4 and 5 CKD and would need greater investigation in secondary 
and primary care. 
• A randomised control study of the use of agents such as antiplatelet agents and 
calcium channel blockers to determine if they are safe and efficacious in patients with 
CKD. These agents have been shown to have limited efficacy CKD in previous studies 
and association with worse outcomes in this thesis and therefore need further 
investigation. 
• A prospective cohort study in CKD patients incorporating routinely and non routinely 
collected primary care data such as bone mineral disorder management and 
inflammatory markers as examples to determine a complete set of predictors of 
mortality and morbidity. This could be a combined primary care and secondary care 
study as these complex non traditional risk factors are more likely to be managed in 
secondary care.  
• The impact of different methods for estimating eGFR such CKD-EPI and other novel 
markers such as NGAL or Cystatin CKD on risk delineation in patients with kidney 
damage. 
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• Translation of basic scientific research in patients with CKD into treatments to reduce 
mortality and cardiovascular risk specific to patients with CKD. Cardiovascular disease 
and mortality may be substituted by surrogate markers for these outcomes such as 
arterial stiffness. 
6.5. Clinical Implications and overall conclusions 
• Stage 3-5 CKD prevalence (4.76%) is much lower than previous estimates. These 
‘more robust’ evaluation of prevalence can allow clinicians to better predict the 
care these patients require. 
• Stage 1-2 CKD prevalence is much less than previous estimates. The proportion of 
this  high risk cohort need to be identified more accurately in the UK by primary 
care practitioners 
• Primary care clinicians need to improve classification of CKD patients in their 
primary care register as this may impact upon management. Potential solutions 
and populations that need to be targeted are identified in this thesis 
• Prognostic/Risk factor in patients with CKD such as blood pressure, cholesterol, 
blood thinning agents and  diuretics have a different relationship to morbidity and 
mortality to the general population and this needs further investigation 
• However the models in this thesis have limitations such as confounding by 
indication and reverse causation of CKD and risk factors. 
• Despite these limitations clinicians are treating a high proportion of CKD patients 
with treatments such as statins, angiotensin blockers and beta blockers which 
appear to have a protective effect. 
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Appendix A 
Figure 1. Histogram of original Cholesterol data pre imputation 
  
Figure 2. Histogram of original Body Mass index pre imputation 
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Figure 3. Histogram of original Systolic blood pressure data pre imputation  
 
Figure 4. Histogram of original Diastolic blood pressure data pre imputation  
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Figure 5. Histogram of original Haemoglobin data pre imputation  
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Table 1. Cox regression analysis for Imputation 1 without transformation and frailty term 
Risk factor/Prescription Beta Standard 
Error 
Hazard 
Ratio 
95% 
Confidence 
intervals: 
Lower Limit 
95% 
Confidence 
intervals: 
Lower Limit 
Age 6.154 0.110 470.761 379.572 583.857 
Male Gender 0.485 0.020 1.625 1.563 1.689 
Race with Caucasian race as reference African –
Caribbean 
-0.517 0.190 0.596 0.411 0.865 
Indian Subcontinent -0.769 0.151 0.464 0.344 0.624 
South East Asian -1.183 1.000 0.306 0.043 2.176 
Townsend Quintile compared to 1th Quintile 
2
nd
  
0.112 0.026 1.118 1.062 1.177 
3
rd
 0.157 0.027 1.170 1.110 1.233 
4
th
 0.179 0.027 1.196 1.133 1.262 
5
th
  0.158 0.031 1.172 1.103 1.245 
Diabetes Mellitus 0.160 0.023 1.173 1.121 1.228 
Heart Failure 0.488 0.024 1.630 1.554 1.709 
Atrial Fibrillation 0.072 0.025 1.074 1.023 1.128 
Coronary Heart Disease 0.063 0.021 1.065 1.021 1.110 
Cerebrovascular Accident 0.221 0.022 1.248 1.194 1.303 
Peripheral Vascular Disease 0.161 0.029 1.175 1.109 1.244 
Ever Smoked 0.145 0.023 1.157 1.106 1.210 
Systolic BP -0.655 0.045 0.519 0.476 0.567 
BMI -0.213 0.019 0.808 0.779 0.839 
Haemoglobin -1.673 0.055 0.188 0.168 0.209 
Glomerular Filtration Rate -2.131 0.101 0.119 0.097 0.145 
Cholesterol -0.676 0.084 0.509 0.431 0.600 
Proteinuria levels with none as reference High -0.050 0.033 0.951 0.891 1.015 
Very High 0.090 0.043 1.094 1.006 1.189 
Anti-platelets 0.080 0.021 1.083 1.040 1.129 
Anticoagulation 0.256 0.033 1.291 1.211 1.377 
Angiotensin Blockade -0.164 0.020 0.849 0.816 0.882 
Beta blockade -0.150 0.021 0.861 0.826 0.897 
Calcium Channel Blocker -0.048 0.022 0.953 0.913 0.995 
Diuretic use 0.208 0.019 1.231 1.185 1.279 
Other -0.140 0.038 0.870 0.808 0.937 
Lipid -0.312 0.023 0.732 0.700 0.765 
Iron Medication 0.129 0.029 1.137 1.075 1.204 
Vitamin D supplementation 0.218 0.026 1.243 1.180 1.309 
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Table 2. Cox regression analysis for Imputation 2 without transformation and frailty term 
Risk factor/Prescription Beta Standard 
Error 
Hazard 
Ratio 
95% 
Confidence 
intervals: 
Lower Limit 
95% 
Confidence 
intervals: 
Lower Limit 
Age 6.224 0.110 504.617 406.974 625.688 
Male Gender 0.475 0.020 1.608 1.547 1.672 
Race with Caucasian race as reference African –
Caribbean 
-0.494 0.190 0.610 0.421 0.885 
Indian Subcontinent -0.777 0.151 0.460 0.342 0.619 
South East Asian -1.174 1.000 0.309 0.044 2.195 
Townsend Quintile compared to 1th Quintile 
2
nd
  
0.123 0.026 1.131 1.074 1.191 
3
rd
 0.163 0.027 1.177 1.117 1.240 
4
th
 0.178 0.027 1.195 1.133 1.261 
5
th
  0.155 0.031 1.168 1.099 1.241 
Diabetes Mellitus 0.183 0.023 1.200 1.147 1.256 
Heart Failure 0.480 0.024 1.616 1.541 1.695 
Atrial Fibrillation 0.070 0.025 1.073 1.021 1.126 
Coronary Heart Disease 0.059 0.021 1.061 1.017 1.106 
Cerebrovascular Accident 0.217 0.022 1.242 1.189 1.297 
Peripheral Vascular Disease 0.155 0.029 1.167 1.102 1.236 
Ever Smoked 0.148 0.023 1.159 1.109 1.212 
Systolic BP -0.675 0.045 0.509 0.466 0.556 
BMI -0.194 0.019 0.823 0.793 0.855 
Haemoglobin -1.602 0.056 0.202 0.181 0.225 
Glomerular Filtration Rate -2.078 0.102 0.125 0.103 0.153 
Cholesterol -0.788 0.084 0.455 0.386 0.537 
Proteinuria levels with none as reference High 0.070 0.035 1.072 1.001 1.149 
Very High 0.320 0.044 1.378 1.265 1.501 
Anti-platelets 0.070 0.021 1.073 1.030 1.118 
Anticoagulation 0.251 0.033 1.286 1.205 1.371 
Angiotensin Blockade -0.172 0.020 0.842 0.810 0.875 
Beta blockade -0.151 0.021 0.860 0.825 0.896 
Calcium Channel Blocker -0.046 0.022 0.955 0.914 0.997 
Diuretic use 0.205 0.019 1.227 1.181 1.275 
Other -0.142 0.038 0.868 0.806 0.935 
Lipid -0.312 0.023 0.732 0.700 0.765 
Iron Medication 0.135 0.029 1.144 1.082 1.211 
Vitamin D supplementation 0.225 0.026 1.252 1.189 1.318 
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Table 3. Cox regression analysis for Imputation 3 without transformation and frailty term 
Risk factor/Prescription Beta Standard 
Error 
Hazard 
Ratio 
95% 
Confidence 
intervals: 
Lower Limit 
95% 
Confidence 
intervals: 
Lower Limit 
Age 6.248 0.110 517.200 416.918 641.604 
Male Gender 0.491 0.020 1.634 1.572 1.698 
Race with Caucasian race as reference African –
Caribbean 
-0.508 0.190 0.601 0.415 0.872 
Indian Subcontinent -0.763 0.151 0.466 0.347 0.628 
South East Asian -1.174 1.000 0.309 0.044 2.196 
Townsend Quintile compared to 1th Quintile 
2
nd
  
0.116 0.026 1.123 1.067 1.182 
3
rd
 0.157 0.027 1.171 1.111 1.234 
4
th
 0.176 0.027 1.192 1.129 1.258 
5
th
  0.166 0.031 1.180 1.111 1.254 
Diabetes Mellitus 0.168 0.023 1.183 1.130 1.239 
Heart Failure 0.483 0.024 1.622 1.546 1.701 
Atrial Fibrillation 0.070 0.025 1.073 1.022 1.127 
Coronary Heart Disease 0.058 0.021 1.060 1.017 1.105 
Cerebrovascular Accident 0.226 0.022 1.254 1.201 1.310 
Peripheral Vascular Disease 0.161 0.029 1.175 1.109 1.244 
Ever Smoked 0.151 0.023 1.163 1.112 1.216 
Systolic BP -0.685 0.045 0.504 0.462 0.550 
BMI -0.157 0.019 0.854 0.823 0.886 
Haemoglobin -1.692 0.055 0.184 0.165 0.205 
Glomerular Filtration Rate -2.141 0.101 0.117 0.096 0.143 
Cholesterol -0.669 0.084 0.512 0.435 0.604 
Proteinuria levels with none as reference High 0.029 0.036 1.030 0.960 1.104 
Very High 0.130 0.045 1.138 1.042 1.244 
Anti-platelets 0.078 0.021 1.081 1.037 1.126 
Anticoagulation 0.261 0.033 1.298 1.216 1.384 
Angiotensin Blockade -0.173 0.020 0.841 0.810 0.875 
Beta blockade -0.152 0.021 0.859 0.824 0.895 
Calcium Channel Blocker -0.038 0.022 0.962 0.922 1.005 
Diuretic use 0.199 0.019 1.220 1.175 1.268 
Other -0.137 0.038 0.872 0.810 0.939 
Lipid -0.310 0.023 0.733 0.702 0.767 
Iron Medication 0.129 0.029 1.138 1.075 1.204 
Vitamin D supplementation 0.224 0.027 1.251 1.188 1.318 
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Table 4, Cox regression analysis for Imputation 4 without transformation and frailty term 
Risk factor/Prescription Beta Standard 
Error 
Hazard 
Ratio 
95% 
Confidence 
intervals: 
Lower Limit 
95% 
Confidence 
intervals: 
Lower Limit 
Age 6.242 0.110 513.685 414.271 636.956 
Male Gender 0.478 0.020 1.613 1.552 1.677 
Race with Caucasian race as reference African –
Caribbean 
-0.486 0.190 0.615 0.424 0.892 
Indian Subcontinent -0.752 0.151 0.471 0.350 0.634 
South East Asian -1.225 1.000 0.294 0.041 2.086 
Townsend Quintile compared to 1th Quintile 
2
nd
  
0.124 0.026 1.132 1.075 1.192 
3
rd
 0.151 0.027 1.163 1.104 1.226 
4
th
 0.171 0.027 1.186 1.124 1.252 
5
th
  0.158 0.031 1.171 1.103 1.244 
Diabetes Mellitus 0.178 0.023 1.195 1.142 1.251 
Heart Failure 0.487 0.024 1.627 1.552 1.706 
Atrial Fibrillation 0.069 0.025 1.071 1.020 1.125 
Coronary Heart Disease 0.064 0.021 1.066 1.022 1.111 
Cerebrovascular Accident 0.219 0.022 1.245 1.192 1.301 
Peripheral Vascular Disease 0.155 0.029 1.167 1.102 1.237 
Ever Smoked 0.146 0.023 1.157 1.106 1.210 
Systolic BP -0.684 0.045 0.505 0.462 0.551 
BMI -0.186 0.019 0.830 0.800 0.862 
Haemoglobin -1.597 0.056 0.203 0.182 0.226 
Glomerular Filtration Rate -2.165 0.101 0.115 0.094 0.140 
Cholesterol -0.687 0.084 0.503 0.426 0.594 
Proteinuria levels with none as reference High 0.033 0.035 1.034 0.964 1.108 
Very High 0.249 0.044 1.283 1.176 1.398 
Anti-platelets 0.078 0.021 1.081 1.038 1.127 
Anticoagulation 0.255 0.033 1.291 1.210 1.377 
Angiotensin Blockade -0.168 0.020 0.846 0.814 0.879 
Beta blockade -0.156 0.021 0.856 0.821 0.892 
Calcium Channel Blocker -0.045 0.022 0.956 0.916 0.998 
Diuretic use 0.200 0.019 1.221 1.176 1.269 
Other -0.134 0.038 0.874 0.812 0.942 
Lipid -0.314 0.023 0.730 0.699 0.763 
Iron Medication 0.137 0.029 1.147 1.084 1.214 
Vitamin D supplementation 0.223 0.026 1.250 1.187 1.316 
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Table 5. Cox regression analysis for Imputation 5 without transformation and frailty term 
Risk factor/Prescription Beta Standard 
Error 
Hazard 
Ratio 
95% 
Confidence 
intervals: 
Lower Limit 
95% 
Confidence 
intervals: 
Lower Limit 
Age 6.292 0.110 540.497 435.740 670.439 
Male Gender 0.481 0.020 1.618 1.557 1.682 
Race with Caucasian race as reference African –
Caribbean 
-0.487 0.190 0.614 0.424 0.891 
Indian Subcontinent -0.753 0.151 0.471 0.350 0.634 
South East Asian -1.210 1.000 0.298 0.042 2.118 
Townsend Quintile compared to 1th Quintile 
2
nd
  
0.116 0.026 1.123 1.067 1.183 
3
rd
 0.153 0.027 1.165 1.106 1.228 
4
th
 0.173 0.027 1.188 1.126 1.254 
5
th
  0.159 0.031 1.172 1.103 1.245 
Diabetes Mellitus 0.159 0.023 1.173 1.120 1.228 
Heart Failure 0.481 0.024 1.617 1.542 1.696 
Atrial Fibrillation 0.065 0.025 1.068 1.017 1.121 
Coronary Heart Disease 0.065 0.021 1.067 1.023 1.112 
Cerebrovascular Accident 0.222 0.022 1.248 1.195 1.304 
Peripheral Vascular Disease 0.164 0.029 1.178 1.112 1.248 
Ever Smoked 0.143 0.023 1.154 1.103 1.207 
Systolic BP -0.680 0.045 0.507 0.464 0.553 
BMI -0.149 0.019 0.861 0.830 0.894 
Haemoglobin -1.586 0.056 0.205 0.184 0.228 
Glomerular Filtration Rate -2.096 0.102 0.123 0.101 0.150 
Cholesterol -0.725 0.085 0.484 0.410 0.572 
Proteinuria levels with none as reference High -0.018 0.035 0.982 0.917 1.052 
Very High 0.217 0.043 1.243 1.143 1.352 
Anti-platelets 0.073 0.021 1.076 1.032 1.121 
Anticoagulation 0.254 0.033 1.290 1.209 1.376 
Angiotensin Blockade -0.169 0.020 0.845 0.813 0.878 
Beta blockade -0.146 0.021 0.864 0.830 0.901 
Calcium Channel Blocker -0.044 0.022 0.957 0.916 0.999 
Diuretic use 0.199 0.019 1.220 1.174 1.267 
Other -0.140 0.038 0.869 0.807 0.936 
Lipid -0.319 0.023 0.727 0.695 0.760 
Iron Medication 0.142 0.029 1.152 1.089 1.219 
Vitamin D supplementation 0.218 0.027 1.243 1.180 1.310 
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Table 6. Cox proportional hazards model with fractional polynomials suggested by mfp algorithm for Imputed Dataset 1 
Risk factor/Prescription Beta Standard 
Error 
Hazard 
Ratio 
95% 
Confidence 
intervals: 
Lower Limit 
95% 
Confidence 
intervals: 
Lower Limit 
Age/100 7.751 0.758 2323.895 526.526 10256.839 
Age/100 x log(Age/100) 0.617 0.537 1.853 0.647 5.308 
Male Gender 0.504 0.020 1.655 1.592 1.721 
Race with Caucasian race as reference African –
Caribbean 
-0.570 0.190 0.566 0.390 0.821 
Indian Subcontinent -0.779 0.152 0.459 0.341 0.617 
South East Asian -1.239 1.000 0.290 0.041 2.056 
Townsend Quintile compared to 1th Quintile 
2
nd
  
0.112 0.026 1.118 1.062 1.177 
3
rd
 0.152 0.027 1.164 1.105 1.227 
4
th
 0.174 0.027 1.190 1.128 1.256 
5
th
  0.152 0.031 1.164 1.096 1.237 
Diabetes Mellitus 0.159 0.023 1.172 1.119 1.227 
Heart Failure 0.472 0.024 1.603 1.529 1.681 
Atrial Fibrillation 0.071 0.025 1.074 1.023 1.128 
Coronary Heart Disease 0.064 0.021 1.066 1.023 1.111 
Cerebrovascular Accident 0.212 0.022 1.236 1.183 1.291 
Peripheral Vascular Disease 0.160 0.029 1.173 1.107 1.242 
Ever Smoked 0.150 0.023 1.162 1.111 1.216 
Systolic BP/100 -3.384 0.311 0.034 0.018 0.062 
(Systolic BP/100)2 0.970 0.108 2.638 2.135 3.260 
BMI/10 -0.648 0.050 0.523 0.474 0.577 
(BMI/10)3 0.018 0.002 1.018 1.014 1.021 
(Haemoglobin/10)-1 x log(Heaemoglobin/10) 5.030 0.363 152.933 75.092 311.464 
(Haemoglobin/10)-1  6.749 0.356 853.205 424.306 1715.644 
(Glomerular Filtration Rate/100)2 -2.303 0.117 0.100 0.079 0.126 
(Cholesterol/10)2 -2.534 0.353 0.079 0.040 0.159 
(Cholesterol/10)3 2.218 0.376 9.189 4.394 19.216 
Proteinuria levels with none as reference High -0.046 0.033 0.955 0.895 1.020 
Very High 0.088 0.042 1.092 1.004 1.186 
Anti-platelets 0.075 0.021 1.078 1.035 1.124 
Anticoagulation 0.261 0.033 1.298 1.217 1.385 
Angiotensin Blockade -0.161 0.020 0.851 0.819 0.885 
Beta blockade -0.146 0.021 0.864 0.829 0.901 
Diuretic use 0.205 0.019 1.227 1.181 1.275 
Other -0.148 0.038 0.863 0.801 0.929 
Lipid -0.292 0.023 0.747 0.714 0.781 
Iron Medication 0.115 0.029 1.122 1.060 1.188 
Vitamin D supplementation 0.209 0.027 1.232 1.169 1.298 
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Table 7. Cox proportional hazards model with fractional polynomials suggested by mfp algorithm for Imputed Dataset 2 
Risk factor/Prescription Beta Standard 
Error 
Hazard 
Ratio 
95% 
Confidence 
intervals: 
Lower Limit 
95% 
Confidence 
intervals: 
Lower Limit 
Age/100 7.518 0.759 1840.514 415.871 8145.528 
Age/100 x log(Age/100) 0.893 0.538 2.443 0.851 7.018 
Male Gender 0.491 0.020 1.633 1.571 1.698 
Race with Caucasian race as reference African –
Caribbean 
-0.541 0.190 0.582 0.401 0.845 
Indian Subcontinent -0.788 0.151 0.455 0.338 0.612 
South East Asian -1.256 1.000 0.285 0.040 2.023 
Townsend Quintile compared to 1th Quintile 
2
nd
  
0.123 0.026 1.131 1.074 1.191 
3
rd
 0.159 0.027 1.173 1.113 1.236 
4
th
 0.175 0.027 1.191 1.129 1.257 
5
th
  0.147 0.031 1.158 1.090 1.231 
Diabetes Mellitus 0.178 0.023 1.195 1.141 1.251 
Heart Failure 0.458 0.024 1.580 1.507 1.657 
Atrial Fibrillation 0.068 0.025 1.071 1.020 1.124 
Coronary Heart Disease 0.059 0.021 1.061 1.018 1.106 
Cerebrovascular Accident 0.207 0.022 1.230 1.178 1.285 
Peripheral Vascular Disease 0.156 0.029 1.168 1.103 1.238 
Ever Smoked 0.152 0.023 1.165 1.114 1.218 
Systolic BP/100 -3.438 0.312 0.032 0.017 0.059 
(Systolic BP/100)2 0.982 0.108 2.671 2.161 3.301 
BMI/10 -1.146 0.100 0.318 0.261 0.386 
(BMI/10)2 0.170 0.017 1.185 1.146 1.226 
(Haemoglobin/10)-1 x log(Heaemoglobin/10) 4.757 0.363 116.365 57.176 236.827 
(Haemoglobin/10)-1  6.387 0.355 593.941 296.027 1191.668 
(Glomerular Filtration Rate/100) -1.946 0.102 0.143 0.117 0.174 
(Cholesterol/10)2 -3.336 0.327 0.036 0.019 0.068 
(Cholesterol/10)3 3.008 0.341 20.252 10.383 39.499 
Proteinuria levels with none as reference High 0.072 0.035 1.075 1.003 1.152 
Very High 0.310 0.044 1.364 1.252 1.485 
Anti-platelets 0.062 0.021 1.064 1.021 1.109 
Anticoagulation 0.264 0.033 1.302 1.220 1.389 
Angiotensin Blockade -0.169 0.020 0.845 0.812 0.878 
Beta blockade -0.146 0.021 0.864 0.829 0.900 
Diuretic use 0.202 0.019 1.224 1.178 1.271 
Other -0.148 0.038 0.862 0.801 0.928 
Lipid -0.298 0.023 0.743 0.710 0.777 
Iron Medication 0.123 0.029 1.131 1.069 1.197 
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Vitamin D supplementation 0.216 0.026 1.241 1.178 1.307 
 
 
Table 8. Cox proportional hazards model with fractional polynomials suggested by mfp algorithm for Imputed Dataset 3 
Risk factor/Prescription Beta Standard 
Error 
Hazard 
Ratio 
95% 
Confidence 
intervals: 
Lower Limit 
95% 
Confidence 
intervals: 
Lower Limit 
Age/100 7.830 0.756 2514.225 571.494 11061.059 
Age/100 x log(Age/100) 0.665 0.536 1.945 0.681 5.558 
Male Gender 0.509 0.020 1.664 1.600 1.730 
Race with Caucasian race as reference African –
Caribbean 
-0.561 0.190 0.571 0.393 0.828 
Indian Subcontinent -0.775 0.151 0.461 0.342 0.620 
South East Asian -1.229 1.000 0.293 0.041 2.078 
Townsend Quintile compared to 1th Quintile 
2
nd
  
0.112 0.026 1.119 1.063 1.178 
3
rd
 0.151 0.027 1.163 1.104 1.226 
4
th
 0.168 0.027 1.183 1.121 1.248 
5
th
  0.154 0.031 1.167 1.098 1.240 
Diabetes Mellitus 0.168 0.024 1.183 1.129 1.239 
Heart Failure 0.464 0.024 1.590 1.516 1.668 
Atrial Fibrillation 0.070 0.025 1.072 1.021 1.126 
Coronary Heart Disease 0.059 0.021 1.061 1.018 1.106 
Cerebrovascular Accident 0.217 0.022 1.242 1.189 1.297 
Peripheral Vascular Disease 0.160 0.029 1.174 1.108 1.243 
Ever Smoked 0.157 0.023 1.170 1.118 1.223 
Systolic BP/100 -3.618 0.308 0.027 0.015 0.049 
(Systolic BP/100)2 1.041 0.107 2.833 2.297 3.494 
(BMI/10)2 x log (BMI/10) 0.175 0.017 1.191 1.153 1.230 
(BMI/10)2 -0.300 0.027 0.741 0.703 0.781 
(Haemoglobin/10)-1 x log(Heaemoglobin/10) 5.017 0.362 151.032 74.285 307.068 
(Haemoglobin/10)-1  6.751 0.355 854.529 425.890 1714.571 
(Glomerular Filtration Rate/100)2 -2.290 0.117 0.101 0.081 0.127 
(Cholesterol/10)2 -2.563 0.345 0.077 0.039 0.151 
(Cholesterol/10)3 2.236 0.364 9.358 4.587 19.091 
Proteinuria levels with none as reference High 0.030 0.036 1.031 0.961 1.105 
Very High 0.130 0.045 1.139 1.042 1.244 
Anti-platelets 0.073 0.021 1.075 1.032 1.120 
Anticoagulation 0.268 0.033 1.307 1.225 1.395 
Angiotensin Blockade -0.171 0.020 0.843 0.810 0.876 
Beta blockade -0.148 0.021 0.863 0.828 0.899 
Diuretic use 0.196 0.019 1.216 1.171 1.264 
Other -0.140 0.038 0.869 0.807 0.936 
Lipid -0.291 0.023 0.747 0.715 0.782 
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Iron Medication 0.114 0.029 1.121 1.059 1.186 
Vitamin D supplementation 0.218 0.027 1.244 1.180 1.310 
 
Table 9. Cox proportional hazards model with fractional polynomials suggested by mfp algorithm for Imputed Dataset 4 
Risk factor/Prescription Beta Standard 
Error 
Hazard 
Ratio 
95% 
Confidence 
intervals: 
Lower Limit 
95% 
Confidence 
intervals: 
Lower Limit 
Age/100 7.684 0.756 2174.100 494.017 9567.902 
Age/100 x log(Age/100) 0.771 0.536 2.162 0.756 6.186 
Male Gender 0.493 0.020 1.637 1.574 1.702 
Race with Caucasian race as reference African –
Caribbean 
-0.537 0.190 0.585 0.403 0.848 
Indian Subcontinent -0.762 0.151 0.467 0.347 0.628 
South East Asian -1.253 1.000 0.286 0.040 2.030 
Townsend Quintile compared to 1th Quintile 
2
nd
  
0.121 0.026 1.129 1.072 1.189 
3
rd
 0.148 0.027 1.159 1.100 1.222 
4
th
 0.167 0.027 1.181 1.119 1.247 
5
th
  0.150 0.031 1.162 1.094 1.234 
Diabetes Mellitus 0.178 0.023 1.195 1.142 1.251 
Heart Failure 0.468 0.024 1.596 1.522 1.674 
Atrial Fibrillation 0.068 0.025 1.071 1.020 1.125 
Coronary Heart Disease 0.065 0.021 1.067 1.023 1.112 
Cerebrovascular Accident 0.210 0.022 1.233 1.181 1.288 
Peripheral Vascular Disease 0.152 0.029 1.164 1.099 1.233 
Ever Smoked 0.151 0.023 1.163 1.112 1.216 
Systolic BP/100 -3.418 0.314 0.033 0.018 0.061 
(Systolic BP/100)2 0.971 0.109 2.641 2.134 3.269 
(BMI/10)2 x log (BMI/10) 0.182 0.017 1.200 1.161 1.239 
(BMI/10)2 -0.316 0.027 0.729 0.692 0.768 
(Haemoglobin/10)-1  6.042 0.354 420.582 209.993 842.358 
(Haemoglobin/10)-2 -2.118 0.176 0.120 0.085 0.170 
(Glomerular Filtration Rate/100)2 -2.331 0.117 0.097 0.077 0.122 
(Cholesterol/10)2 -2.495 0.346 0.083 0.042 0.162 
(Cholesterol/10)3 2.154 0.365 8.616 4.215 17.613 
Proteinuria levels with none as reference High 0.034 0.035 1.034 0.965 1.109 
Very High 0.243 0.044 1.275 1.170 1.390 
Anti-platelets 0.074 0.021 1.077 1.033 1.122 
Anticoagulation 0.264 0.033 1.302 1.221 1.389 
Angiotensin Blockade -0.165 0.020 0.848 0.816 0.882 
Beta blockade -0.152 0.021 0.859 0.824 0.895 
Diuretic use 0.197 0.019 1.218 1.172 1.265 
Other -0.138 0.038 0.871 0.809 0.938 
Lipid -0.294 0.023 0.745 0.713 0.780 
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Iron Medication 0.113 0.029 1.120 1.058 1.185 
Vitamin D supplementation 0.217 0.027 1.243 1.180 1.309 
Table 10. Cox proportional hazards model with fractional polynomials suggested by mfp algorithm for Imputed Dataset 5 
Risk factor/Prescription Beta Standard 
Error 
Hazard 
Ratio 
95% 
Confidence 
intervals: 
Lower Limit 
95% 
Confidence 
intervals: 
Lower Limit 
Age/100 7.852 0.755 2571.771 585.354 11299.155 
Age/100 x log(Age/100) 0.691 0.536 1.997 0.699 5.703 
Male Gender 0.497 0.020 1.644 1.581 1.709 
Race with Caucasian race as reference African –
Caribbean 
-0.539 0.190 0.583 0.402 0.846 
Indian Subcontinent -0.768 0.151 0.464 0.345 0.625 
South East Asian -1.263 1.000 0.283 0.040 2.008 
Townsend Quintile compared to 1th Quintile 
2
nd
  
0.115 0.026 1.122 1.066 1.182 
3
rd
 0.148 0.027 1.160 1.101 1.222 
4
th
 0.167 0.027 1.181 1.119 1.246 
5
th
  0.153 0.031 1.166 1.097 1.238 
Diabetes Mellitus 0.154 0.024 1.166 1.114 1.221 
Heart Failure 0.458 0.024 1.581 1.508 1.659 
Atrial Fibrillation 0.065 0.025 1.067 1.016 1.120 
Coronary Heart Disease 0.064 0.021 1.066 1.023 1.111 
Cerebrovascular Accident 0.213 0.022 1.237 1.185 1.292 
Peripheral Vascular Disease 0.162 0.029 1.176 1.110 1.245 
Ever Smoked 0.150 0.023 1.162 1.111 1.215 
Systolic BP/100 -3.387 0.314 0.034 0.018 0.063 
(Systolic BP/100)2 0.961 0.109 2.615 2.113 3.235 
(BMI/10)2 x log (BMI/10) 0.179 0.016 1.196 1.158 1.235 
(BMI/10)2 -0.306 0.027 0.737 0.699 0.776 
(Haemoglobin/10)-1  4.620 0.352 101.490 50.888 202.409 
(Haemoglobin/10)-2 6.253 0.348 519.538 262.917 1026.633 
(Glomerular Filtration Rate/100)2 -2.245 0.117 0.106 0.084 0.133 
(Cholesterol/10)2 2.855 0.334 17.377 9.038 33.409 
(Cholesterol/10)2*log(Cholesterol/10) -0.437 0.072 0.646 0.561 0.743 
Proteinuria levels with none as reference High -0.017 0.035 0.983 0.918 1.053 
Very High 0.218 0.043 1.243 1.143 1.352 
Anti-platelets 0.068 0.021 1.071 1.028 1.116 
Anticoagulation 0.262 0.033 1.299 1.218 1.386 
Angiotensin Blockade -0.166 0.020 0.847 0.815 0.881 
Beta blockade -0.142 0.021 0.868 0.832 0.904 
Diuretic use 0.194 0.019 1.214 1.169 1.261 
Other -0.144 0.038 0.866 0.804 0.932 
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Lipid -0.306 0.023 0.737 0.704 0.771 
Iron Medication 0.126 0.029 1.135 1.072 1.201 
Vitamin D supplementation 0.211 0.027 1.235 1.172 1.301 
Table 11.Cox regression analysis for Imputation 1 without transformation but with frailty term 
Risk factor/Prescription Beta Standard 
Error 
Hazard Ratio 95% 
Confidence 
intervals: 
Lower Limit 
95% 
Confidence 
intervals: 
Lower Limit 
Age 6.162 0.111 474.518 382.039 589.383 
Male Gender 0.485 0.020 1.624 1.562 1.688 
Race with Caucasian race as reference 
African –Caribbean 
-0.516 0.191 0.597 0.411 0.868 
Indian Subcontinent -0.756 0.153 0.470 0.348 0.634 
South East Asian -1.197 1.000 0.302 0.043 2.147 
Townsend Quintile compared to 1th 
Quintile 2
nd
  
0.107 0.027 1.113 1.056 1.173 
3
rd
 0.152 0.027 1.164 1.103 1.228 
4
th
 0.174 0.028 1.190 1.126 1.257 
5
th
  0.154 0.032 1.166 1.095 1.242 
Diabetes Mellitus 0.157 0.024 1.170 1.118 1.226 
Heart Failure 0.489 0.024 1.630 1.554 1.710 
Atrial Fibrillation 0.067 0.025 1.069 1.018 1.123 
Coronary Heart Disease 0.063 0.022 1.065 1.021 1.111 
Cerebrovascular Accident 0.218 0.022 1.243 1.190 1.299 
Peripheral Vascular Disease 0.156 0.030 1.169 1.103 1.239 
Ever Smoked 0.144 0.024 1.154 1.101 1.210 
Systolic BP -0.655 0.045 0.519 0.476 0.567 
BMI -0.213 0.019 0.808 0.778 0.838 
Haemoglobin -1.671 0.056 0.188 0.169 0.210 
Glomerular Filtration Rate -2.152 0.102 0.116 0.095 0.142 
Cholesterol -0.674 0.085 0.510 0.432 0.602 
Proteinuria levels with none as reference 
High 
-0.048 0.034 0.953 0.892 1.018 
Very High 0.103 0.043 1.109 1.020 1.206 
Anti-platelets 0.079 0.021 1.082 1.038 1.128 
Anticoagulation 0.258 0.033 1.295 1.213 1.381 
Angiotensin Blockade -0.164 0.020 0.849 0.817 0.883 
Beta blockade -0.149 0.021 0.861 0.826 0.898 
Calcium Channel Blocker -0.050 0.022 0.952 0.911 0.994 
Diuretic use 0.206 0.020 1.229 1.182 1.276 
Other -0.139 0.038 0.870 0.808 0.937 
Lipid -0.309 0.023 0.734 0.702 0.768 
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Iron Medication 0.128 0.029 1.137 1.074 1.203 
Vitamin D supplementation 0.219 0.027 1.244 1.181 1.311 
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Table 12. Cox regression analysis for Imputation 2 without transformation but with frailty term 
Risk factor/Prescription Beta Standard 
Error 
Hazard 
Ratio 
95% 
Confidence 
intervals: 
Lower Limit 
95% 
Confidence 
intervals: 
Lower Limit 
Age 6.236 0.111 510.811 411.340 634.337 
Male Gender 0.475 0.020 1.608 1.546 1.671 
Race with Caucasian race as reference African –
Caribbean 
-0.498 0.191 0.608 0.418 0.884 
Indian Subcontinent -0.764 0.153 0.466 0.345 0.629 
South East Asian -1.186 1.000 0.306 0.043 2.171 
Townsend Quintile compared to 1th Quintile 2
nd
  0.119 0.027 1.126 1.069 1.187 
3
rd
 0.158 0.027 1.171 1.110 1.235 
4
th
 0.174 0.028 1.189 1.126 1.257 
5
th
  0.152 0.032 1.165 1.094 1.240 
Diabetes Mellitus 0.180 0.023 1.197 1.143 1.253 
Heart Failure 0.480 0.024 1.616 1.541 1.696 
Atrial Fibrillation 0.065 0.025 1.067 1.016 1.121 
Coronary Heart Disease 0.060 0.022 1.061 1.018 1.107 
Cerebrovascular Accident 0.214 0.022 1.238 1.185 1.293 
Peripheral Vascular Disease 0.149 0.030 1.161 1.096 1.230 
Ever Smoked 0.146 0.024 1.157 1.104 1.213 
Systolic BP -0.677 0.045 0.508 0.465 0.555 
BMI -0.194 0.019 0.824 0.793 0.855 
Haemoglobin -1.603 0.056 0.201 0.181 0.225 
Glomerular Filtration Rate -2.100 0.102 0.123 0.100 0.150 
Cholesterol -0.785 0.085 0.456 0.387 0.539 
Proteinuria levels with none as reference High 0.072 0.035 1.074 1.002 1.152 
Very High 0.337 0.044 1.400 1.285 1.526 
Anti-platelets 0.070 0.021 1.073 1.029 1.118 
Anticoagulation 0.255 0.033 1.290 1.209 1.376 
Angiotensin Blockade -0.171 0.020 0.843 0.811 0.877 
Beta blockade -0.150 0.021 0.861 0.826 0.897 
Calcium Channel Blocker -0.049 0.022 0.952 0.912 0.994 
Diuretic use 0.202 0.020 1.224 1.178 1.272 
Other -0.141 0.038 0.869 0.806 0.936 
Lipid -0.308 0.023 0.735 0.703 0.768 
Iron Medication 0.133 0.029 1.142 1.079 1.208 
Vitamin D supplementation 0.226 0.027 1.254 1.190 1.321 
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Table 13. Cox regression analysis for Imputation 3 without transformation but with frailty term 
Risk factor/Prescription Beta Standard 
Error 
Hazard 
Ratio 
95% 
Confidence 
intervals: 
Lower Limit 
95% 
Confidence 
intervals: 
Lower Limit 
Age 6.257 0.111 521.495 419.779 647.858 
Male Gender 0.490 0.020 1.633 1.570 1.697 
Race with Caucasian race as reference African –
Caribbean 
-0.508 0.191 0.602 0.414 0.875 
Indian Subcontinent -0.750 0.153 0.473 0.350 0.638 
South East Asian -1.188 1.001 0.305 0.043 2.166 
Townsend Quintile compared to 1th Quintile 
2
nd
  
0.113 0.027 1.119 1.062 1.179 
3
rd
 0.152 0.027 1.164 1.104 1.228 
4
th
 0.169 0.028 1.184 1.121 1.251 
5
th
  0.163 0.032 1.177 1.105 1.253 
Diabetes Mellitus 0.165 0.024 1.179 1.126 1.235 
Heart Failure 0.484 0.024 1.622 1.546 1.701 
Atrial Fibrillation 0.066 0.025 1.068 1.017 1.122 
Coronary Heart Disease 0.058 0.022 1.060 1.016 1.106 
Cerebrovascular Accident 0.224 0.022 1.251 1.197 1.306 
Peripheral Vascular Disease 0.156 0.030 1.169 1.103 1.239 
Ever Smoked 0.149 0.024 1.160 1.107 1.216 
Systolic BP -0.687 0.045 0.503 0.461 0.549 
BMI -0.158 0.019 0.854 0.823 0.886 
Haemoglobin -1.689 0.056 0.185 0.166 0.206 
Glomerular Filtration Rate -2.165 0.102 0.115 0.094 0.140 
Cholesterol -0.668 0.084 0.513 0.435 0.605 
Proteinuria levels with none as reference High 0.028 0.036 1.029 0.959 1.103 
Very High 0.138 0.045 1.148 1.050 1.255 
Anti-platelets 0.077 0.021 1.080 1.036 1.126 
Anticoagulation 0.263 0.033 1.301 1.219 1.388 
Angiotensin Blockade -0.172 0.020 0.842 0.810 0.875 
Beta blockade -0.151 0.021 0.860 0.825 0.896 
Calcium Channel Blocker -0.040 0.022 0.961 0.920 1.003 
Diuretic use 0.196 0.020 1.217 1.171 1.264 
Other -0.136 0.038 0.873 0.810 0.940 
Lipid -0.307 0.023 0.736 0.703 0.769 
Iron Medication 0.129 0.029 1.138 1.075 1.204 
Vitamin D supplementation 0.225 0.027 1.253 1.189 1.320 
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Table 14. Cox regression analysis for Imputation 4 without transformation but with frailty term 
Risk factor/Prescription Beta Standard 
Error 
Hazard 
Ratio 
95% 
Confidence 
intervals: 
Lower Limit 
95% 
Confidence 
intervals: 
Lower Limit 
Age 6.248 0.111 516.823 416.181 641.802 
Male Gender 0.478 0.020 1.612 1.551 1.676 
Race with Caucasian race as reference African –
Caribbean 
-0.488 0.191 0.614 0.422 0.893 
Indian Subcontinent -0.739 0.153 0.478 0.354 0.645 
South East Asian -1.246 1.001 0.288 0.040 2.044 
Townsend Quintile compared to 1th Quintile 2
nd
  0.121 0.027 1.128 1.071 1.189 
3
rd
 0.145 0.027 1.156 1.096 1.220 
4
th
 0.164 0.028 1.178 1.115 1.245 
5
th
  0.154 0.032 1.166 1.096 1.242 
Diabetes Mellitus 0.176 0.024 1.192 1.138 1.248 
Heart Failure 0.487 0.024 1.628 1.552 1.707 
Atrial Fibrillation 0.064 0.025 1.066 1.015 1.120 
Coronary Heart Disease 0.064 0.022 1.066 1.022 1.112 
Cerebrovascular Accident 0.216 0.022 1.241 1.188 1.297 
Peripheral Vascular Disease 0.150 0.030 1.161 1.096 1.231 
Ever Smoked 0.143 0.024 1.154 1.101 1.209 
Systolic BP -0.686 0.045 0.504 0.461 0.550 
BMI -0.187 0.019 0.830 0.800 0.861 
Haemoglobin -1.597 0.056 0.202 0.181 0.226 
Glomerular Filtration Rate -2.188 0.101 0.112 0.092 0.137 
Cholesterol -0.682 0.085 0.506 0.428 0.597 
Proteinuria levels with none as reference High 0.035 0.036 1.035 0.966 1.110 
Very High 0.259 0.044 1.296 1.188 1.413 
Anti-platelets 0.079 0.021 1.082 1.038 1.127 
Anticoagulation 0.258 0.033 1.295 1.214 1.382 
Angiotensin Blockade -0.167 0.020 0.846 0.814 0.879 
Beta blockade -0.155 0.021 0.856 0.821 0.892 
Calcium Channel Blocker -0.047 0.022 0.954 0.914 0.997 
Diuretic use 0.198 0.020 1.219 1.173 1.266 
Other -0.133 0.038 0.876 0.813 0.943 
Lipid -0.311 0.023 0.733 0.701 0.766 
Iron Medication 0.136 0.029 1.145 1.082 1.212 
Vitamin D supplementation 0.224 0.027 1.250 1.187 1.318 
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Table 15. Cox regression analysis for Imputation 5 without transformation but with frailty term 
Risk factor/Prescription Beta Standard 
Error 
Hazard 
Ratio 
95% 
Confidence 
intervals: 
Lower Limit 
95% 
Confidence 
intervals: 
Lower Limit 
Age 6.301 0.111 545.008 438.791 676.936 
Male Gender 0.480 0.020 1.617 1.555 1.681 
Race with Caucasian race as reference African –
Caribbean 
-0.486 0.191 0.615 0.423 0.894 
Indian Subcontinent -0.741 0.153 0.476 0.353 0.643 
South East Asian -1.221 1.001 0.295 0.042 2.097 
Townsend Quintile compared to 1th Quintile 
2
nd
  
0.112 0.027 1.119 1.062 1.179 
3
rd
 0.147 0.027 1.158 1.098 1.222 
4
th
 0.166 0.028 1.180 1.117 1.247 
5
th
  0.154 0.032 1.167 1.096 1.242 
Diabetes Mellitus 0.157 0.024 1.170 1.117 1.225 
Heart Failure 0.481 0.024 1.617 1.542 1.696 
Atrial Fibrillation 0.060 0.025 1.062 1.011 1.116 
Coronary Heart Disease 0.065 0.022 1.067 1.023 1.113 
Cerebrovascular Accident 0.219 0.022 1.244 1.191 1.300 
Peripheral Vascular Disease 0.159 0.030 1.172 1.106 1.242 
Ever Smoked 0.142 0.024 1.152 1.099 1.208 
Systolic BP -0.679 0.045 0.507 0.464 0.554 
BMI -0.149 0.019 0.861 0.830 0.894 
Haemoglobin -1.582 0.056 0.206 0.184 0.229 
Glomerular Filtration Rate -2.120 0.102 0.120 0.098 0.147 
Cholesterol -0.728 0.085 0.483 0.409 0.570 
Proteinuria levels with none as reference High -0.015 0.035 0.985 0.919 1.055 
Very High 0.228 0.043 1.257 1.155 1.367 
Anti-platelets 0.072 0.021 1.075 1.031 1.120 
Anticoagulation 0.257 0.033 1.293 1.212 1.380 
Angiotensin Blockade -0.168 0.020 0.845 0.813 0.879 
Beta blockade -0.145 0.021 0.865 0.830 0.902 
Calcium Channel Blocker -0.046 0.022 0.955 0.914 0.997 
Diuretic use 0.196 0.020 1.217 1.171 1.264 
Other -0.140 0.038 0.870 0.807 0.937 
Lipid -0.316 0.023 0.729 0.697 0.762 
Iron Medication 0.141 0.029 1.151 1.088 1.219 
Vitamin D supplementation 0.219 0.027 1.245 1.181 1.311 
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Table 16. Cox proportional hazards model with fractional polynomials suggested by mfp algorithm for Imputed Dataset 1 
with frailty term 
Risk factor/Prescription Beta Standard 
Error 
Hazard 
Ratio 
95% CI 
Lower Limit 
95% CI 
Lower Limit 
Age/100 7.755 0.759 2334.143 526.851 10341.113 
Age/100 x log(Age/100) 0.625 0.538 1.867 0.651 5.359 
Male Gender 0.503 0.020 1.654 1.591 1.720 
Race with Caucasian race as reference African –
Caribbean 
-0.567 0.191 0.567 0.390 0.825 
Indian Subcontinent -0.765 0.153 0.466 0.345 0.628 
South East Asian -1.248 1.000 0.287 0.040 2.039 
Townsend Quintile compared to 1th Quintile 
2
nd
  
0.107 0.027 1.113 1.056 1.172 
3
rd
 0.147 0.027 1.158 1.098 1.221 
4
th
 0.169 0.028 1.184 1.120 1.251 
5
th
  0.147 0.032 1.159 1.088 1.234 
Diabetes Mellitus 0.157 0.024 1.169 1.117 1.225 
Heart Failure 0.472 0.024 1.604 1.529 1.682 
Atrial Fibrillation 0.066 0.025 1.069 1.017 1.122 
Coronary Heart Disease 0.064 0.021 1.066 1.023 1.112 
Cerebrovascular Accident 0.209 0.022 1.232 1.180 1.287 
Peripheral Vascular Disease 0.155 0.030 1.167 1.102 1.237 
Ever Smoked 0.149 0.024 1.161 1.107 1.217 
Systolic BP/100 -3.318 0.313 0.036 0.020 0.067 
(Systolic BP/100)2 0.947 0.108 2.577 2.084 3.187 
BMI/10 -0.649 0.050 0.522 0.473 0.577 
(BMI/10)3 0.018 0.002 1.018 1.014 1.022 
(Haemoglobin/10)-1 x log(Heaemoglobin/10) 5.006 0.363 149.247 73.236 304.147 
(Haemoglobin/10)-1  6.725 0.357 832.889 413.870 1676.138 
(Glomerular Filtration Rate/100)2 -2.329 0.118 0.097 0.077 0.123 
(Cholesterol/10)2 -2.520 0.354 0.080 0.040 0.161 
(Cholesterol/10)3 2.203 0.377 9.049 4.320 18.958 
Proteinuria levels with none as reference High -0.043 0.034 0.958 0.897 1.023 
Very High 0.101 0.043 1.106 1.017 1.203 
Anti-platelets 0.075 0.021 1.077 1.034 1.123 
Anticoagulation 0.264 0.033 1.302 1.220 1.389 
Angiotensin Blockade -0.161 0.020 0.852 0.819 0.886 
Beta blockade -0.146 0.021 0.865 0.829 0.901 
Diuretic use 0.203 0.020 1.224 1.178 1.272 
Other -0.147 0.038 0.863 0.801 0.930 
Lipid -0.289 0.023 0.749 0.716 0.784 
Iron Medication 0.114 0.029 1.121 1.059 1.187 
Vitamin D supplementation 0.209 0.027 1.233 1.170 1.299 
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Table 17. Cox proportional hazards model with fractional polynomials suggested by mfp algorithm for Imputed Dataset 2 
with frailty term 
Risk factor/Prescription Beta Standard 
Error 
Hazard 
Ratio 
95% 
Confidence 
intervals: 
Lower Limit 
95% 
Confidence 
intervals: 
Lower Limit 
Age/100 7.517 0.761 1839.226 413.784 8175.164 
Age/100 x log(Age/100) 0.910 0.540 2.484 0.863 7.151 
Male Gender 0.490 0.020 1.633 1.570 1.698 
Race with Caucasian race as reference African –
Caribbean 
-0.544 0.191 0.580 0.399 0.844 
Indian Subcontinent -0.774 0.153 0.461 0.342 0.623 
South East Asian -1.263 1.000 0.283 0.040 2.010 
Townsend Quintile compared to 1th Quintile 2
nd
  0.118 0.027 1.126 1.068 1.186 
3
rd
 0.154 0.027 1.167 1.106 1.231 
4
th
 0.170 0.028 1.185 1.121 1.252 
5
th
  0.144 0.032 1.155 1.084 1.230 
Diabetes Mellitus 0.175 0.024 1.191 1.138 1.248 
Heart Failure 0.459 0.024 1.582 1.508 1.660 
Atrial Fibrillation 0.063 0.025 1.065 1.014 1.119 
Coronary Heart Disease 0.060 0.022 1.061 1.018 1.107 
Cerebrovascular Accident 0.205 0.022 1.227 1.175 1.282 
Peripheral Vascular Disease 0.151 0.030 1.163 1.097 1.232 
Ever Smoked 0.151 0.024 1.163 1.110 1.219 
Systolic BP/100 -3.368 0.313 0.034 0.019 0.064 
(Systolic BP/100)2 0.957 0.109 2.603 2.104 3.220 
BMI/10 -1.154 0.100 0.315 0.259 0.384 
(BMI/10)2 0.171 0.017 1.187 1.147 1.227 
(Haemoglobin/10)-1 x log(Heaemoglobin/10) 4.756 0.363 116.222 57.044 236.791 
(Haemoglobin/10)-1  6.389 0.356 594.963 296.171 1195.194 
(Glomerular Filtration Rate/100) -1.965 0.103 0.140 0.115 0.171 
(Cholesterol/10)2 -3.326 0.328 0.036 0.019 0.068 
(Cholesterol/10)3 3.000 0.341 20.075 10.282 39.199 
Proteinuria levels with none as reference High 0.074 0.035 1.077 1.004 1.154 
Very High 0.325 0.044 1.384 1.271 1.509 
Anti-platelets 0.063 0.021 1.064 1.021 1.109 
Anticoagulation 0.267 0.033 1.306 1.224 1.394 
Angiotensin Blockade -0.168 0.020 0.846 0.813 0.879 
Beta blockade -0.146 0.021 0.865 0.829 0.901 
Diuretic use 0.199 0.020 1.221 1.175 1.268 
Other -0.148 0.038 0.863 0.801 0.929 
Lipid -0.295 0.023 0.745 0.712 0.779 
Iron Medication 0.121 0.029 1.129 1.066 1.195 
Vitamin D supplementation 0.218 0.027 1.243 1.180 1.310 
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Table 18. Cox proportional hazards model with fractional polynomials suggested by mfp algorithm for Imputed Dataset 3 
with frailty term 
Risk factor/Prescription Beta Standard 
Error 
Hazard 
Ratio 
95% 
Confidence 
intervals: 
Lower Limit 
95% 
Confidence 
intervals: 
Lower Limit 
Age/100 7.831 0.758 2517.446 569.820 11121.995 
Age/100 x log(Age/100) 0.676 0.537 1.966 0.686 5.630 
Male Gender 0.509 0.020 1.663 1.599 1.729 
Race with Caucasian race as reference African –
Caribbean 
-0.561 0.191 0.571 0.393 0.830 
Indian Subcontinent -0.760 0.153 0.468 0.346 0.631 
South East Asian -1.239 1.001 0.290 0.041 2.059 
Townsend Quintile compared to 1th Quintile 2
nd
  0.109 0.027 1.115 1.058 1.175 
3
rd
 0.146 0.027 1.157 1.097 1.220 
4
th
 0.161 0.028 1.175 1.112 1.241 
5
th
  0.152 0.032 1.164 1.093 1.239 
Diabetes Mellitus 0.164 0.024 1.179 1.125 1.235 
Heart Failure 0.465 0.024 1.591 1.517 1.669 
Atrial Fibrillation 0.065 0.025 1.067 1.016 1.121 
Coronary Heart Disease 0.059 0.022 1.061 1.017 1.107 
Cerebrovascular Accident 0.214 0.022 1.239 1.186 1.294 
Peripheral Vascular Disease 0.156 0.030 1.168 1.103 1.238 
Ever Smoked 0.155 0.024 1.167 1.114 1.223 
Systolic BP/100 -3.568 0.310 0.028 0.015 0.052 
(Systolic BP/100)2 1.023 0.108 2.780 2.252 3.432 
(BMI/10)2 x log (BMI/10) 0.176 0.017 1.192 1.154 1.232 
(BMI/10)2 -0.301 0.027 0.740 0.702 0.780 
(Haemoglobin/10)-1 x log(Heaemoglobin/10) 5.002 0.363 148.725 73.026 302.894 
(Haemoglobin/10)-1  6.733 0.356 839.914 417.861 1688.257 
(Glomerular Filtration Rate/100)2 -2.320 0.118 0.098 0.078 0.124 
(Cholesterol/10)2 -2.534 0.346 0.079 0.040 0.156 
(Cholesterol/10)3 2.203 0.365 9.054 4.426 18.523 
Proteinuria levels with none as reference High 0.029 0.036 1.030 0.960 1.104 
Very High 0.137 0.045 1.147 1.050 1.254 
Anti-platelets 0.072 0.021 1.075 1.032 1.120 
Anticoagulation 0.271 0.033 1.312 1.229 1.400 
Angiotensin Blockade -0.171 0.020 0.843 0.811 0.877 
Beta blockade -0.147 0.021 0.863 0.828 0.900 
Diuretic use 0.193 0.020 1.213 1.167 1.260 
Other -0.139 0.038 0.870 0.808 0.937 
Lipid -0.288 0.023 0.749 0.716 0.784 
Iron Medication 0.113 0.029 1.120 1.058 1.186 
Vitamin D supplementation 0.219 0.027 1.245 1.181 1.312 
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Table 19. Cox proportional hazards model with fractional polynomials suggested by mfp algorithm for Imputed Dataset 4 
with frailty term 
Risk factor/Prescription Beta Standard 
Error 
Hazard 
Ratio 
95% 
Confidence 
intervals: 
Lower Limit 
95% 
Confidence 
intervals: 
Lower Limit 
Age/100 7.681 0.758 2166.569 490.207 9575.586 
Age/100 x log(Age/100) 0.783 0.538 2.188 0.763 6.275 
Male Gender 0.493 0.020 1.637 1.574 1.702 
Race with Caucasian race as reference African –
Caribbean 
-0.537 0.191 0.584 0.402 0.850 
Indian Subcontinent -0.748 0.153 0.473 0.351 0.639 
South East Asian -1.269 1.001 0.281 0.040 1.998 
Townsend Quintile compared to 1th Quintile 
2
nd
  
0.117 0.027 1.124 1.067 1.185 
3
rd
 0.141 0.027 1.152 1.092 1.215 
4
th
 0.159 0.028 1.173 1.110 1.239 
5
th
  0.145 0.032 1.156 1.086 1.231 
Diabetes Mellitus 0.176 0.024 1.192 1.139 1.249 
Heart Failure 0.468 0.024 1.597 1.523 1.676 
Atrial Fibrillation 0.064 0.025 1.066 1.015 1.119 
Coronary Heart Disease 0.065 0.022 1.067 1.023 1.113 
Cerebrovascular Accident 0.207 0.022 1.230 1.178 1.285 
Peripheral Vascular Disease 0.147 0.030 1.158 1.093 1.227 
Ever Smoked 0.148 0.024 1.160 1.106 1.215 
Systolic BP/100 -3.354 0.315 0.035 0.019 0.065 
(Systolic BP/100)2 0.948 0.109 2.581 2.083 3.197 
(BMI/10)2 x log (BMI/10) 0.183 0.017 1.201 1.162 1.241 
(BMI/10)2 -0.318 0.027 0.728 0.690 0.767 
(Haemoglobin/10)-1  6.023 0.355 412.733 206.021 826.847 
(Haemoglobin/10)-2 -2.106 0.176 0.122 0.086 0.172 
(Glomerular Filtration Rate/100)2 -2.359 0.117 0.095 0.075 0.119 
(Cholesterol/10)2 -2.460 0.347 0.085 0.043 0.168 
(Cholesterol/10)3 2.120 0.366 8.327 4.064 17.062 
Proteinuria levels with none as reference High 0.036 0.036 1.036 0.966 1.111 
Very High 0.253 0.044 1.288 1.181 1.404 
Anti-platelets 0.074 0.021 1.077 1.033 1.123 
Anticoagulation 0.268 0.033 1.307 1.224 1.395 
Angiotensin Blockade -0.164 0.020 0.848 0.816 0.882 
Beta blockade -0.151 0.021 0.860 0.825 0.896 
Diuretic use 0.195 0.020 1.215 1.169 1.262 
Other -0.137 0.038 0.872 0.810 0.939 
Lipid -0.291 0.023 0.748 0.715 0.783 
Iron Medication 0.111 0.029 1.118 1.056 1.183 
Vitamin D supplementation 0.218 0.027 1.243 1.180 1.310 
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Table 20. Cox proportional hazards model with fractional polynomials suggested by mfp algorithm for Imputed Dataset 5 
with frailty term 
Risk factor/Prescription Beta Standard 
Error 
Hazard 
Ratio 
95% 
Confidence 
intervals: 
Lower Limit 
95% 
Confidence 
intervals: 
Lower Limit 
Age/100 7.865 0.757 2605.552 590.688 11493.213 
Age/100 x log(Age/100) 0.696 0.537 2.005 0.700 5.739 
Male Gender 0.496 0.020 1.643 1.580 1.708 
Race with Caucasian race as reference African –
Caribbean 
-0.538 0.191 0.584 0.402 0.849 
Indian Subcontinent -0.755 0.153 0.470 0.348 0.635 
South East Asian -1.271 1.001 0.281 0.039 1.994 
Townsend Quintile compared to 1th Quintile 2
nd
  0.111 0.027 1.118 1.061 1.178 
3
rd
 0.142 0.027 1.153 1.093 1.216 
4
th
 0.159 0.028 1.173 1.110 1.239 
5
th
  0.148 0.032 1.160 1.090 1.235 
Diabetes Mellitus 0.152 0.024 1.164 1.111 1.219 
Heart Failure 0.459 0.024 1.582 1.508 1.660 
Atrial Fibrillation 0.059 0.025 1.061 1.010 1.115 
Coronary Heart Disease 0.064 0.022 1.067 1.023 1.112 
Cerebrovascular Accident 0.210 0.022 1.234 1.181 1.289 
Peripheral Vascular Disease 0.157 0.030 1.170 1.104 1.240 
Ever Smoked 0.149 0.024 1.161 1.107 1.217 
Systolic BP/100 -3.316 0.315 0.036 0.020 0.067 
(Systolic BP/100)2 0.936 0.109 2.550 2.059 3.158 
(BMI/10)2 x log (BMI/10) 0.180 0.016 1.197 1.159 1.236 
(BMI/10)2 -0.307 0.027 0.736 0.698 0.775 
(Haemoglobin/10)-1  4.617 0.353 101.180 50.654 202.104 
(Haemoglobin/10)-2 6.246 0.348 515.997 260.716 1021.235 
(Glomerular Filtration Rate/100)2 -2.273 0.118 0.103 0.082 0.130 
(Cholesterol/10)2 -0.442 0.072 0.643 0.558 0.740 
(Cholesterol/10)2*log(Cholesterol/10) 2.839 0.334 17.102 8.882 32.931 
Proteinuria levels with none as reference High -0.014 0.035 0.986 0.921 1.057 
Very High 0.229 0.043 1.257 1.155 1.367 
Anti-platelets 0.068 0.021 1.070 1.027 1.115 
Anticoagulation 0.265 0.033 1.303 1.221 1.390 
Angiotensin Blockade -0.165 0.020 0.848 0.815 0.881 
Beta blockade -0.141 0.021 0.868 0.833 0.905 
Diuretic use 0.192 0.020 1.211 1.166 1.258 
Other -0.144 0.038 0.866 0.804 0.933 
Lipid -0.303 0.023 0.739 0.706 0.773 
Iron Medication 0.125 0.029 1.133 1.071 1.200 
Vitamin D supplementation 0.212 0.027 1.236 1.173 1.303 
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Figure 6. Age versus log relative hazards ratio for imputations 1-5  with frailty term 
 
Figure 7. Systolic Blood pressure versus log relative hazards ratio for imputations 1-5  with frailty term 
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Figure 8. Haemoglobin versus log relative hazards ratio for imputations 1-5  with frailty term 
 
Figure 9. Body Mass Index versus log relative hazards ratio for imputations 1-5  with frailty term 
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Figure 10. Cholesterol versus log relative hazards ratio for imputations 1-5  with frailty term 
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Appendix B. Schoenfeld residuals for Mortality Model 
Figure 1. Scaled Schoenfeld Residuals for Antiplatelet versus Time 
 
Figure 2. Scaled Schoenfeld Residuals for Atrial Fibrillation versus Time 
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Figure 3. Scaled Schoenfeld Residuals for AFC race versus Time 
 
Figure 4. Scaled Schoenfeld Residuals for Age  versus Time
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Figure 5. Scaled Schoenfeld Residuals Age for versus Time 
 
Figure 6. Scaled Schoenfeld Residuals for betablockade versus Time 
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Figure 7. Scaled Schoenfeld Residuals BMI for versus Time
 
Figure 8.  Scaled Schoenfeld Residuals for BMI versus Time 
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Figure 9.  Scaled Schoenfeld Residuals CHD for versus Time 
Figure 10.  Scaled Schoenfeld Residuals cholesterol for versus Time 
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Figure 11.  Scaled Schoenfeld Residuals Cholesterol  versus Time
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Figure 12.  Scaled Schoenfeld Residuals CVA versus Time 
 
Figure 13.  Scaled Schoenfeld Residuals for Diuretics versus Time
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Figure 14.  Scaled Schoenfeld Residuals Iron supplements for versus Time 
 
Figure 15.  Scaled Schoenfeld Residuals GFR for versus Time
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Figure 16.  Scaled Schoenfeld Residuals for HB versus Time 
 
Figure 17.  Scaled Schoenfeld Residuals for versus Time
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Figure 18.  Scaled Schoenfeld Residuals for Heart failure versus Time 
 
Figure 19.  Scaled Schoenfeld Residuals for ISC race versus Time
 
  
 329 of 375 
 
Figure 20.  Scaled Schoenfeld Residuals for lipid lowering agents versus Time 
 
Figure 21.  Scaled Schoenfeld Residuals for other anti-hypertensive versus Time
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Figure 22.  Scaled Schoenfeld Residuals for Very High proteinuria versus Time
 
Figure 23.  Scaled Schoenfeld Residuals for versus Time 
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Figure 24. Scaled Schoenfeld Residuals for Angiotensin blockade versus Time
 
Figure 25. Scaled Schoenfeld Residuals for gender versus Time
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Figure 26. Scaled Schoenfeld Residuals for Smokers/Ex Smokers  versus Time
 
Figure 27. Scaled Schoenfeld Residuals for systolic BP versus Time
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Figure 28. Scaled Schoenfeld Residuals for Systolic BP versus Time 
 
Figure 29. Scaled Schoenfeld Residuals for Townsend Quintile 2 versus Time
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Figure 30. Scaled Schoenfeld Residuals for Townsend Quintile 3 versus Time 
Figure 31. Scaled Schoenfeld Residuals for Townsend Quintile 4 versus Time 
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Figure 32. Scaled Schoenfeld Residuals for Townsend Quintile 5 versus Time 
 
Figure 33. Scaled Schoenfeld Residuals for Vit D versus Time 
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Appendix C 
Figure 1. Histogram of original Cholesterol data pre imputation 
 
Figure 2. Histogram of original Body Mass index pre imputation 
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Figure 3. Histogram of original Systolic blood pressure data pre imputation 
 
Figure 4. Histogram of original Diastolic blood pressure data pre imputation 
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Figure 5. Histogram of original Haemoglobin data pre imputation 
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Table 1. Cox regression analysis for Imputation 1 without transformation and frailty term 
Risk factor/Prescription Beta Standard 
Error 
Hazard 
Ratio 
95% 
Confidence 
intervals 
Lower Limit 
95% 
Confidence 
intervals 
Lower Limit 
Age 0.04842 0.00101 1.05 1.05 1.05 
Male Gender -0.49218 0.02041 0.61 0.59 0.64 
Race with African Caribbean  
Race as reference 
African –Caribbean 
-0.41615 0.15713 0.66 0.48 0.90 
Indian Subcontinent -0.25705 0.11647 0.77 0.62 0.97 
South East Asian -0.50717 0.57761 0.60 0.19 1.87 
Townsend Quintile compared to 
1
th
 Quintile 
2
nd
 
0.08576 0.02671 1.09 1.03 1.15 
3
rd
 0.11812 0.02753 1.13 1.07 1.19 
4
th
 0.15209 0.02844 1.16 1.10 1.23 
5
th
 0.20154 0.03229 1.22 1.15 1.30 
Diabetes Mellitus 0.17665 0.02483 1.19 1.14 1.25 
Heart Failure 0.54364 0.03024 1.72 1.62 1.83 
Atrial Fibrillation 0.22331 0.02836 1.25 1.18 1.32 
Ever Smoked 0.23456 0.02396 1.26 1.21 1.33 
Systolic BP -0.00219 0.000462 1.00 1.00 1.00 
BMI -0.01941 0.00188 0.98 0.98 0.98 
Haemoglobin -0.11735 0.00592 0.89 0.88 0.90 
Glomerular Filtration Rate -0.01552 0.00113 0.98 0.98 0.99 
Cholesterol -0.02845 0.00818 0.97 0.96 0.99 
Proteinuria levels with none as 
reference 
High 
0.15116 0.03363 1.16 1.09 1.24 
Very High 0.49561 0.04197 1.64 1.51 1.78 
Aspirin 0.22012 0.02101 1.25 1.20 1.30 
Anticoagulation 0.21485 0.03899 1.24 1.15 1.34 
Diuretic use 0.08411 0.01985 1.09 1.05 1.13 
Other -0.1224 0.03904 0.88 0.82 0.96 
Angiotensin Blockade -0.17006 0.02036 0.84 0.81 0.88 
Iron Medication 0.13689 0.03419 1.15 1.07 1.23 
Vitamin D supplementation 0.17716 0.02953 1.19 1.13 1.26 
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Table 2. Cox regression analysis for Imputation 2 without transformation and frailty term 
Risk factor/Prescription Beta Standard 
Error 
Hazard 
Ratio 
95% 
Confidence 
intervals 
Lower Limit 
95% 
Confidence 
intervals 
Lower Limit 
Age 0.04841 0.00101 1.05 1.05 1.05 
Male Gender -0.48303 0.02048 0.62 0.59 0.64 
Race with African Caribbean  
Race as reference 
African –Caribbean -0.42724 0.15714 0.65 0.48 0.89 
Indian Subcontinent -0.27402 0.11654 0.76 0.61 0.96 
South East Asian -0.50589 0.57767 0.60 0.19 1.87 
Townsend Quintile compared to 
1
th
 Quintile 
2
nd
 0.08885 0.02667 1.09 1.04 1.15 
3
rd
 0.11346 0.02756 1.12 1.06 1.18 
4
th
 0.14299 0.02853 1.15 1.09 1.22 
5
th
 0.1781 0.03254 1.19 1.12 1.27 
Diabetes Mellitus 0.16943 0.02471 1.18 1.13 1.24 
Heart Failure 0.53526 0.03032 1.71 1.61 1.81 
Atrial Fibrillation 0.21496 0.02834 1.24 1.17 1.31 
Ever Smoked 0.22948 0.02398 1.26 1.20 1.32 
Systolic BP -0.00224 0.000459 1.00 1.00 1.00 
BMI -0.02041 0.00189 0.98 0.98 0.98 
Haemoglobin -0.11185 0.00594 0.89 0.88 0.90 
Glomerular Filtration Rate -0.01557 0.00113 0.98 0.98 0.99 
Cholesterol -0.04343 0.00823 0.96 0.94 0.97 
Proteinuria levels with none as 
reference 
High 0.17037 0.03429 1.19 1.11 1.27 
Very High 0.48867 0.04323 1.63 1.50 1.77 
Aspirin 0.20915 0.02104 1.23 1.18 1.28 
Anticoagulation 0.19884 0.0389 1.22 1.13 1.32 
Diuretic use 0.08948 0.0199 1.09 1.05 1.14 
Other -0.12648 0.03903 0.88 0.82 0.95 
Angiotensin Blockade -0.16935 0.02039 0.84 0.81 0.88 
Iron Medication 0.14908 0.03413 1.16 1.09 1.24 
Vitamin D supplementation 0.1675 0.02952 1.18 1.12 1.25 
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Table 3. Cox regression analysis for Imputation 3 without transformation and frailty term 
Risk factor/Prescription Beta Standard 
Error 
Hazard 
Ratio 
95% 
Confidence 
intervals 
Lower Limit 
95% 
Confidence 
intervals 
Lower Limit 
Age 0.0493 0.00101 1.05 1.05 1.05 
Male Gender -0.49306 0.02051 0.61 0.59 0.64 
Race with African Caribbean  
Race as reference 
African –Caribbean -0.43145 0.15713 0.65 0.48 0.88 
Indian Subcontinent -0.26388 0.11645 0.77 0.61 0.96 
South East Asian -0.42055 0.57767 0.66 0.21 2.04 
Townsend Quintile compared to 
1
th
 Quintile 
2
nd
 0.0793 0.02668 1.08 1.03 1.14 
3
rd
 0.11506 0.02752 1.12 1.06 1.18 
4
th
 0.1507 0.02842 1.16 1.10 1.23 
5
th
 0.17923 0.03244 1.20 1.12 1.27 
Diabetes Mellitus 0.16297 0.02472 1.18 1.12 1.24 
Heart Failure 0.54316 0.03027 1.72 1.62 1.83 
Atrial Fibrillation 0.22588 0.02829 1.25 1.19 1.32 
Ever Smoked 0.24077 0.02399 1.27 1.21 1.33 
Systolic BP -0.00265 0.000463 1.00 1.00 1.00 
BMI -0.01266 0.00184 0.99 0.98 0.99 
Haemoglobin -0.12049 0.00593 0.89 0.88 0.90 
Glomerular Filtration Rate -0.01588 0.00113 0.98 0.98 0.99 
Cholesterol -0.02782 0.00823 0.97 0.96 0.99 
Proteinuria levels with none as 
reference 
High 0.20771 0.03443 1.23 1.15 1.32 
Very High 0.4515 0.04326 1.57 1.44 1.71 
Aspirin 0.2233 0.02103 1.25 1.20 1.30 
Anticoagulation 0.19659 0.03896 1.22 1.13 1.31 
Diuretic use 0.0767 0.0199 1.08 1.04 1.12 
Other -0.12347 0.03904 0.88 0.82 0.95 
Angiotensin Blockade -0.16834 0.02039 0.85 0.81 0.88 
Iron Medication 0.14261 0.03419 1.15 1.08 1.23 
Vitamin D supplementation 0.1718 0.02955 1.19 1.12 1.26 
 
  
 343 of 375 
 
Table 4, Cox regression analysis for Imputation 4 without transformation and frailty term 
Risk factor/Prescription Beta Standard 
Error 
Hazard 
Ratio 
95% 
Confidence 
intervals 
Lower Limit 
95% 
Confidence 
intervals 
Lower Limit 
Age 0.04885 0.00101 1.05 1.05 1.05 
Male Gender -0.4939 0.02047 0.61 0.59 0.64 
Race with African Caribbean  
Race as reference 
African –Caribbean -0.42634 0.15714 0.65 0.48 0.89 
Indian Subcontinent -0.26383 0.11647 0.77 0.61 0.97 
South East Asian -0.6401 0.57811 0.53 0.17 1.64 
Townsend Quintile compared to 
1
th
 Quintile 
2
nd
 0.09896 0.02669 1.10 1.05 1.16 
3
rd
 0.13878 0.02754 1.15 1.09 1.21 
4
th
 0.15799 0.0285 1.17 1.11 1.24 
5
th
 0.1973 0.03245 1.22 1.14 1.30 
Diabetes Mellitus 0.16631 0.02482 1.18 1.12 1.24 
Heart Failure 0.53911 0.0303 1.71 1.62 1.82 
Atrial Fibrillation 0.21938 0.02832 1.25 1.18 1.32 
Ever Smoked 0.23315 0.02396 1.26 1.20 1.32 
Systolic BP -0.00244 0.000464 1.00 1.00 1.00 
BMI -0.0175 0.00187 0.98 0.98 0.99 
Haemoglobin -0.11354 0.00596 0.89 0.88 0.90 
Glomerular Filtration Rate -0.0156 0.00113 0.98 0.98 0.99 
Cholesterol -0.02268 0.00813 0.98 0.96 0.99 
Proteinuria levels with none as 
reference 
High 0.13478 0.03457 1.14 1.07 1.22 
Very High 0.42549 0.0431 1.53 1.41 1.67 
Aspirin 0.22096 0.02101 1.25 1.20 1.30 
Anticoagulation 0.1976 0.03892 1.22 1.13 1.32 
Diuretic use 0.08123 0.01986 1.08 1.04 1.13 
Other -0.12372 0.03908 0.88 0.82 0.95 
Angiotensin Blockade -0.16016 0.02038 0.85 0.82 0.89 
Iron Medication 0.16259 0.03412 1.18 1.10 1.26 
Vitamin D supplementation 0.17201 0.02953 1.19 1.12 1.26 
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Table 5. Cox regression analysis for Imputation 5 without transformation and frailty term 
Risk factor/Prescription Beta Standard 
Error 
Hazard 
Ratio 
95% 
Confidence 
intervals 
Lower Limit 
95% 
Confidence 
intervals 
Lower Limit 
Age 0.04898 0.00102 1.05 1.05 1.05 
Male Gender -0.48506 0.02046 0.62 0.59 0.64 
Race with African Caribbean  
Race as reference 
African –Caribbean -0.43105 0.15717 0.65 0.48 0.88 
Indian Subcontinent -0.26216 0.11654 0.77 0.61 0.97 
South East Asian -0.66425 0.57783 0.51 0.17 1.60 
Townsend Quintile compared to 
1
th
 Quintile 
2
nd
 0.0967 0.02671 1.10 1.05 1.16 
3
rd
 0.12154 0.02758 1.13 1.07 1.19 
4
th
 0.14219 0.02854 1.15 1.09 1.22 
5
th
 0.19873 0.03233 1.22 1.14 1.30 
Diabetes Mellitus 0.14489 0.02514 1.16 1.10 1.21 
Heart Failure 0.54025 0.03031 1.72 1.62 1.82 
Atrial Fibrillation 0.21821 0.02844 1.24 1.18 1.32 
Ever Smoked 0.2385 0.02398 1.27 1.21 1.33 
Systolic BP -0.00273 0.0004626 1.00 1.00 1.00 
BMI -0.01567 0.00188 0.98 0.98 0.99 
Haemoglobin -0.11058 0.00597 0.90 0.88 0.91 
Glomerular Filtration Rate -0.01481 0.00113 0.99 0.98 0.99 
Cholesterol -0.03418 0.00831 0.97 0.95 0.98 
Proteinuria levels with none as 
reference 
High 0.00606 0.03223 1.01 0.94 1.07 
Very High 0.41909 0.04114 1.52 1.40 1.65 
Aspirin 0.22485 0.02146 1.25 1.20 1.31 
Anticoagulation 0.20493 0.03907 1.23 1.14 1.33 
Diuretic use 0.07983 0.01991 1.08 1.04 1.13 
Other -0.12723 0.03908 0.88 0.82 0.95 
Angiotensin Blockade -0.16572 0.0206 0.85 0.81 0.88 
Iron Medication 0.13598 0.03426 1.15 1.07 1.23 
Vitamin D supplementation 0.17614 0.02953 1.19 1.13 1.26 
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Table 6. Cox proportional hazards model with fractional polynomials suggested by mfp algorithm for 
Imputed Dataset 1 
Risk factor/Prescription Beta Standard 
Error 
Hazard 
Ratio 
95% 
Confidence 
intervals 
Lower Limit 
95% 
Confidence 
intervals 
Lower Limit 
Age
2
 3.31 0.07 27.32 23.99 31.14 
Male Gender 0.50 0.02 1.65 1.59 1.72 
Race with African Caribbean  
Race as reference 
African –Caribbean -0.45 0.16 0.64 0.47 0.86 
Indian Subcontinent -0.26 0.12 0.77 0.61 0.97 
South East Asian -0.54 0.58 0.58 0.19 1.80 
Townsend Quintile compared to 
1
th
 Quintile 
2
nd
 0.08 0.03 1.09 1.03 1.15 
3
rd
 0.12 0.03 1.12 1.06 1.18 
4
th
 0.15 0.03 1.16 1.10 1.23 
5
th
 0.20 0.03 1.22 1.14 1.30 
Diabetes Mellitus 0.19 0.02 1.20 1.15 1.26 
Heart Failure 0.52 0.03 1.68 1.59 1.79 
Atrial Fibrillation 0.22 0.03 1.24 1.18 1.32 
Ever Smoked 0.24 0.02 1.27 1.21 1.33 
(Systolic BP/100)0.5 -10.00 1.59 0.00 0.00 0.00 
(Systolic BP/100) 3.98 0.66 53.32 14.53 195.56 
(BMI/10)-0.5 3.12 0.28 22.70 13.04 39.48 
(BMI/10)3 0.01 0.00 1.01 1.00 1.01 
(Hb/10)-1 4.03 0.34 56.17 28.84 109.33 
(Hb/10)-2 -1.31 0.17 0.27 0.19 0.38 
Gfr/100 -1.42 0.11 0.24 0.19 0.30 
Cholesterol/10 -0.28 0.08 0.76 0.64 0.89 
Proteinuria levels with none as 
reference 
High 0.15 0.03 1.17 1.09 1.25 
Very High 0.49 0.04 1.64 1.51 1.78 
Aspirin 0.23 0.02 1.26 1.20 1.31 
Anticoagulation 0.23 0.04 1.26 1.16 1.36 
Diuretic use -0.16 0.02 0.85 0.82 0.88 
Other 0.09 0.02 1.09 1.05 1.13 
Angiotensin Blockade -0.12 0.04 0.88 0.82 0.95 
Iron Medication 0.10 0.03 1.11 1.04 1.19 
Vitamin D supplementation 0.16 0.03 1.18 1.11 1.25 
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Table 7. Cox proportional hazards model with fractional polynomials suggested by mfp algorithm for 
Imputed Dataset 2 
Risk factor/Prescription Beta Standard 
Error 
Hazard 
Ratio 
95% 
Confidence 
intervals 
Lower Limit 
95% 
Confidence 
intervals 
Lower Limit 
Age
2
 3.30 0.07 26.98 23.66 30.76 
Male Gender 0.49 0.02 1.63 1.57 1.70 
Race with African Caribbean  Race as 
reference 
African –Caribbean -0.46 0.16 0.63 0.46 0.86 
Indian Subcontinent -0.28 0.12 0.75 0.60 0.95 
South East Asian -0.53 0.58 0.59 0.19 1.82 
Townsend Quintile compared to 1
th
 
Quintile 
2
nd
 0.09 0.03 1.09 1.04 1.15 
3
rd
 0.11 0.03 1.12 1.06 1.18 
4
th
 0.14 0.03 1.15 1.09 1.21 
5
th
 0.17 0.03 1.19 1.11 1.26 
Diabetes Mellitus 0.17 0.02 1.19 1.13 1.25 
Heart Failure 0.52 0.03 1.67 1.58 1.78 
Atrial Fibrillation 0.21 0.03 1.24 1.17 1.31 
Ever Smoked 0.23 0.02 1.26 1.20 1.32 
(Systolic BP/100)
2
 -0.63 0.11 0.53 0.43 0.65 
(Systolic BP/100)
2
 x log(Systolic 
BP/100) 0.63 0.11 1.88 1.50 2.35 
(BMI/10)
3
 0.01 0.00 1.01 1.00 1.01 
Log (BMI/10) -1.04 0.10 0.35 0.29 0.43 
(Hb/10)
3
 -0.68 0.05 0.51 0.46 0.55 
(Hb/10)
3 
X log(Hb/10) 0.76 0.07 2.13 1.87 2.43 
(Gfr/100)2 -1.63 0.13 0.19 0.15 0.25 
Cholesterol/10 -0.44 0.08 0.64 0.55 0.75 
Proteinuria levels with none as 
reference 
High 0.17 0.03 1.19 1.11 1.27 
Very High 0.48 0.04 1.61 1.48 1.75 
Aspirin 0.21 0.02 1.24 1.19 1.29 
Anticoagulation 0.21 0.04 1.23 1.14 1.33 
Diuretic use -0.16 0.02 0.85 0.82 0.89 
Other 0.09 0.02 1.10 1.05 1.14 
Angiotensin Blockade -0.12 0.04 0.89 0.82 0.96 
Iron Medication 0.12 0.03 1.13 1.05 1.20 
Vitamin D supplementation 0.16 0.03 1.17 1.11 1.24 
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Table 8. Cox proportional hazards model with fractional polynomials suggested by mfp algorithm for 
Imputed Dataset 3 
Risk factor/Prescription Beta Standard 
Error 
Hazard 
Ratio 
95% 
Confidence 
intervals 
Lower Limit 
95% 
Confidence 
intervals 
Lower Limit 
Age
2
 3.37 0.07 29.00 25.48 33.01 
Male Gender 0.50 0.02 1.65 1.58 1.72 
Race with African Caribbean  Race as 
reference 
African –Caribbean -0.46 0.16 0.63 0.46 0.86 
Indian Subcontinent -0.26 0.12 0.77 0.61 0.97 
South East Asian -0.47 0.58 0.63 0.20 1.95 
Townsend Quintile compared to 1
th
 
Quintile 
2
nd
 0.08 0.03 1.08 1.03 1.14 
3
rd
 0.11 0.03 1.12 1.06 1.18 
4
th
 0.15 0.03 1.16 1.10 1.23 
5
th
 0.17 0.03 1.19 1.12 1.27 
Diabetes Mellitus 0.08 0.02 1.08 1.04 1.13 
Heart Failure 0.52 0.03 1.69 1.59 1.79 
Atrial Fibrillation 0.22 0.03 1.25 1.18 1.32 
Ever Smoked 0.24 0.02 1.27 1.22 1.34 
(Systolic BP/100) -2.19 0.34 0.11 0.06 0.22 
(Systolic BP/100)
2
 0.66 0.12 1.94 1.55 2.44 
(BMI/10)-
2
 1.19 0.15 3.28 2.45 4.40 
(Hb/10)
3
 -0.70 0.05 0.50 0.46 0.55 
(Hb/10)
3 
X log(Hb/10) 0.75 0.07 2.12 1.86 2.41 
Gfr/100 -1.46 0.11 0.23 0.19 0.29 
Cholesterol/10 -0.27 0.08 0.76 0.65 0.89 
Proteinuria levels with none as 
reference 
High 0.20 0.03 1.23 1.15 1.31 
Very High 0.44 0.04 1.55 1.43 1.69 
Aspirin 0.23 0.02 1.25 1.20 1.31 
Anticoagulation 0.21 0.04 1.23 1.14 1.33 
Diuretic use -0.16 0.02 0.85 0.82 0.89 
Other 0.17 0.02 1.18 1.13 1.24 
Angiotensin Blockade -0.12 0.04 0.89 0.82 0.96 
Iron Medication 0.11 0.03 1.12 1.05 1.20 
Vitamin D supplementation 0.16 0.03 1.17 1.11 1.25 
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Table 9. Cox proportional hazards model with fractional polynomials suggested by mfp algorithm for 
Imputed Dataset 4 
Risk factor/Prescription Beta Standard 
Error 
Hazard 
Ratio 
95% 
Confidence 
intervals 
Lower Limit 
95% 
Confidence 
intervals 
Lower Limit 
Age
2
 3.34 0.07 28.31 24.84 32.26 
Male Gender 0.52 0.02 1.67 1.61 1.74 
Race with African Caribbean  Race 
as reference 
African –Caribbean -0.45 0.16 0.64 0.47 0.87 
Indian Subcontinent -0.26 0.12 0.77 0.61 0.97 
South East Asian -0.67 0.58 0.51 0.16 1.58 
Townsend Quintile compared to 1
th
 
Quintile 
2
nd
 0.10 0.03 1.10 1.05 1.16 
3
rd
 0.14 0.03 1.15 1.09 1.21 
4
th
 0.15 0.03 1.17 1.10 1.23 
5
th
 0.19 0.03 1.21 1.14 1.29 
Diabetes Mellitus 0.18 0.02 1.20 1.15 1.26 
Heart Failure 0.52 0.03 1.69 1.59 1.79 
Atrial Fibrillation 0.22 0.03 1.24 1.17 1.31 
Ever Smoked 0.23 0.02 1.26 1.21 1.32 
(Systolic BP/100) -2.10 0.35 0.12 0.06 0.24 
(Systolic BP/100)
2
 0.64 0.12 1.89 1.51 2.38 
(BMI/10)-0.5 2.73 0.29 15.41 8.80 26.97 
(BMI/10)3 0.01 0.00 1.01 1.00 1.01 
(Hb/10)
3
 -0.70 0.04 0.50 0.46 0.54 
(Hb/10)
3 
X log(Hb/10) 0.77 0.06 2.17 1.92 2.46 
Gfr/100 -1.42 0.11 0.24 0.19 0.30 
Proteinuria levels with none as 
reference 
High 0.13 0.03 1.14 1.07 1.22 
Very High 0.41 0.04 1.51 1.39 1.65 
Aspirin 0.23 0.02 1.26 1.21 1.31 
Anticoagulation 0.21 0.04 1.24 1.15 1.34 
Diuretic use -0.15 0.02 0.86 0.83 0.90 
Other 0.08 0.02 1.09 1.05 1.13 
Angiotensin Blockade -0.12 0.04 0.89 0.82 0.96 
Iron Medication 0.14 0.03 1.15 1.07 1.23 
Vitamin D supplementation 0.16 0.03 1.18 1.11 1.25 
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Table 10. Cox proportional hazards model with fractional polynomials suggested by mfp algorithm for 
Imputed Dataset 5 
Risk factor/Prescription Beta Standard 
Error 
Hazard 
Ratio 
95% 
Confidence 
intervals 
Lower Limit 
95% 
Confidence 
intervals 
Lower Limit 
Age
2
 3.37 0.07 29.01 25.47 33.03 
Male Gender 0.49 0.02 1.63 1.57 1.70 
Race with African Caribbean  
Race as reference 
African –Caribbean -0.46 0.16 0.63 0.47 0.86 
Indian Subcontinent -0.27 0.12 0.76 0.61 0.96 
South East Asian -0.73 0.58 0.48 0.16 1.50 
Townsend Quintile compared to 
1
th
 Quintile 
2
nd
 0.10 0.03 1.10 1.04 1.16 
3
rd
 0.12 0.03 1.13 1.07 1.19 
4
th
 0.14 0.03 1.15 1.09 1.21 
5
th
 0.19 0.03 1.21 1.14 1.29 
Diabetes Mellitus 0.08 0.02 1.09 1.04 1.13 
Heart Failure 0.52 0.03 1.69 1.59 1.79 
Atrial Fibrillation 0.21 0.03 1.24 1.17 1.31 
Ever Smoked 0.24 0.02 1.27 1.21 1.33 
(Systolic BP/100)
1
 -3.23 0.46 0.04 0.02 0.10 
(Systolic BP/100)
1
 x log(Systolic 
BP/100) 2.18 0.34 8.87 4.58 17.19 
(BMI/10)-
2
 1.44 0.15 4.20 3.14 5.62 
(Hb/10)
3
 -0.68 0.05 0.51 0.46 0.55 
(Hb/10)
3 
X log(Hb/10) 0.75 0.07 2.13 1.87 2.42 
Gfr/100 -1.35 0.11 0.26 0.21 0.32 
Cholesterol/10 -0.34 0.08 0.72 0.61 0.84 
Proteinuria levels with none as 
reference 
High 0.01 0.03 1.01 0.95 1.07 
Very High 0.41 0.04 1.51 1.39 1.63 
Aspirin 0.22 0.02 1.24 1.19 1.30 
Anticoagulation 0.21 0.04 1.23 1.14 1.33 
Diuretic use -0.16 0.02 0.85 0.82 0.88 
Other 0.14 0.02 1.15 1.09 1.20 
Angiotensin Blockade -0.13 0.04 0.88 0.82 0.95 
Iron Medication 0.10 0.03 1.11 1.04 1.19 
Vitamin D supplementation 0.16 0.03 1.18 1.11 1.25 
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Table 11. Cox regression analysis for Imputation 1 without transformation but with frailty term 
Risk 
factor/Prescript
ion 
Beta Standard Error Hazard Ratio 95% Confidence 
intervals 
Lower Limit 
95% Confidence 
intervals 
Lower Limit 
Age 0.05 0.00 1.05 1.05 1.05 
Male Gender 0.49 0.02 1.64 1.57 1.70 
Race with 
African 
Caribbean  Race 
as reference 
African –
Caribbean 
-0.37 0.16 0.69 0.50 0.95 
Indian 
Subcontinent 
-0.21 0.12 0.81 0.64 1.03 
South East 
Asian 
-0.51 0.58 0.60 0.19 1.87 
Townsend 
Quintile 
compared to 1
th
 
Quintile 
2
nd
 
0.08 0.03 1.08 1.03 1.14 
3
rd
 0.11 0.03 1.12 1.06 1.18 
4
th
 0.14 0.03 1.15 1.09 1.22 
5
th
 0.20 0.03 1.22 1.14 1.30 
Diabetes 
Mellitus 
0.17 0.03 1.19 1.13 1.25 
Heart Failure 0.55 0.03 1.73 1.63 1.84 
Atrial 
Fibrillation 
0.23 0.03 1.26 1.19 1.34 
Ever Smoked 0.24 0.03 1.27 1.20 1.33 
Systolic BP 0.00 0.00 0.998 0.997 0.999 
BMI -0.02 0.00 0.98 0.98 0.98 
Haemoglobin -0.12 0.01 0.89 0.88 0.90 
Glomerular 
Filtration Rate 
-0.01 0.00 0.99 0.98 0.99 
Cholesterol -0.03 0.01 0.97 0.96 0.99 
Proteinuria 
levels with none 
as reference 
High 
0.16 0.03 1.18 1.10 1.26 
Very High 0.52 0.04 1.68 1.54 1.82 
Aspirin 0.21 0.02 1.24 1.19 1.29 
Anticoagulation 0.19 0.04 1.21 1.12 1.31 
Diuretic use -0.17 0.02 0.84 0.81 0.88 
Other 0.07 0.02 1.08 1.04 1.12 
Angiotensin 
Blockade 
-0.12 0.04 0.89 0.82 0.96 
Iron Medication 0.14 0.03 1.15 1.07 1.23 
Vitamin D 
supplementatio
n 
0.17 0.03 1.18 1.11 1.25 
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Table 12. Cox regression analysis for Imputation 2 without transformation but with frailty term 
 
Risk factor/Prescription Beta Standard 
Error 
Hazard 
Ratio 
95% 
Confidence 
intervals 
Lower Limit 
95% 
Confidence 
intervals 
Lower Limit 
Age 0.05 0.00 1.05 1.05 1.05 
Male Gender 0.49 0.02 1.62 1.56 1.69 
Race with African Caribbean  
Race as reference 
African –Caribbean 
-0.39 0.16 0.68 0.50 0.93 
Indian Subcontinent -0.23 0.12 0.80 0.63 1.01 
South East Asian -0.50 0.58 0.61 0.19 1.88 
Townsend Quintile compared to 
1
th
 Quintile 
2
nd
 
0.08 0.03 1.09 1.03 1.14 
3
rd
 0.11 0.03 1.11 1.05 1.18 
4
th
 0.13 0.03 1.14 1.08 1.21 
5
th
 0.17 0.03 1.19 1.11 1.27 
Diabetes Mellitus 0.17 0.02 1.18 1.12 1.24 
Heart Failure 0.54 0.03 1.72 1.62 1.83 
Atrial Fibrillation 0.23 0.03 1.26 1.19 1.33 
Ever Smoked 0.23 0.03 1.26 1.20 1.32 
Systolic BP 0.00 0.00 0.998 0.997 0.999 
BMI -0.02 0.00 0.98 0.98 0.98 
Haemoglobin -0.11 0.01 0.89 0.88 0.90 
Glomerular Filtration Rate -0.01 0.00 0.99 0.98 0.99 
Cholesterol -0.04 0.01 0.96 0.94 0.97 
Proteinuria levels with none as 
reference 
High 
0.18 0.03 1.19 1.11 1.27 
Very High 0.51 0.04 1.66 1.52 1.81 
Aspirin 0.20 0.02 1.22 1.17 1.28 
Anticoagulation 0.17 0.04 1.19 1.10 1.28 
Diuretic use -0.17 0.02 0.84 0.81 0.88 
Other 0.08 0.02 1.08 1.04 1.13 
Angiotensin Blockade -0.12 0.04 0.88 0.82 0.95 
Iron Medication 0.15 0.03 1.16 1.09 1.25 
Vitamin D supplementation 0.16 0.03 1.17 1.10 1.24 
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Table 13. Cox regression analysis for Imputation 3 without transformation but with frailty term 
 
Risk factor/Prescription Beta Standard 
Error 
Hazard 
Ratio 
95% 
Confidence 
intervals 
Lower Limit 
95% 
Confidence 
intervals 
Lower Limit 
Age 0.05 0.00 1.05 1.05 1.05 
Male Gender 0.49 0.02 1.64 1.58 1.71 
Race with African Caribbean  
Race as reference 
African –Caribbean 
-0.38 0.16 0.68 0.50 0.93 
Indian Subcontinent -0.22 0.12 0.81 0.63 1.02 
South East Asian -0.43 0.58 0.65 0.21 2.01 
Townsend Quintile compared to 
1
th
 Quintile 
2
nd
 
0.07 0.03 1.07 1.02 1.13 
3
rd
 0.11 0.03 1.12 1.05 1.18 
4
th
 0.14 0.03 1.15 1.09 1.22 
5
th
 0.17 0.03 1.19 1.11 1.27 
Diabetes Mellitus 0.16 0.02 1.17 1.11 1.23 
Heart Failure 0.55 0.03 1.74 1.63 1.84 
Atrial Fibrillation 0.24 0.03 1.27 1.20 1.34 
Ever Smoked 0.24 0.03 1.28 1.21 1.34 
Systolic BP 0.00 0.00 0.997 0.996 0.998 
BMI -0.01 0.00 0.99 0.98 0.99 
Haemoglobin -0.12 0.01 0.89 0.88 0.90 
Glomerular Filtration Rate -0.02 0.00 0.99 0.98 0.99 
Cholesterol -0.03 0.01 0.97 0.96 0.99 
Proteinuria levels with none as 
reference 
High 
0.22 0.03 1.24 1.16 1.33 
Very High 0.46 0.04 1.59 1.46 1.73 
Aspirin 0.22 0.02 1.24 1.19 1.29 
Anticoagulation 0.17 0.04 1.19 1.10 1.28 
Diuretic use -0.17 0.02 0.84 0.81 0.88 
Other 0.07 0.02 1.07 1.03 1.11 
Angiotensin Blockade -0.12 0.04 0.89 0.82 0.96 
Iron Medication 0.15 0.03 1.16 1.08 1.24 
Vitamin D supplementation 0.16 0.03 1.17 1.11 1.25 
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Table 14. Cox regression analysis for Imputation 4 without transformation but with frailty term 
 
Risk factor/Prescription Beta Standard 
Error 
Hazard 
Ratio 
95% 
Confidence 
intervals 
Lower Limit 
95% 
Confidence 
intervals 
Lower Limit 
Age 0.05 0.00 1.05 1.05 1.05 
Male Gender 0.49 0.02 1.64 1.58 1.71 
Race with African Caribbean  
Race as reference 
African –Caribbean 
-0.38 0.16 0.69 0.50 0.94 
Indian Subcontinent -0.22 0.12 0.80 0.63 1.02 
South East Asian -0.64 0.58 0.53 0.17 1.64 
Townsend Quintile compared to 
1
th
 Quintile 
2
nd
 
0.09 0.03 1.10 1.04 1.16 
3
rd
 0.13 0.03 1.14 1.08 1.21 
4
th
 0.15 0.03 1.16 1.09 1.23 
5
th
 0.19 0.03 1.21 1.13 1.30 
Diabetes Mellitus 0.16 0.03 1.17 1.12 1.23 
Heart Failure 0.55 0.03 1.73 1.63 1.83 
Atrial Fibrillation 0.23 0.03 1.26 1.19 1.33 
Ever Smoked 0.23 0.03 1.26 1.20 1.33 
Systolic BP 0.00 0.00 0.998 0.997 0.998 
BMI -0.02 0.00 0.98 0.98 0.99 
Haemoglobin -0.11 0.01 0.89 0.88 0.90 
Glomerular Filtration Rate -0.01 0.00 0.99 0.98 0.99 
Cholesterol -0.02 0.01 0.98 0.96 0.99 
Proteinuria levels with none as 
reference 
High 
0.14 0.03 1.15 1.07 1.23 
Very High 0.44 0.04 1.55 1.43 1.69 
Aspirin 0.22 0.02 1.24 1.19 1.29 
Anticoagulation 0.18 0.04 1.19 1.10 1.29 
Diuretic use -0.16 0.02 0.85 0.82 0.89 
Other 0.07 0.02 1.07 1.03 1.12 
Angiotensin Blockade -0.12 0.04 0.89 0.82 0.96 
Iron Medication 0.17 0.03 1.18 1.11 1.26 
Vitamin D supplementation 0.16 0.03 1.17 1.11 1.25 
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Table 15. Cox regression analysis for Imputation 5 without transformation but with frailty term 
 
Risk factor/Prescription Beta Standard 
Error 
Hazard 
Ratio 
95% 
Confidence 
intervals 
Lower Limit 
95% 
Confidence 
intervals 
Lower Limit 
Age 0.05 0.00 1.05 1.05 1.05 
Male Gender 0.49 0.02 1.63 1.56 1.69 
Race with African Caribbean  
Race as reference 
African –Caribbean 
-0.39 0.16 0.68 0.49 0.93 
Indian Subcontinent -0.22 0.12 0.80 0.63 1.02 
South East Asian -0.68 0.58 0.51 0.16 1.58 
Townsend Quintile compared to 
1
th
 Quintile 
2
nd
 
0.09 0.03 1.09 1.04 1.16 
3
rd
 0.12 0.03 1.12 1.06 1.19 
4
th
 0.13 0.03 1.14 1.08 1.21 
5
th
 0.19 0.03 1.21 1.14 1.30 
Diabetes Mellitus 0.14 0.03 1.15 1.10 1.21 
Heart Failure 0.55 0.03 1.73 1.63 1.84 
Atrial Fibrillation 0.23 0.03 1.26 1.19 1.33 
Ever Smoked 0.24 0.03 1.27 1.21 1.34 
Systolic BP 0.00 0.00 0.997 0.996 0.998 
BMI -0.02 0.00 0.98 0.98 0.99 
Haemoglobin -0.11 0.01 0.90 0.89 0.91 
Glomerular Filtration Rate -0.01 0.00 0.99 0.98 0.99 
Cholesterol -0.03 0.01 0.97 0.95 0.98 
Proteinuria levels with none as 
reference 
High 
0.01 0.03 1.01 0.95 1.08 
Very High 0.43 0.04 1.54 1.42 1.67 
Aspirin 0.22 0.02 1.24 1.19 1.30 
Anticoagulation 0.18 0.04 1.20 1.11 1.30 
Diuretic use -0.17 0.02 0.84 0.81 0.88 
Other 0.07 0.02 1.07 1.03 1.12 
Angiotensin Blockade -0.12 0.04 0.88 0.82 0.95 
Iron Medication 0.14 0.03 1.15 1.08 1.23 
Vitamin D supplementation 0.17 0.03 1.18 1.11 1.25 
 
  
 355 of 375 
 
Table 16. Cox proportional hazards model with fractional polynomials suggested by mfp algorithm 
for Imputed Dataset 1 with frailty term 
 
Risk factor/Prescription Beta Standard 
Error 
Hazard 
Ratio 
95% 
Confidence 
intervals 
Lower Limit 
95% 
Confidence 
intervals 
Lower Limit 
Age
2
 3.28 0.07 26.67 23.36 30.45 
Male Gender 0.50 0.02 1.65 1.59 1.72 
Race with African Caribbean  
Race as reference 
African –Caribbean -0.40 0.16 0.67 0.49 0.92 
Indian Subcontinent -0.21 0.12 0.81 0.64 1.03 
South East Asian -0.54 0.58 0.58 0.19 1.82 
Townsend Quintile compared to 
1
th
 Quintile 
2
nd
 0.08 0.03 1.08 1.02 1.14 
3
rd
 0.11 0.03 1.11 1.05 1.18 
4
th
 0.14 0.03 1.15 1.08 1.21 
5
th
 0.19 0.03 1.21 1.13 1.30 
Diabetes Mellitus 0.18 0.03 1.20 1.14 1.26 
Heart Failure 0.53 0.03 1.69 1.59 1.80 
Atrial Fibrillation 0.23 0.03 1.26 1.19 1.33 
Ever Smoked 0.24 0.03 1.27 1.21 1.33 
(Systolic BP/100)0.5 -9.77 1.60 0.00 0.00 0.00 
(Systolic BP/100) 3.88 0.67 48.21 12.99 178.93 
(BMI/10)-0.5 3.18 0.28 24.00 13.77 41.83 
(BMI/10)3 0.01 0.00 1.01 1.00 1.01 
(Hb/10)-1 3.96 0.34 52.69 27.10 102.45 
(Hb/10)-2 -1.27 0.17 0.28 0.20 0.39 
Gfr/100 -1.33 0.11 0.26 0.21 0.33 
Cholesterol/10 -0.29 0.08 0.75 0.64 0.88 
Proteinuria levels with none as 
reference 
High 0.16 0.03 1.18 1.10 1.26 
Very High 0.51 0.04 1.67 1.54 1.82 
Aspirin 0.22 0.02 1.25 1.20 1.30 
Anticoagulation 0.21 0.04 1.23 1.14 1.33 
Diuretic use -0.17 0.02 0.85 0.81 0.88 
Other 0.08 0.02 1.08 1.04 1.12 
Angiotensin Blockade -0.12 0.04 0.89 0.82 0.96 
Iron Medication 0.11 0.03 1.11 1.04 1.19 
Vitamin D supplementation 0.15 0.03 1.16 1.10 1.23 
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Table 17. Cox proportional hazards model with fractional polynomials suggested by mfp algorithm 
for Imputed Dataset 2 with frailty term 
 
Risk factor/Prescription Beta Standard 
Error 
Hazard 
Ratio 
95% 
Confidence 
intervals 
Lower Limit 
95% 
Confidence 
intervals 
Lower Limit 
Age
2
 3.27 0.07 26.35 23.07 30.10 
Male Gender 0.49 0.02 1.64 1.57 1.70 
Race with African Caribbean  Race as 
reference 
African –Caribbean -0.41 0.16 0.66 0.48 0.91 
Indian Subcontinent -0.23 0.12 0.79 0.62 1.01 
South East Asian -0.53 0.58 0.59 0.19 1.83 
Townsend Quintile compared to 1
th
 
Quintile 
2
nd
 0.08 0.03 1.08 1.03 1.14 
3
rd
 0.10 0.03 1.11 1.05 1.17 
4
th
 0.13 0.03 1.13 1.07 1.20 
5
th
 0.16 0.03 1.18 1.10 1.26 
Diabetes Mellitus 0.17 0.02 1.18 1.13 1.24 
Heart Failure 0.52 0.03 1.69 1.59 1.79 
Atrial Fibrillation 0.22 0.03 1.25 1.18 1.32 
Ever Smoked 0.23 0.03 1.26 1.20 1.33 
(Systolic BP/100)
2
 -0.62 0.11 0.54 0.44 0.67 
(Systolic BP/100)
2
 x log(Systolic 
BP/100) 0.61 0.12 1.84 1.47 2.31 
(BMI/10)
3
 0.01 0.00 1.01 1.00 1.01 
Log (BMI/10) -1.06 0.10 0.35 0.28 0.42 
(Hb/10)
3
 -0.69 0.05 0.50 0.46 0.55 
(Hb/10)
3 
X log(Hb/10) 0.77 0.07 2.16 1.89 2.47 
(Gfr/100)2 -1.53 0.13 0.22 0.17 0.28 
Cholesterol/10 -0.44 0.08 0.64 0.55 0.76 
Proteinuria levels with none as 
reference 
High 0.17 0.03 1.19 1.11 1.27 
Very High 0.49 0.04 1.63 1.50 1.78 
Aspirin 0.21 0.02 1.23 1.18 1.28 
Anticoagulation 0.18 0.04 1.20 1.11 1.29 
Diuretic use -0.16 0.02 0.85 0.82 0.89 
Other 0.08 0.02 1.09 1.05 1.13 
Angiotensin Blockade -0.12 0.04 0.89 0.82 0.96 
Iron Medication 0.12 0.03 1.13 1.06 1.21 
Vitamin D supplementation 0.15 0.03 1.16 1.10 1.23 
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Table 18. Cox proportional hazards model with fractional polynomials suggested by mfp algorithm 
for Imputed Dataset 3 with frailty term 
Risk factor/Prescription Beta Standard 
Error 
Hazard 
Ratio 
95% 
Confidence 
intervals 
Lower Limit 
95% 
Confidence 
intervals 
Lower Limit 
Age
2
 3.34 0.07 28.25 24.77 32.22 
Male Gender 0.50 0.02 1.65 1.59 1.72 
Race with African Caribbean  
Race as reference 
African –Caribbean -0.41 0.16 0.66 0.48 0.91 
Indian Subcontinent -0.21 0.12 0.81 0.64 1.03 
South East Asian -0.48 0.58 0.62 0.20 1.93 
Townsend Quintile compared to 
1
th
 Quintile 
2
nd
 0.07 0.03 1.07 1.02 1.13 
3
rd
 0.11 0.03 1.11 1.05 1.18 
4
th
 0.14 0.03 1.15 1.08 1.22 
5
th
 0.17 0.03 1.18 1.11 1.27 
Diabetes Mellitus 0.16 0.02 1.18 1.12 1.24 
Heart Failure 0.53 0.03 1.70 1.61 1.81 
Atrial Fibrillation 0.23 0.03 1.26 1.19 1.33 
Ever Smoked 0.24 0.03 1.28 1.21 1.34 
(Systolic BP/100) -2.13 0.35 0.12 0.06 0.23 
(Systolic BP/100)
2
 0.64 0.12 1.90 1.51 2.39 
(BMI/10)-
2
 1.21 0.15 3.34 2.49 4.48 
(Hb/10)
3
 -0.71 0.05 0.49 0.45 0.54 
(Hb/10)
3 
X log(Hb/10) 0.77 0.07 2.17 1.90 2.48 
Gfr/100 -1.37 0.11 0.25 0.20 0.32 
Cholesterol/10 -0.28 0.08 0.76 0.64 0.89 
Proteinuria levels with none as 
reference 
High 0.21 0.03 1.24 1.16 1.32 
Very High 0.45 0.04 1.57 1.44 1.71 
Aspirin 0.22 0.02 1.24 1.19 1.30 
Anticoagulation 0.18 0.04 1.20 1.11 1.29 
Diuretic use -0.16 0.02 0.85 0.82 0.89 
Other 0.07 0.02 1.07 1.03 1.12 
Angiotensin Blockade -0.12 0.04 0.89 0.82 0.96 
Iron Medication 0.12 0.03 1.12 1.05 1.20 
Vitamin D supplementation 0.15 0.03 1.16 1.09 1.23 
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Table 19. Cox proportional hazards model with fractional polynomials suggested by mfp algorithm 
for Imputed Dataset 4 with frailty term 
 
Risk factor/Prescription Beta Standard 
Error 
Hazard 
Ratio 
95% 
Confidence 
intervals 
Lower Limit 
95% 
Confidence 
intervals 
Lower Limit 
Age
2
 3.32 0.07 27.67 24.23 31.59 
Male Gender 0.52 0.02 1.68 1.61 1.74 
Race with African Caribbean  Race 
as reference 
African –Caribbean -0.40 0.16 0.67 0.49 0.92 
Indian Subcontinent -0.21 0.12 0.81 0.64 1.03 
South East Asian -0.67 0.58 0.51 0.16 1.59 
Townsend Quintile compared to 
1
th
 Quintile 
2
nd
 0.09 0.03 1.10 1.04 1.16 
3
rd
 0.13 0.03 1.14 1.08 1.21 
4
th
 0.14 0.03 1.15 1.09 1.22 
5
th
 0.18 0.03 1.20 1.12 1.29 
Diabetes Mellitus 0.18 0.02 1.19 1.14 1.25 
Heart Failure 0.53 0.03 1.70 1.60 1.81 
Atrial Fibrillation 0.23 0.03 1.25 1.19 1.33 
Ever Smoked 0.24 0.03 1.27 1.20 1.33 
(Systolic BP/100) -2.05 0.35 0.13 0.07 0.25 
(Systolic BP/100)
2
 0.62 0.12 1.86 1.48 2.33 
(BMI/10)-0.5 2.79 0.29 16.36 9.33 28.69 
(BMI/10)3 0.01 0.00 1.01 1.00 1.01 
(Hb/10)
3
 -0.71 0.05 0.49 0.45 0.54 
(Hb/10)
3 
X log(Hb/10) 0.79 0.07 2.20 1.93 2.50 
Gfr/100 -1.33 0.11 0.26 0.21 0.33 
Proteinuria levels with none as 
reference 
High 0.14 0.03 1.15 1.07 1.23 
Very High 0.43 0.04 1.54 1.41 1.67 
Aspirin 0.23 0.02 1.25 1.20 1.31 
Anticoagulation 0.19 0.04 1.21 1.12 1.31 
Diuretic use -0.15 0.02 0.86 0.83 0.90 
Other 0.07 0.02 1.08 1.04 1.12 
Angiotensin Blockade -0.11 0.04 0.89 0.83 0.96 
Iron Medication 0.14 0.03 1.15 1.08 1.23 
Vitamin D supplementation 0.15 0.03 1.16 1.10 1.23 
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Table 20. Cox proportional hazards model with fractional polynomials suggested by mfp algorithm 
for Imputed Dataset 5 with frailty term 
 
Risk factor/Prescription Beta Standard 
Error 
Hazard 
Ratio 
95% 
Confidence 
intervals 
Lower Limit 
95% 
Confidence 
intervals 
Lower Limit 
Age
2
 3.34 0.07 28.26 24.77 32.25 
Male Gender 0.49 0.02 1.63 1.57 1.70 
Race with African Caribbean  
Race as reference 
African –Caribbean -0.41 0.16 0.66 0.48 0.91 
Indian Subcontinent -0.22 0.12 0.80 0.63 1.02 
South East Asian -0.74 0.58 0.48 0.15 1.48 
Townsend Quintile compared to 
1
th
 Quintile 
2
nd
 0.09 0.03 1.09 1.04 1.15 
3
rd
 0.11 0.03 1.12 1.06 1.19 
4
th
 0.13 0.03 1.14 1.07 1.20 
5
th
 0.19 0.03 1.21 1.13 1.29 
Diabetes Mellitus 0.07 0.02 1.08 1.03 1.12 
Heart Failure 0.53 0.03 1.70 1.60 1.81 
Atrial Fibrillation 0.23 0.03 1.25 1.18 1.32 
Ever Smoked 0.24 0.03 1.27 1.21 1.34 
(Systolic BP/100)
1
 -3.16 0.47 0.04 0.02 0.11 
(Systolic BP/100)
1
 x log(Systolic 
BP/100) 2.12 0.34 8.36 4.29 16.27 
(BMI/10)-
2
 1.46 0.15 4.30 3.21 5.75 
(Hb/10)
3
 -0.69 0.05 0.50 0.46 0.55 
(Hb/10)
3 
X log(Hb/10) 0.77 0.07 2.16 1.89 2.46 
Gfr/100 -1.27 0.11 0.28 0.22 0.35 
Cholesterol/10 -0.33 0.08 0.72 0.61 0.84 
Proteinuria levels with none as 
reference 
High 0.01 0.03 1.01 0.95 1.08 
Very High 0.42 0.04 1.52 1.40 1.65 
Aspirin 0.21 0.02 1.24 1.18 1.29 
Anticoagulation 0.19 0.04 1.21 1.12 1.30 
Diuretic use -0.17 0.02 0.85 0.81 0.88 
Other 0.13 0.02 1.14 1.09 1.20 
Angiotensin Blockade -0.12 0.04 0.88 0.82 0.96 
Iron Medication 0.11 0.03 1.12 1.04 1.19 
Vitamin D supplementation 0.16 0.03 1.17 1.10 1.24 
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Figure 6. Systolic Blood pressure versus log relative hazards ratio for imputations 1-5  with frailty term 
 
 
 
Figure 7. Age versus log relative hazards ratio for imputations 1-5  with frailty term 
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Figure 8. Haemoglobin versus log relative hazards ratio for imputations 1-5  with frailty term 
 
 
Figure 9. Body Mass Index versus log relative hazards ratio for imputations 1-5  with frailty term 
 
 
-2.00
-1.00
0.00
1.00
2.00
3.00
4.00
0 5 10 15 20 25L
o
g
 r
e
la
ti
v
e
 h
a
za
rd
 r
a
ti
o
Haemoglobin g/dl
1
2
3
4
5
-1.50
-1.00
-0.50
0.00
0.50
1.00
1.50
2.00
2.50
3.00
0 20 40 60 80Lo
g
 R
e
la
ti
v
e
 H
a
za
rd
 R
a
ti
o
Body Mass Index kg/m2
1
2
3
4
5
 362 of 375 
 
Appendix D. Schoenfeld residuals for Composite Model 
1. Scaled Schoenfeld residuals for age versus Time in days 
Figure 2. Scaled Schoenfeld Residuals for(Hb/10)
3
 versus Time 
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Figure 3. Scaled Schoenfeld Residuals for Hb/10*3 x log Hb/10 versus Time 
 
Figure 4. Scaled Schoenfeld Residuals for Heart Failure versus Time 
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Figure 5. Scaled Schoenfeld Residuals for Gender versus Time 
Figure 6. Scaled Schoenfeld Residuals for Anticoagulation versus Time 
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Figure 7. Scaled Schoenfeld Residuals for Angiotensin blockade versus Time 
Figure 8. Scaled Schoenfeld Residuals for Atrial Fibrillation versus Time 
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Figure 9. Scaled Schoenfeld Residuals for AFC race versus Time 
Figure 10. Scaled Schoenfeld Residuals for Aspirin versus Time 
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Figure 11. Scaled Schoenfeld Residuals for BMI/10*-2 versus Time 
Figure 12. Scaled Schoenfeld Residuals for Cholesterol/10 versus Time 
 
 
  
 368 of 375 
 
Figure 13. Scaled Schoenfeld Residuals for Diuretics versus Time 
 
Figure 14. Scaled Schoenfeld Residuals for Diabetes versus Time 
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Figure 15. Scaled Schoenfeld Residuals for iron supplements versus Time 
 
Figure 16. Scaled Schoenfeld Residuals for other hypertensive versus Time 
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Figure 17. Scaled Schoenfeld Residuals for High proteinuria versus Time 
 
Figure 18. Scaled Schoenfeld Residuals for Very high proteinuria versus Time. 
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Figure 19. Scaled Schoenfeld Residuals for Ex/Current Smokers versus Time 
 
Figure 20. Scaled Schoenfeld Residuals for sys bp/100 versus Time 
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Figure 21. Scaled Schoenfeld Residuals for Systolic  bp/100 squared versus Time 
 
Figure 22. . Scaled Schoenfeld Residuals for Townsend Quintile 2 versus Time 
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Figure 23. Scaled Schoenfeld Residuals for Townsend Quintile 3 versus Time 
 
Figure 24. Scaled Schoenfeld residuals for Townsend Quintile 4 versus time 
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Figure 25. Scaled Schoenfeld residuals for Townsend Quintile 4 versus time 
 
 
Figure 26. Scaled Schoenfeld residuals for Vit D supplementation versus time 
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Figure 27. Scaled Schoenfeld residuals for ISC race versus time 
Figure 28. Scaled Schoenfeld residuals for GFR versus time 
 
